{"id":15879,"date":"2021-12-14T13:06:22","date_gmt":"2021-12-14T13:06:22","guid":{"rendered":"https:\/\/incilab.az\/hormonlar-testl%c9%99r-qrupu\/"},"modified":"2023-09-14T09:09:10","modified_gmt":"2023-09-14T09:09:10","slug":"hormones-test-group","status":"publish","type":"page","link":"https:\/\/incilab.az\/en\/hormones-test-group\/","title":{"rendered":"Hormones test group"},"content":{"rendered":"

[vc_row][vc_column]

\r\n \r\n <\/div>\r\n
<\/div>
\r\n

11-DEOKS\u0130KORT\u0130ZOL<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Compound S<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<8 ng\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>11 \u03b2-hidroksilaza \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131 il\u0259 \u0259laq\u0259dar adrenokortikal hiperplaziya, adrenal karsinomalar v\u0259 ACTH s\u0259viyy\u0259sinin artd\u0131\u011f\u0131 hal\u00adlarda serumda 11-deoksikortizolun s\u0259viyy\u0259si d\u0259 art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

C-PEPTID<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u0130nsulin C-peptid; CPR; Birl\u0259\u015fdirici peptid; C-peptid reak\u00adtivliyi)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>0.15-1.30 pmol\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0C-peptid yaln\u0131z\u00a0 m\u0259d\u0259alt\u0131 v\u0259zin \u03b2 h\u00fcceyr\u0259l\u0259rind\u0259n ifraz olun\u00addu\u011fu \u00fc\u00e7\u00fcn, x\u00fcsusil\u0259 ekzogen insulin istifad\u0259 ed\u0259n diabet x\u0259st\u0259l\u0259rind\u0259, en\u00addogen insulin ifraz\u0131n\u0131n qiym\u0259tl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. \u0130nsu\u00adlinoma, oral hipoqlikemik d\u0259\u00adr\u00adman\u00adlar, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, II tip \u015f\u0259k\u0259rli diabet, ql\u00fckoza q\u0259bulu, azan sinirin sti\u00admuliyasiyas\u0131, tirotoksikoz, Cu\u00adshing sindromu, hipokalemiya, ha\u00admil\u0259lik v\u0259 akromeqaliya zaman\u0131 se\u00adrumda C-peptid s\u0259viyy\u0259si art\u0131r, I tip\u00a0 \u015f\u0259k\u0259rli diabet, insulin m\u00fcalic\u0259si, tiazid qrupundan olan diuretikl\u0259r, alkaqol q\u0259bulu v\u0259 pan\u00adkreatek\u00adto\u00admi\u00adyadan sonra is\u0259 C-peptid s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

17-H\u0130DROKS\u0130PPRO\u00adGES\u00adTERON, EKSTRAKS\u0130YALI<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sutkal\u0131q rit\u00admi var. S\u0259h\u0259rl\u0259r 17-OH proqesteron s\u0259viyy\u0259si maksimum olur<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Ekstraksiya + RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>17-Hidroksiproqesteron il\u0259 eyni<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0X\u00fcsusil\u0259 k\u00f6rp\u0259 yeni do\u00ad\u011fulan m\u0259rh\u0259l\u0259d\u0259 dig\u0259r hormonlar\u0131n \u00e7arpaz reaksiya verm\u0259si il\u0259 \u0259laq\u0259dar olaraq 17-Hidroksiproqesteronun eks\u00ad\u00adtrak\u00ad\u00adsiyadan sonra t\u0259yini fay\u00adda\u00adl\u0131d\u0131r. Ekstraksiya say\u0259sind\u0259 yalan\u00e7\u0131 y\u00fcks\u0259k n\u0259tic\u0259l\u0259rin qar\u015f\u0131s\u0131 al\u0131n\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

17-H\u0130DROKS\u0130PROGESTERON<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>17-OH progesteron<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Sutkal\u0131q ritmi var. S\u0259h\u0259rl\u0259r 17-OH pro\u00adqesteron s\u0259viyy\u0259si maksimum olur<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n9.0-50.0 ng\/mL<\/td>\n<\/tr>\n
Yenido\u011fulan<\/td>\n0.3-5.6 ng\/mL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n0.2-2.3 ng\/mL<\/td>\n<\/tr>\n
7 g\u00fcn-5 ya\u015f<\/td>\n0.1-0.9 ng\/mL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n0.1-1.0 ng\/mL<\/td>\n<\/tr>\n
16-50<\/td>\n0.2-1.0 ng\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n0.2-0.5 ng\/mL<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n0.2-1.0 ng\/mL<\/td>\n<\/tr>\n
Menopauza<\/td>\n0.1-0.5 ng\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n0.2-1.0 ng\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n0.2-1.0 ng\/mL<\/td>\n<\/tr>\n
L\u00fcteal faza<\/td>\n0.2-3.0 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a011-Hidroksilaza v\u0259 ya 21-Hidroksilaza \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 \u0259laq\u0259li olan kongenital adrenal hiper\u00adpla\u00adzi\u00adyalar \u00fc\u00e7\u00fcn \u0259n \u0259lveri\u015fli skrininq test\u00add\u0131r. Hir\u015futizm v\u0259 ya sonsuzlu\u011fu olan qad\u0131nlarda, adult-onset kongenital ad\u00adrenal hiperplaziyalar\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259sind\u0259 v\u0259 kongenital adrenal hiperplaziya s\u0259b\u0259bi il\u0259 qliko\u00adkor\u00adtikoid m\u00fcalic\u0259si alan x\u0259st\u0259l\u0259rin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

17-KETOSTERO\u0130DLER<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a017-KS<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu \u00fcz\u0259\u00adrin\u0259 toplanmal\u0131d\u0131r. 6N HCL v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan n\u00fcmu\u00adn\u0259l\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>10 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Xromatoqrafik, spektro\u00adfotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
<1 ya\u015f<\/td>\n<1 mg\/g\u00fcn<\/td>\n<\/tr>\n
2-5 ya\u015f<\/td>\n1-2 mg\/g\u00fcn<\/td>\n<\/tr>\n
6-11 ya\u015f<\/td>\n1-4 mg\/g\u00fcn<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
12-15 ya\u015f<\/td>\n5-12 mg\/g\u00fcn<\/td>\n3-10 mg\/g\u00fcn<\/td>\n<\/tr>\n
16-30 ya\u015f<\/td>\n9-22 mg\/g\u00fcn<\/td>\n6-15 mg\/g\u00fcn<\/td>\n<\/tr>\n
>30 ya\u015f<\/td>\n8-20 mg\/g\u00fcn<\/td>\n6-15 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Ki\u015fil\u0259rd\u0259 androgen m\u0259n\u00ad\u015f\u0259li adrenal v\u0259 testikuliyar, qad\u0131n\u00adlarda is\u0259 androgen m\u0259n\u015f\u0259li adrenal hormon sintezinin qiym\u0259tl\u0259ndi\u00adril\u00adm\u0259\u00adsind\u0259 istifad\u0259 olunur. Bununla yana\u015f\u0131 adrenal androgen sintezinin qiym\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 qanda DHEA-S miq\u00addar\u0131n\u0131n t\u0259yini daha qiym\u0259tlidir. Testikulyar \u015fi\u015fl\u0259r, l\u00fctein h\u00fcceyr\u0259li y\u00fcm\u00fcrtal\u0131q karsinomas\u0131, Cushing x\u0259st\u0259liyi, ektopik ACTH sintez ed\u0259n \u015fi\u015fl\u0259r, adrenal \u015fi\u015fl\u0259r, stres, hami\u00adl\u0259\u00adliyin son trimesteri v\u0259 Stein-Le\u00adventhall sindromunda 17-KS s\u0259\u00adviy\u00ady\u0259si art\u0131r, ikincili qad\u0131n hipoqo\u00adnadizmi, hipotiroidizim v\u0259 birincili hipoqonadizmind\u0259 (Kleinifelter sind\u00adromu, kastrasiya v\u0259 s.) 17-KS s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

17-KS (17-KETOSTERO\u0130DLER)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a017-KS<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu \u00fcz\u0259\u00adrin\u0259 toplanmal\u0131d\u0131r. 6N HCL v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan n\u00fcmu\u00adn\u0259l\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>10 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Xromatoqrafik, spektro\u00adfotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
<1 ya\u015f<\/td>\n<1 mg\/g\u00fcn<\/td>\n<\/tr>\n
2-5 ya\u015f<\/td>\n1-2 mg\/g\u00fcn<\/td>\n<\/tr>\n
6-11 ya\u015f<\/td>\n1-4 mg\/g\u00fcn<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
12-15 ya\u015f<\/td>\n5-12 mg\/g\u00fcn<\/td>\n3-10 mg\/g\u00fcn<\/td>\n<\/tr>\n
16-30 ya\u015f<\/td>\n9-22 mg\/g\u00fcn<\/td>\n6-15 mg\/g\u00fcn<\/td>\n<\/tr>\n
>30 ya\u015f<\/td>\n8-20 mg\/g\u00fcn<\/td>\n6-15 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Ki\u015fil\u0259rd\u0259 androgen m\u0259n\u00ad\u015f\u0259li adrenal v\u0259 testikuliyar, qad\u0131n\u00adlarda is\u0259 androgen m\u0259n\u015f\u0259li adrenal hormon sintezinin qiym\u0259tl\u0259ndi\u00adril\u00adm\u0259\u00adsind\u0259 istifad\u0259 olunur. Bununla yana\u015f\u0131 adrenal androgen sintezinin qiym\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 qanda DHEA-S miq\u00addar\u0131n\u0131n t\u0259yini daha qiym\u0259tlidir. Testikulyar \u015fi\u015fl\u0259r, l\u00fctein h\u00fcceyr\u0259li y\u00fcm\u00fcrtal\u0131q karsinomas\u0131, Cushing x\u0259st\u0259liyi, ektopik ACTH sintez ed\u0259n \u015fi\u015fl\u0259r, adrenal \u015fi\u015fl\u0259r, stres, hami\u00adl\u0259\u00adliyin son trimesteri v\u0259 Stein-Le\u00adventhall sindromunda 17-KS s\u0259\u00adviy\u00ady\u0259si art\u0131r, ikincili qad\u0131n hipoqo\u00adnadizmi, hipotiroidizim v\u0259 birincili hipoqonadizmind\u0259 (Kleinifelter sind\u00adromu, kastrasiya v\u0259 s.) 17-KS s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

5-H\u0130DROKS\u0130 TR\u0130PTAM\u0130N (SEROTON\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>5-OH triptamin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259< qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Serotonin t\u0259rkilbi qoz, banan, bad\u0131mcan, po\u00admidor, f\u0131nd\u0131q, f\u0131st\u0131q, avokado v\u0259 s. b\u0259zi meyv\u0259 v\u0259 t\u0259r\u0259v\u0259zl\u0259r son 72 saat \u0259rzind\u0259 yeyilm\u0259m\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n
Serum<\/td>\n>15 ya\u015f<\/td>\n50-230 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Karsinoid \u015fi\u015fl\u0259rin di\u00adaq\u00adnoz v\u0259 m\u00fcalic\u0259sinin\u00a0 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Karsinoid sindrom, miqren, \u015fizofreniya, esensial hiper\u00adten\u00adziya, Huntington x\u0259st\u0259liyi v\u0259 Duchenne \u0259z\u0259l\u0259 distrofiyas\u0131nda se\u00adrumda serotonin miqdar\u0131art\u0131r. Dum\u00adping sindromu, k\u0259skin ba\u011f\u0131rsaq obstruksiyas\u0131, kistik fibrozis v\u0259 k\u0259s\u00adkin miokard infarkt\u0131nda da se\u00adrotonin s\u0259viyy\u0259sind\u0259 y\u00fcng\u00fcl y\u00fcks\u0259lm\u0259 ola bil\u0259r. Litium, MAO inhibitorlar\u0131, me\u00adtildopa, morfin v\u0259 rezerpin isti\u00adfad\u0259si serotonin s\u0259viyy\u0259sin\u0259 tesir ed\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ACTH (ADRENOKORT\u0130KOTROP HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ACTH; Kortikotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir. N\u00fcmun\u0259nin al\u0131nma zaman\u0131 \u0259h\u0259miyy\u0259tlidir. Plazmadak\u0131 ACTH miqdar\u0131\u00a0 saat 06.00 \u2013 08.00 aras\u0131nda maksimum, 21.00 \u2013 22.00 aras\u0131nda is\u0259 minimum s\u0259viyy\u0259d\u0259 olur. Bundan ba\u015fqa hamil\u0259lik, mens\u00adtrual sikl v\u0259 stres zaman\u0131 da plaz\u00admadak\u0131 s\u0259viyy\u0259 d\u0259yi\u015fir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
S\u0259h\u0259r<\/td>\n<100 pg\/ml<\/td>\n<\/tr>\n
Ax\u015fam<\/td>\n<80 pg\/ml<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ADH (ANT\u0130D\u0130URET\u0130K HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ADH; Vazoperssin; Argi\u00adnin vazopressin hormon; AVP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 Plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00ad\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00ad\u00adliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 t\u0259\u00adcili ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6n\u00add\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Plazmadak\u0131 ADH s\u0259viyy\u0259sin\u0259 t\u0259sir ed\u0259n bir \u00e7ox fak\u00ad\u00adtor var. Ayaq \u00fcst\u0259 durmaq, a\u011fr\u0131, sters, gimnastika, plazma osmol\u00adyar\u00adl\u0131\u00ad\u011f\u0131n\u0131n (osmolalite) artmas\u0131 v\u0259 qan\u0131n h\u0259c\u00adminin, yaxud, arterial t\u0259zyiqin azal\u00admas\u0131 v\u0259 gec\u0259l\u0259r ADH ifraz\u0131 art\u0131r, isti\u00adra\u00adh\u0259t, hipoosmolyarl\u0131q, qan\u0131n h\u0259c\u00ad\u00adminin art\u00admas\u0131 v\u0259 hipertenziya zaman\u0131is\u0259 aza\u00adl\u0131r. H\u0259m\u00e7inin xlor\u00adpro\u00adpa\u00admid, tiazid, di\u00adu\u00adretk\u00adl\u0259r v\u0259 s. d\u0259r\u00admanlar da ADH ifraz\u0131n\u0131 art\u0131r\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin tam qan olaraq g\u00f6nd\u0259rilm\u0259si<\/p>\n

Referens:<\/strong>\u00a0<8 pg\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Ektopik ADH ifraz ed\u0259n \u015fi\u015f\u00adl\u0259r, k\u0259skin intermittant porfiriya, Gu\u00adillian-Barre sindromu, beyin \u015fi\u015f\u00adl\u0259ri, vas\u00adkulyar v\u0259 infeksion beyin x\u0259s\u00adt\u0259lik\u00adl\u0259\u00adri, pnevmoniya, a\u011fciy\u0259r v\u0259\u00adr\u0259mi, v\u0259\u00adr\u0259m meningiti v\u0259 beyin m\u0259n\u00ad\u015f\u0259li \u015f\u0259\u00adk\u0259r\u00adsiz diabet, psixogen poli\u00addipsiya v\u0259 nef\u00adrotik sindromda ADH s\u0259viyy\u0259si azal\u0131r. M\u0259rk\u0259zi v\u0259 nefro\u00adgen \u015f\u0259k\u0259rsiz diabet v\u0259 ya psixogen polidipsiyan\u0131n diffe\u00adren\u00adsial diaqnos\u00adi\u00adkas\u0131 \u00fc\u00e7\u00fcn ADH stimuli\u00adyasiya testl\u0259ri istifad\u0259 olunur<\/p>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

COMPOUND F (KORT\u0130ZOL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Hidrokortizon; Compound F<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum v\u0259 ya EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), b\u0259n\u00f6v\u015f\u0259yi qa\u00adpaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 plazma)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Sut\u00adkal\u0131q variasiyas\u0131 oldu\u011fundan qan al\u00adma zaman\u0131 \u0259h\u0259miyy\u0259tlidir. S\u0259h\u0259r saat 06.00-08.00 aras\u0131nda maksi\u00admum, g\u00fcnortadan sonra saat 16.00-a is\u0259 minimum s\u0259viyy\u0259d\u0259 olur. N\u00fcmu\u00adn\u0259nin al\u0131nd\u0131\u011f\u0131 saat laboratoriyaya bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131\u00adl\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n
S\u0259h\u0259r<\/td>\n7.0-29.0 \u03bcg\/dL<\/td>\n<\/tr>\n
Ax\u015fam<\/td>\n7.0-17.5 \u03bcg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipotalamus-hipofiz-ad\u00adre\u00adnal korteks \u0259ks \u0259laq\u0259sinin qiym\u0259t\u00adl\u0259n\u00ad\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. Cushing x\u0259st\u0259liyi, b\u00f6yr\u0259k\u00fcst\u00fc v\u0259zin adenomalar\u0131 v\u0259 karsinomalar\u0131, ekto\u00adpik ACTH sindromu, hamil\u0259lik v\u0259 eksternal esterogen istifad\u0259si il\u0259 se\u00adrumda kortizolun s\u0259viyy\u0259si art\u0131r, Ad\u00addison\u00a0 x\u0259st\u0259liyi, kongenital adrenal hiperplaziya v\u0259 hipopituiterizmd\u0259 kortizolun s\u0259viyy\u0259si azal\u0131r. K\u0259skin stress, alkoqolizm, depressiya v\u0259 b\u0259zi d\u0259rmanlar normal sutkal\u0131q va\u00adriyasiyan\u0131 pozaraq bazal s\u0259viyy\u0259y\u0259 t\u0259sir edir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

C\u0130NS\u0130 HORMON-B\u0130RL\u018f\u015e\u00adD\u0130R\u0130C\u0130 QLOBUL\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>SHBG; Testosteron-estra\u00addiol-binding globulin; TeBG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rz\u0131m\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>FIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
1-12 ya\u015f<\/td>\n4.9-9.0 mg\/L<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n1.8-9.0 mg\/L<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n0.9-6.3 mg\/L<\/td>\n1.8-9.0 mg\/L<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n0.6-4.7 mg\/L<\/td>\n1.2-7.7 mg\/L<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n0.6-4.5 mg\/L<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Testesteron v\u0259 estero\u00adgen\u00adl\u0259r m\u0259n\u015f\u0259li cinsi hormonlar SHBG t\u0259r\u0259find\u0259n birl\u0259\u015fdirilir\u0259k qanda da\u00ad\u015f\u0131n\u0131r. Hipertiroidizim, anoreksiya\u00a0 ner\u00advosa, hamil\u0259lik v\u0259 sirrozda SHBG s\u0259viyy\u0259si azal\u0131r, hipoti\u00adroidizim, hir\u015futizm, piyl\u0259nm\u0259 v\u0259 yu\u00admurtal\u0131qlar\u0131n polikistoz sindromunda is\u0259 bu g\u00f6st\u0259rici art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CEA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Karsinoembirionik antigen<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<4 ng\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Yo\u011fun v\u0259 d\u00fcz ba\u011f\u0131rsaq, a\u011fciy\u0259r, s\u00fcd v\u0259zi, qaraciy\u0259r, pan\u00adkreaz, prostat, m\u0259d\u0259 v\u0259 yumurtal\u0131q x\u0259r\u00e7\u0259ngl\u0259rind\u0259 CEA s\u0259viyy\u0259si art\u0131r. \u018fsas\u0259n kolorektal x\u0259r\u00e7\u0259ngl\u0259r v\u0259 s\u00fcd v\u0259zi x\u0259r\u00e7\u0259ngl\u0259rinin gec d\u00f6vrl\u0259rinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 edilir. Xo\u015f\u00adxass\u0259li qaraciy\u0259r x\u0259st\u0259likl\u0259ri, xoral\u0131 kolit v\u0259 polipoz kimi b\u0259zi xo\u015fxass\u0259li m\u0259d\u0259-ba\u011f\u0131rsaq prosesl\u0259ri, xo\u015fxass\u0259li s\u00fcd v\u0259zi x\u0259st\u0259likl\u0259ri, a\u011fciy\u0259r in\u00adfek\u00adsiyalar\u0131, emfizema v\u0259 b\u00f6yr\u0259k \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131nda da CEA s\u0259viyy\u0259si arta bil\u0259r. H\u0259m\u00e7inin siqaret \u00e7\u0259k\u0259nl\u0259rd\u0259 d\u0259 CEA s\u0259viyy\u0259sind\u0259 m\u00fclayim y\u00fck\u00ads\u0259lm\u0259 qeyd edilir. Buna g\u00f6r\u0259 d\u0259 skrininq testi kimi istifad\u0259 olun\u00admamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CA 72-4<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>X\u0259r\u00e7\u0259ng antigeni 72-4; TAG 72; Tumor associated glico\u00adpro\u00adtein 72<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens: <<\/strong>6.9 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>Qastrointestinal sistem, yumurtal\u0131q v\u0259 s\u00fcd v\u0259zi toxumas\u0131n\u0131n ilkin adenokarsinomalar\u0131n\u0131n t\u0259krar\u00adlan\u00admas\u0131 v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. X\u00fcsusil\u0259 meta\u00adstatik m\u0259d\u0259 karsinomalar\u0131nda CA72-4 s\u0259viyy\u0259si y\u00fcks\u0259lir. H\u0259m\u00e7inin b\u0259zi xo\u015fxass\u0259li halarda da (pankreatit, qaraciy\u0259r sirrozu, a\u011fciy\u0259r x\u0259s\u00adt\u0259\u00adlik\u00adl\u0259ri, revmatoid x\u0259st\u0259\u00adlikl\u0259r, ginekoloji x\u0259st\u0259likl\u0259r, qastrointestinal sistem x\u0259st\u0259likl\u0259ri v\u0259 s.) CA72-4 s\u0259viyy\u0259si arta bil\u0259r. Skrininq test kimi istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CA 19-9<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>X\u0259r\u00e7\u0259ng antigeni 19-9; Karbohidrat antigeni 19-9<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens: <<\/strong>37 U\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>B\u00fct\u00fcn qastrointestinal sistem x\u0259r\u00e7\u0259ngl\u0259ri (m\u0259d\u0259alt\u0131 v\u0259z x\u0259r\u00e7\u0259ngl\u0259ri, xolangiokarsinomalar, yogun ba\u011f\u0131rsaq x\u0259r\u00e7\u0259ngl\u0259ri v\u0259 s.) v\u0259 dig\u0259r adenokarsinomalarda\u00a0 CA19-9-un s\u0259viyy\u0259si art\u0131r. M\u0259d\u0259alt\u0131 v\u0259z x\u0259r\u00e7\u0259ngl\u0259rind\u0259 h\u0259ssasl\u0131\u011f\u0131 70-80 %-dir. CA19-9 s\u0259viyy\u0259si il\u0259 \u015fi\u015fin k\u00fctl\u0259si aras\u0131nda \u0259laq\u0259 yoxdur. CEA il\u0259 b\u0259rab\u0259r istifad\u0259 olunduqda m\u0259d\u0259 x\u0259rc\u0259nginin t\u0259krarlanmas\u0131n\u0131n t\u0259yi\u00adnind\u0259 h\u0259sasl\u0131\u011f\u0131 94 %-\u0259 q\u0259d\u0259r y\u00fck\u00ads\u0259lir. H\u0259m\u00e7inin xroniki pankreatit, xolangit v\u0259 sirroz kimi b\u0259zi xo\u015f\u00adxa\u00ads\u0259\u00adli prosesl\u0259rd\u0259 d\u0259 CA19-9 s\u0259viy\u00ady\u0259\u00adsind\u0259 y\u00fcks\u0259lm\u0259 m\u00fc\u015fahid\u0259 oluna bi\u00adl\u0259r. Skrininq testi kimi istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CA 15-3<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Canser antigen 15-3, X\u0259r\u00e7\u0259ng antigeni 15-3<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong><<\/strong>29 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0S\u00fcd v\u0259zi x\u0259r\u00e7\u0259nginin diaq\u00adno\u00adzunda, x\u0259st\u0259liyin t\u0259krarlan\u00admas\u0131n\u0131n v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur. X\u00fcsusil\u0259 metastatik s\u00fcd v\u0259\u00adzi x\u0259r\u00e7\u0259ngl\u0259rinin 80%-d\u0259 CA 15-3 s\u0259\u00adviyy\u0259si art\u0131r. H\u0259m\u00e7inin b\u0259zi b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r (m\u0259d\u0259alt\u0131 v\u0259z, a\u011fciy\u0259r, yu\u00admur\u00adtal\u0131q, yo\u011fun ba\u011f\u0131rsaq, qaraciy\u0259r v\u0259 s.), hepatit, sirroz, sarkoidoz, v\u0259r\u0259m v\u0259 SLE-d\u0259 d\u0259 CA 15-3 s\u0259viyy\u0259si y\u00fck\u00ads\u0259lir. Skrininq testi kimi istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CA 125<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Canser antigen 125, X\u0259r\u00e7\u0259ng antigeni125<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Ovul\u00adyasiya v\u0259 menstruasiya m\u0259rh\u0259l\u0259l\u0259ri n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens: <<\/strong>35 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u018fsas\u0259n yumurtal\u0131q x\u0259r\u00ad\u00e7\u0259ngl\u0259rinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunan onkomarkerdir. Seroz, endo\u00admetrial, \u015f\u0259ffaf h\u00fcceyr\u0259li v\u0259 dif\u00adfe\u00adren\u00adsiasiya etm\u0259y\u0259n yumurtal\u0131q karsino\u00admalar\u0131, endometrium v\u0259 ya fallop bo\u00adru\u00adlar\u0131n\u0131n adenokarsinomalar\u0131, b\u0259zi qey\u00adri-genikoloji b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r v\u0259 b\u0259zi xo\u015f xass\u0259li hallarda (hami\u00adl\u0259\u00adlik, menstruasiya, peritoneal v\u0259 ya plev\u00adral iltihabi prosesl\u0259r, yumurtal\u0131q kistalar\u0131, endometrioz) CA 125-in s\u0259\u00adviy\u00ady\u0259si art\u0131r. H\u0259m\u00e7inin sa\u011flam insanlar\u0131n 1%-d\u0259 d\u0259 CA 125 s\u0259\u00adviyy\u0259si y\u00fcks\u0259k ola bil\u0259r. Buna g\u00f6r\u0259 d\u0259 normal hallarda skrininq m\u0259q\u00ads\u0259dil\u0259 istifad\u0259 olunma\u00admal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

C-21 STERO\u0130D (PROQESTERON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0C-21 steroid; P4<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<12 ya\u015f<\/td>\n0.10-0.31 ng\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n0.10-1.00 ng\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n0.10-1.10 ng\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n0.10-1.10 ng\/mL<\/td>\n<\/tr>\n
L\u00fcteal faza<\/td>\n3.00-20.00 ng\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<12 ya\u015f<\/td>\n0.10-0.31 ng\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n0.10-1.00 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0 Ovulyasiya, sar\u0131 cisimin funksiyalar\u0131 v\u0259 hamil\u0259likd\u0259 plasental funksiyalar\u0131n qiym\u0259tl\u0259ndirilm\u0259si, in\u00adduk\u00adsiyan\u0131n m\u00fc\u015fahid\u0259si, proqes\u00adteron m\u00fcalic\u0259sinin v\u0259 erk\u0259n abort riski olan x\u0259st\u0259l\u0259rin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur. Anadang\u0259lm\u0259 ad\u00adre\u00adnal hiper\u00adpla\u00adziya, lipoid yumurtal\u0131q \u015fi\u015fl\u0259ri, teka l\u00fctein kistas\u0131, molyar hamil\u0259lik v\u0259 yumurtal\u0131q xorioepi\u00adteliomalar\u0131nda pro\u00adqesteron s\u0259viyy\u0259si art\u0131r, d\u00fc\u015f\u00fck (abortus) riskind\u0259, bi\u00adrin\u00adcili v\u0259 ya ikincili hipoqonadizm v\u0259 q\u0131sa l\u00fcteal faza sindromunda is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BORUCUQ FOSFAT REABSORBS\u0130YASI<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Tubulyar fosfat reabsorb\u00adsiyas\u0131, TRP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0S\u0259h\u0259r 2-4 saatl\u0131q\u00a0 sidik v\u0259 eyni zamanda al\u0131nan serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum). Y\u0131\u011f\u0131lan sidik so\u00adyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6n\u00add\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL serum v\u0259 10 mL sidik<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0X\u0259st\u0259 m\u00fca\u00adyin\u0259d\u0259n\u00a0 \u0259vv\u0259lki 5 g\u00fcn \u0259rzind\u0259 nor\u00admal kalsium v\u0259 fosfor t\u0259rkibli p\u0259hriz q\u0259bul etm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a078-91 %<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Paratiroid v\u0259zi funksi\u00adya\u00adlar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur. Hipoparatiroidizm v\u0259 psev\u00addohipoparatiroidizmd\u0259 TRP ar\u00adt\u0131r, hiperparatiroidizmd\u0259 is\u0259 azal\u0131r. Hiperparatiroidizmi olan x\u0259st\u0259l\u0259rin 25 %-d\u0259 yalan\u00e7\u0131 neqativ n\u0259tic\u0259 \u0259ld\u0259 oluna bil\u0259r.
\nTRP %=100x(1<\/strong>– sidik fosforu\u00a0x<\/strong>\u00a0serum kreatinini\u00a0\/<\/strong>\u00a0sidik kreatinini\u00a0x\u00a0<\/strong>serum fosforu)<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BGP (OSTEOKALS\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0S\u00fcm\u00fck gla proteini; BGP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0S\u0259h\u0259r acl\u0131\u011f\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n
6 ay-5 ya\u015f<\/td>\n10-40 ng\/mL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n5-60 ng\/mL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n2-15 ng\/mL<\/td>\n<\/tr>\n
<50 ya\u015f<\/td>\nKi\u015fi: 2-10 ng\/mL<\/td>\n<\/tr>\n
Qad\u0131n: 2-22 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Serumda osteokalsin s\u0259\u00adviy\u00ady\u0259si s\u00fcm\u00fck sintezi il\u0259 \u0259laq\u0259lidir. Bu bax\u0131mdan osteokalsin s\u0259viy\u00ady\u0259\u00adsinin y\u00fcks\u0259lm\u0259si osteoblastik aktiv\u00adli\u00adyin artd\u0131\u011f\u0131n\u0131 g\u00f6st\u0259rir. Serumda os\u00adteokalsin s\u0259viyy\u0259si q\u0259l\u0259vi fosfataza s\u0259viyy\u0259si il\u0259 paralel d\u0259yi\u015fir. Paget x\u0259st\u0259liyi, b\u00f6yr\u0259k m\u0259n\u015f\u0259li os\u00adteodistrofiya, birincili v\u0259 ikincili hipertiroidizim, skelet metastazlar\u0131 v\u0259 xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131nda osteokalsinin s\u0259viyy\u0259si art\u0131r, birincili biliar sirroz, hamil\u0259lik, qliko\u00adkor\u00adti\u00adkoid m\u00fcalic\u0259si v\u0259 GH \u00e7at\u0131\u015fmaz\u00adl\u0131\u00ad\u011f\u0131nda is\u0259 bu g\u00f6st\u0259rici azal\u0131r. Os\u00adteoparozda is\u0259 osteokalsin s\u0259viyy\u0259si y\u00fcks\u0259k v\u0259 ya a\u015fa\u011f\u0131 ola bil\u0259r. H\u0259m\u00e7inin kalsitriol m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 d\u0259 osteokalsin istifa\u00add\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BETA-KAROT\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim: \u03b2<\/strong>-karoten; Karoten<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum (i\u015f\u0131qdan qo\u00adru\u00adnaraq g\u00f6nd\u0259rilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r. 0-6 ay aras\u0131 ya\u015f qrupu son 24 saat \u0259rzind\u0259, daha b\u00f6y\u00fckl\u0259r is\u0259 son 48 saat \u0259rzind\u0259 vitamin v\u0259 ya A vitamini il\u0259 z\u0259ngin olan yem\u0259kl\u0259rd\u0259n istifad\u0259 etm\u0259m\u0259lidirl\u0259r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz, da\u015f\u0131nma m\u00fcdd\u0259tind\u0259 n\u00fcmu\u00adn\u0259nin i\u015f\u0131\u011fa m\u0259ruz qalmas\u0131<\/p>\n

Referens:<\/strong>\u00a060-200 \u03bcg\/dL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Malabrosbsiya sind\u00adro\u00adma\u00adlar\u0131 v\u0259 A vitaminin\u00a0 hipervita\u00admi\u00adno\u00adzu\u00adnun diaqnostikas\u0131nda istifad\u0259 olu\u00adnur. Qaraciy\u0259r x\u0259st\u0259likl\u0259ri, diabetes mellitus, hipotiroidizim, p\u0259hriz il\u0259 h\u0259dd\u0259n art\u0131q A vitaminin q\u0259bulu, hiperlipidemiya, hamil\u0259lik, yar\u0131m\u00adk\u0259skin tiroidit, miksedema, xroniki nefrit v\u0259 nefrotik sindromda serumda\u00a0\u03b2-<\/strong>karotinin s\u0259viyy\u0259si art\u0131r, y\u00fcks\u0259k temperatur, enteritl\u0259r, mukovissidoz v\u0259 a\u011f\u0131r malabsorsiyada is\u0259 bu g\u00f6s\u00adt\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BETA-hCG (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim: \u03b2<\/strong>-hCG; Human chorionic gonadotropin; Hamil\u0259lik testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik (s\u0259\u00adh\u0259r ilk sidik m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259ril\u00adm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Strip<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hamil\u0259liyin t\u0259yinind\u0259 is\u00adti\u00adfad\u0259 edilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BETA-hCG (K\u0259miyy\u0259t)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim: \u03b2<\/strong>-hCG; Human chorionic gonadotropin; Hamil\u0259lik testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA \/ MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Qad\u0131n<\/td>\n<12 ya\u015f<\/td>\n2 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n6 mIU\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<2 mIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hamil\u0259liyin t\u0259yini, ekto\u00adpik (u\u015faql\u0131qdan k\u0259nar) hamil\u0259lik s\u00fcb\u00adh\u0259sinin qiym\u0259tl\u0259ndirilm\u0259si v\u0259 in vitro fertilizasiya x\u0259st\u0259l\u0259rinin m\u00fc\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. H\u0259m\u00e7inin mol hidatiform, koryo karsinomas\u0131, xayalar\u0131n \u015fi\u015fl\u0259ri, yumurtal\u0131\u011f\u0131n r\u00fc\u00ad\u015feym h\u00fcceyr\u0259li \u015fi\u015fl\u0259rinin qiym\u0259t\u00adl\u0259ndirilm\u0259si v\u0259 m\u00fc\u015fahid\u0259sind\u0259 d\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BETA-2 M\u0130KROGLOBUL\u0130N (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, Bir\u00add\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Si\u00addiyin pH-\u0131 <6.0 olarsa \u00fcz\u0259rin\u0259 1M NaOH \u0259lav\u0259 edil\u0259r\u0259k\u00a0\u03b2<\/strong>2<\/sub>M-nin sta\u00adbilliyi qorunmal\u0131d\u0131r. Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131d\u0131r. 24 saatl\u0131q sidik n\u00fc\u00admu\u00adn\u0259l\u0259rinin g\u00f6t\u00fcr\u00fclm\u0259si daha \u0259lve\u00adri\u015f\u00adlidir. Sidik n\u00fcmun\u0259l\u0259ri menstu\u00adra\u00adsiya d\u00f6vr\u00fcnd\u0259 g\u00f6t\u00fcr\u00fclm\u0259m\u0259lidir, 24 saatl\u0131q sidiyin h\u0259cmi bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0pH-\u0131 <6.0 olan sidik n\u00fcmun\u0259l\u0259ri<\/p>\n

Referens:<\/strong>\u00a00.02-0.25 mg\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Normal insanlarda\u00a0\u03b2<\/strong>2<\/sub>M sabit s\u00fcr\u0259tl\u0259 sintez olunur. Sonra b\u00f6y\u00adr\u0259kl\u0259rd\u0259 \u00f6nc\u0259 filtirasiya olunur v\u0259 ard\u0131nca reabsorbsiya edilir. Son olaraq\u00a0\u03b2<\/strong>2<\/sub>M proksimal tubulyar h\u00fc\u00adceyr\u0259l\u0259rd\u0259 katabolizm\u0259 u\u011fray\u0131r. Nor\u00admal halda sidikd\u0259\u00a0\u03b2<\/strong>2<\/sub>M-in miqdar\u0131 \u00e7ox az olur, lakin d\u0259rman, m\u00fcxt\u0259lif x\u0259st\u0259likl\u0259r, a\u011f\u0131r metallar v\u0259 s. s\u0259b\u0259b\u00adl\u0259rd\u0259n proksimal tubulyar h\u00fcceyr\u0259 z\u0259d\u0259l\u0259nm\u0259si ba\u015f verdikd\u0259 sidikl\u0259\u00a0\u03b2<\/strong>2<\/sub>M-in ifraz\u0131 art\u0131r. Bu bax\u0131mdan b\u00f6y\u00adr\u0259kl\u0259rin tubulyar funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BETA-2 M\u0130KROGLOBUL\u0130N (BOM)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

Referens:<\/strong>\u00a0<2.4 mg\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>M\u0259rk\u0259zi sinir sistemini \u0259hat\u0259 ed\u0259n k\u0259skin leykoz v\u0259 limfo\u00admalarda BOM-da\u00a0\u03b2<\/strong>2<\/sub>M arta bil\u0259r. Eyni zamanda serumdak\u0131 s\u0259viyy\u0259\u00adsi\u00adnin d\u0259 t\u0259yin olunmas\u0131 daha m\u0259qs\u0259\u00add\u0259uy\u011fundur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BETA-2 M\u0130KROGLOBUL\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim: \u03b2<\/strong>2<\/sub>M; Timotaksin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a00.6-3.8 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130ltihab, autoimmun x\u0259s\u00adtl\u0259\u00ad\u00adlikl\u0259r, limfa v\u0259zil\u0259rinin b\u0259dxass\u0259li \u015fi\u015fl\u0259ri (M\u0259s. multiple myleoma) v\u0259 vi\u00adrus infeksiyalar\u0131nda serumda\u00a0\u03b2<\/strong>2<\/sub>M s\u0259viyy\u0259si arta bil\u0259r. X\u00fcsusil\u0259, mul\u00adtiple myelomada proqnostik \u0259h\u0259\u00admiy\u00ady\u0259t\u0259 malikdir. 4 mg\/L-d\u0259n y\u00fcks\u0259k n\u0259tic\u0259l\u0259r m\u0259nfi proqnozu bildirir. H\u0259m\u00e7inin tubulyar funksiya poz\u00ad\u011funlu\u011fu olan x\u0259st\u0259l\u0259rd\u0259 serumda\u00a0\u03b2<\/strong>2<\/sub>M miqdar\u0131 azal\u0131r, sidikd\u0259\u00a0\u03b2<\/strong>2<\/sub>M miq\u00addar\u0131 y\u00fcks\u0259k olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AVP (ANT\u0130D\u0130URET\u0130K HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ADH; Vazoperssin; Argi\u00adnin vazopressin hormon; AVP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 Plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00ad\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00ad\u00adliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 t\u0259\u00adcili ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6n\u00add\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Plazmadak\u0131 ADH s\u0259viyy\u0259sin\u0259 t\u0259sir ed\u0259n bir \u00e7ox fak\u00ad\u00adtor var. Ayaq \u00fcst\u0259 durmaq, a\u011fr\u0131, sters, gimnastika, plazma osmol\u00adyar\u00adl\u0131\u00ad\u011f\u0131n\u0131n (osmolalite) artmas\u0131 v\u0259 qan\u0131n h\u0259c\u00adminin, yaxud, arterial t\u0259zyiqin azal\u00admas\u0131 v\u0259 gec\u0259l\u0259r ADH ifraz\u0131 art\u0131r, isti\u00adra\u00adh\u0259t, hipoosmolyarl\u0131q, qan\u0131n h\u0259c\u00ad\u00adminin art\u00admas\u0131 v\u0259 hipertenziya zaman\u0131is\u0259 aza\u00adl\u0131r. H\u0259m\u00e7inin xlor\u00adpro\u00adpa\u00admid, tiazid, di\u00adu\u00adretk\u00adl\u0259r v\u0259 s. d\u0259r\u00admanlar da ADH ifraz\u0131n\u0131 art\u0131r\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin tam qan olaraq g\u00f6nd\u0259rilm\u0259si<\/p>\n

Referens:<\/strong>\u00a0<8 pg\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Ektopik ADH ifraz ed\u0259n \u015fi\u015f\u00adl\u0259r, k\u0259skin intermittant porfiriya, Gu\u00adillian-Barre sindromu, beyin \u015fi\u015f\u00adl\u0259ri, vas\u00adkulyar v\u0259 infeksion beyin x\u0259s\u00adt\u0259lik\u00adl\u0259\u00adri, pnevmoniya, a\u011fciy\u0259r v\u0259\u00adr\u0259mi, v\u0259\u00adr\u0259m meningiti v\u0259 beyin m\u0259n\u00ad\u015f\u0259li \u015f\u0259\u00adk\u0259r\u00adsiz diabet, psixogen poli\u00addipsiya v\u0259 nef\u00adrotik sindromda ADH s\u0259viyy\u0259si azal\u0131r. M\u0259rk\u0259zi v\u0259 nefro\u00adgen \u015f\u0259k\u0259rsiz diabet v\u0259 ya psixogen polidipsiyan\u0131n diffe\u00adren\u00adsial diaqnos\u00adi\u00adkas\u0131 \u00fc\u00e7\u00fcn ADH stimuli\u00adyasiya testl\u0259ri istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130D\u0130URET\u0130K HORMON (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a024 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxla\u00adn\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 sa\u00adat\u00adl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

Referens:<\/strong>\u00a030-95 ng\/g\u00fcn<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130D\u0130URET\u0130K HORMON<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ADH; Vazoperssin; Argi\u00adnin vazopressin hormon; AVP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 Plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00ad\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00ad\u00adliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 t\u0259\u00adcili ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6n\u00add\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Plazmadak\u0131 ADH s\u0259viyy\u0259sin\u0259 t\u0259sir ed\u0259n bir \u00e7ox fak\u00ad\u00adtor var. Ayaq \u00fcst\u0259 durmaq, a\u011fr\u0131, sters, gimnastika, plazma osmol\u00adyar\u00adl\u0131\u00ad\u011f\u0131n\u0131n (osmolalite) artmas\u0131 v\u0259 qan\u0131n h\u0259c\u00adminin, yaxud, arterial t\u0259zyiqin azal\u00admas\u0131 v\u0259 gec\u0259l\u0259r ADH ifraz\u0131 art\u0131r, isti\u00adra\u00adh\u0259t, hipoosmolyarl\u0131q, qan\u0131n h\u0259c\u00ad\u00adminin art\u00admas\u0131 v\u0259 hipertenziya zaman\u0131is\u0259 aza\u00adl\u0131r. H\u0259m\u00e7inin xlor\u00adpro\u00adpa\u00admid, tiazid, di\u00adu\u00adretk\u00adl\u0259r v\u0259 s. d\u0259r\u00admanlar da ADH ifraz\u0131n\u0131 art\u0131r\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin tam qan olaraq g\u00f6nd\u0259rilm\u0259si<\/p>\n

Referens:<\/strong>\u00a0<8 pg\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Ektopik ADH ifraz ed\u0259n \u015fi\u015f\u00adl\u0259r, k\u0259skin intermittant porfiriya, Gu\u00adillian-Barre sindromu, beyin \u015fi\u015f\u00adl\u0259ri, vas\u00adkulyar v\u0259 infeksion beyin x\u0259s\u00adt\u0259lik\u00adl\u0259\u00adri, pnevmoniya, a\u011fciy\u0259r v\u0259\u00adr\u0259mi, v\u0259\u00adr\u0259m meningiti v\u0259 beyin m\u0259n\u00ad\u015f\u0259li \u015f\u0259\u00adk\u0259r\u00adsiz diabet, psixogen poli\u00addipsiya v\u0259 nef\u00adrotik sindromda ADH s\u0259viyy\u0259si azal\u0131r. M\u0259rk\u0259zi v\u0259 nefro\u00adgen \u015f\u0259k\u0259rsiz diabet v\u0259 ya psixogen polidipsiyan\u0131n diffe\u00adren\u00adsial diaqnos\u00adi\u00adkas\u0131 \u00fc\u00e7\u00fcn ADH stimuli\u00adyasiya testl\u0259ri istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANG\u0130OTENZ\u0130N II<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u00fcsi<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011f\u00adramadan soyuq \u015f\u0259raitd\u0259 tez ayr\u0131l\u00adma\u00adl\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259\u00adrilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>N\u00fcmun\u0259 al\u0131n\u00ad\u00admazdan \u0259vv\u0259l x\u0259st\u0259 30 d\u0259qiq\u0259 istirah\u0259t etm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131\u00adl\u0131q, n\u00fcmun\u0259nin soyuq \u015f\u0259raitd\u0259 g\u00f6n\u00add\u0259\u00adrilm\u0259m\u0259si v\u0259 tam qan olaraq g\u00f6n\u00add\u0259rilm\u0259si<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
1 ay-5 ya\u015f<\/td>\n2-25 pmol\/L<\/td>\n<\/tr>\n
6-11 ya\u015f<\/td>\n15-40 pmol\/L<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n20-40 pmol\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Renin-angiotenzin siste\u00admi\u00adnin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Hipertoniya, renin ifraz ed\u0259n \u015fi\u015f\u00adl\u0259r,\u00a0h\u0259cmin y\u00fckl\u0259m\u0259si<\/strong>, konjestiv (dur\u00ad\u011funluq) \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 sirrozda plazmada angiotenzin II-nin miqdar\u0131 art\u0131r. Birincili aldoste\u00adro\u00adnizm, Cushing sindromu v\u0259 ACE in\u00adhibitorlar\u0131 is\u0259 angiotenzin II-nin miq\u00addar\u0131n\u0131 azald\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANDROSTENED\u0130ON<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>G\u00fcn\u00add\u0259lik variasiyas\u0131 var. S\u0259h\u0259r saat 06.00-08.00 aras\u0131nda maksimum, g\u00fcnortadan sonra saat 16.00-da is\u0259 minumum s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya v\u0259 yax\u0131n zamanda radioizotop istifad\u0259si<\/p>\n

Referens:\u00a0<\/strong>0.4-4.5 ng\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Androstenedion androgen v\u0259 esterogenl\u0259rin sintezind\u0259 \u0259sas pre\u00adkursordur. Androgen poz\u011funluq\u00adla\u00adr\u0131n\u0131n diaqnoqnozu v\u0259 m\u00fc\u015fahid\u0259\u00adsind\u0259 dig\u0259r hormon testl\u0259ri il\u0259 b\u0259rab\u0259r isti\u00adfad\u0259 olunur. Yumurtal\u0131qlar\u0131n poli\u00adkis\u00adtoz\u00a0 sindromu, t\u00fckl\u0259nm\u0259 (hir\u015futizim), anadang\u0259lm\u0259 adrenal hiper\u00adplaziya, Cushing sindromu, ektopik ACTH sintez ed\u0259n b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r v\u0259 yumurtal\u0131q \u015fi\u015fl\u0259rind\u0259 androstenedion s\u0259viyy\u0259si art\u0131r, \u0259ksin\u0259 oraq h\u00fcceyr\u0259li anemiya, adrenal \u00e7at\u0131\u015fmazl\u0131q v\u0259 yu\u00admurtal\u0131q \u00e7at\u0131\u00e7mazl\u0131qlar\u0131nda is\u0259 aza\u00adl\u0131r. Androstenedion n\u0259tic\u0259l\u0259ri qiy\u00adm\u0259t\u00adl\u0259n\u00addiril\u0259rk\u0259n x\u0259st\u0259nin dig\u0259r kli\u00adnik \u0259lam\u0259tl\u0259rini d\u0259 n\u0259z\u0259r\u0259 almaq laz\u0131md\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALFA-FETOPROTE\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AFP; \u221e -Fetoprotein<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz v\u0259 lipemiya<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n
< 7 g\u00fcn<\/td>\n100-270 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hepatosellular r\u00fc\u015feym h\u00fcceyr\u0259li (nonseminomalar) karsino\u00admalarda istifad\u0259 olunan onko\u00admar\u00adkerdir. X\u00fcsusil\u0259 hepatosellular kar\u00adsinomalarda proqnozun v\u0259 m\u00fca\u00adli\u00adc\u0259nin effektivliyinin m\u00fc\u015fahid\u0259si ba\u00adx\u0131m\u0131ndan \u00e7ox faydal\u0131d\u0131r. R\u00fc\u015feym h\u00fc\u00adceyr\u0259li karsinomalar\u0131n t\u0259snifat\u0131 v\u0259 d\u0259r\u0259c\u0259l\u0259ndirilm\u0259sind\u0259 hCG il\u0259 bir\u00adlik\u00adt\u0259 istifad\u0259 olunur. Dig\u0259r b\u0259zi x\u0259r\u00ad\u00e7\u0259ngl\u0259rd\u0259 d\u0259 (m\u0259s. pankreas, m\u0259d\u0259, yo\u011fun ba\u011f\u0131rsaq, a\u011fciy\u0259r v\u0259 s.) AFP s\u0259viyy\u0259si y\u00fcks\u0259l\u0259 bil\u0259r. H\u0259m\u00e7inin sirroz, hepatit v\u0259 alkaqol il\u0259 \u0259laq\u0259li qaraciy\u0259r x\u0259st\u0259likl\u0259ri kimi b\u0259zi xo\u015f\u00adxass\u0259li prosesl\u0259rd\u0259 d\u0259 serumda AFP s\u0259viyy\u0259l\u0259rind\u0259 y\u00fcks\u0259lm\u0259 m\u00fc\u015fahid\u0259 oluna bil\u0259r (Bax C\u0259dv\u0259l-7). Ha\u00admi\u00adl\u0259lik m\u00fcdd\u0259tind\u0259 maternal AFP s\u0259\u00adviyy\u0259sinin \u00f6l\u00e7\u00fclm\u0259sid\u0259 \u0259h\u0259miyy\u0259t\u00adli\u00addir. Maternal AFP 12-ci h\u0259ft\u0259d\u0259n eti\u00adbar\u0259n artma\u011fa ba\u015flay\u0131r (hamil\u0259likd\u0259 AFP-nin istifad\u0259si \u00fc\u00e7\u00fcn\u00a0 bax: \u00dc\u00e7l\u00fc skrininq testi v\u0259 AFP \u2013 hamil\u0259lik)<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALDOSTERON (Sidikd\u0259)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a024 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a024 saatl\u0131q sidik ase\u00adtat tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131laraq\u00a0 g\u00f6nd\u0259\u00adrilm\u0259lidir. Bor tur\u015fusu v\u0259 6 N HCl \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidik n\u00fcmun\u0259l\u0259ri, h\u0259m\u00ad\u00e7inin y\u0131\u011f\u0131ld\u0131qdan sonra soyuq \u015f\u0259raitd\u0259 saxlanan sidikl\u0259r d\u0259 q\u0259bul edil\u0259 bil\u0259r. N\u00fcmun\u0259l\u0259r labora\u00adto\u00adriya\u00adya soyuq \u015f\u0259\u00adraitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>N\u00fcmun\u0259 g\u00f6\u00adt\u00fcr\u00fclm\u0259zd\u0259n \u0259vv\u0259l x\u0259st\u0259 normal duzlu p\u0259hriz saxlamal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>R\u0130A<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
< 12 ya\u015f<\/td>\n1.0-11.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
\u00a0>12 ya\u015f<\/td>\n2.8-30.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>B\u00f6yr\u0259k funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. X\u00fcsusil\u0259 hipertenziyan\u0131n qiy\u00adm\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 v\u0259 renal hiper\u00adten\u00adziya diaqnozunun t\u0259yinind\u0259 \u0259h\u0259\u00admiyy\u0259tlidir. H\u0259m\u00e7inin birincili v\u0259 ikincili aldosteronizmin t\u0259dqiqind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALDOSTERON<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Normal duz\u00adlu p\u0259hriz veril\u0259n x\u0259st\u0259\u00a0 son iki saat ey\u00adni v\u0259ziyy\u0259td\u0259 durmal\u0131d\u0131r (ayaq\u00fcst\u0259 v\u0259 ya istirah\u0259t v\u0259ziyy\u0259tind\u0259). Bundan ba\u015f\u00adqa son iki h\u0259ft\u0259d\u0259 diuretik, esterogen v\u0259 siklik progestasional d\u0259rmanlar\u00a0 istifad\u0259 etm\u0259m\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz v\u0259 lipemiya<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
< 6 ay<\/td>\n20-1600 pg\/mL<\/td>\n<\/tr>\n
7-12ay<\/td>\n20-760 pg\/mL<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n20-500 pg\/mL<\/td>\n<\/tr>\n
>\u00a03ya\u015f<\/td>\n20-240 pg\/mL<\/td>\n<\/tr>\n
\u0130stirah\u0259t<\/td>\n10-180 pg\/mL<\/td>\n<\/tr>\n
Stresd\u0259n sonra\u00a0< 1 ay<\/td>\n50-300 pg\/mL<\/td>\n<\/tr>\n
2-12ay<\/td>\n50-1600 pg\/mL<\/td>\n<\/tr>\n
>12 ay<\/td>\n50-300 pg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndrilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Aldosteron ifraz ed\u0259n adeno\u00adma\u00adlar, karsinomalar, pseudoprimer al\u00addosteronizm v\u0259 ikincili aldoste\u00adro\u00adnizmd\u0259 serumda aldosteron s\u0259viy\u00ady\u0259\u00adsi art\u0131r. \u0130zol\u0259 aldosteron \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, Addison x\u0259st\u0259liyi v\u0259 renin \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131nda is\u0259 aldosteron s\u0259viyy\u0259si aza\u00adl\u0131r. Aldosteron v\u0259 renin miqdar\u0131n\u0131n eyni zamanda t\u0259yini birincili-ikincili (primer-sekonder) hiperaldoste\u00adro\u00adniz\u00ad\u00admin differensiasiyas\u0131 \u00fc\u00e7\u00fcn \u0259h\u0259\u00admiy\u00ady\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AGR\u0130N\u0130N VAZOPRESS\u0130N HORMON (ANT\u0130D\u0130URET\u0130K HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ADH; Vazoperssin; Argi\u00adnin vazopressin hormon; AVP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 Plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00ad\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00ad\u00adliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 t\u0259\u00adcili ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6n\u00add\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Plazmadak\u0131 ADH s\u0259viyy\u0259sin\u0259 t\u0259sir ed\u0259n bir \u00e7ox fak\u00ad\u00adtor var. Ayaq \u00fcst\u0259 durmaq, a\u011fr\u0131, sters, gimnastika, plazma osmol\u00adyar\u00adl\u0131\u00ad\u011f\u0131n\u0131n (osmolalite) artmas\u0131 v\u0259 qan\u0131n h\u0259c\u00adminin, yaxud, arterial t\u0259zyiqin azal\u00admas\u0131 v\u0259 gec\u0259l\u0259r ADH ifraz\u0131 art\u0131r, isti\u00adra\u00adh\u0259t, hipoosmolyarl\u0131q, qan\u0131n h\u0259c\u00ad\u00adminin art\u00admas\u0131 v\u0259 hipertenziya zaman\u0131is\u0259 aza\u00adl\u0131r. H\u0259m\u00e7inin xlor\u00adpro\u00adpa\u00admid, tiazid, di\u00adu\u00adretk\u00adl\u0259r v\u0259 s. d\u0259r\u00admanlar da ADH ifraz\u0131n\u0131 art\u0131r\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin tam qan olaraq g\u00f6nd\u0259rilm\u0259si<\/p>\n

Referens:<\/strong>\u00a0<8 pg\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Ektopik ADH ifraz ed\u0259n \u015fi\u015f\u00adl\u0259r, k\u0259skin intermittant porfiriya, Gu\u00adillian-Barre sindromu, beyin \u015fi\u015f\u00adl\u0259ri, vas\u00adkulyar v\u0259 infeksion beyin x\u0259s\u00adt\u0259lik\u00adl\u0259\u00adri, pnevmoniya, a\u011fciy\u0259r v\u0259\u00adr\u0259mi, v\u0259\u00adr\u0259m meningiti v\u0259 beyin m\u0259n\u00ad\u015f\u0259li \u015f\u0259\u00adk\u0259r\u00adsiz diabet, psixogen poli\u00addipsiya v\u0259 nef\u00adrotik sindromda ADH s\u0259viyy\u0259si azal\u0131r. M\u0259rk\u0259zi v\u0259 nefro\u00adgen \u015f\u0259k\u0259rsiz diabet v\u0259 ya psixogen polidipsiyan\u0131n diffe\u00adren\u00adsial diaqnos\u00adi\u00adkas\u0131 \u00fc\u00e7\u00fcn ADH stimuli\u00adyasiya testl\u0259ri istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AFP (ALFA-FETOPROTE\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AFP; \u221e -Fetoprotein<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz v\u0259 lipemiya<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n
>6ay<\/td>\n<14ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hepatosellular r\u00fc\u015feym h\u00fcceyr\u0259li (nonseminomalar) karsino\u00admalarda istifad\u0259 olunan onko\u00admar\u00adkerdir. X\u00fcsusil\u0259 hepatosellular kar\u00adsinomalarda proqnozun v\u0259 m\u00fca\u00adli\u00adc\u0259nin effektivliyinin m\u00fc\u015fahid\u0259si ba\u00adx\u0131m\u0131ndan \u00e7ox faydal\u0131d\u0131r. R\u00fc\u015feym h\u00fc\u00adceyr\u0259li karsinomalar\u0131n t\u0259snifat\u0131 v\u0259 d\u0259r\u0259c\u0259l\u0259ndirilm\u0259sind\u0259 hCG il\u0259 bir\u00adlik\u00adt\u0259 istifad\u0259 olunur. Dig\u0259r b\u0259zi x\u0259r\u00ad\u00e7\u0259ngl\u0259rd\u0259 d\u0259 (m\u0259s. pankreas, m\u0259d\u0259, yo\u011fun ba\u011f\u0131rsaq, a\u011fciy\u0259r v\u0259 s.) AFP s\u0259viyy\u0259si y\u00fcks\u0259l\u0259 bil\u0259r. H\u0259m\u00e7inin sirroz, hepatit v\u0259 alkaqol il\u0259 \u0259laq\u0259li qaraciy\u0259r x\u0259st\u0259likl\u0259ri kimi b\u0259zi xo\u015f\u00adxass\u0259li prosesl\u0259rd\u0259 d\u0259 serumda AFP s\u0259viyy\u0259l\u0259rind\u0259 y\u00fcks\u0259lm\u0259 m\u00fc\u015fahid\u0259 oluna bil\u0259r (Bax C\u0259dv\u0259l-7). Ha\u00admi\u00adl\u0259lik m\u00fcdd\u0259tind\u0259 maternal AFP s\u0259\u00adviyy\u0259sinin \u00f6l\u00e7\u00fclm\u0259sid\u0259 \u0259h\u0259miyy\u0259t\u00adli\u00addir. Maternal AFP 12-ci h\u0259ft\u0259d\u0259n eti\u00adbar\u0259n artma\u011fa ba\u015flay\u0131r (hamil\u0259likd\u0259 AFP-nin istifad\u0259si \u00fc\u00e7\u00fcn\u00a0 bax: \u00dc\u00e7l\u00fc skrininq testi v\u0259 AFP \u2013 hamil\u0259lik).<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AFP (ALFA-FETOPROTE\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AFP; \u221e -Fetoprotein<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz v\u0259 lipemiya<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n
>6ay<\/td>\n<14ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hepatosellular r\u00fc\u015feym h\u00fcceyr\u0259li (nonseminomalar) karsino\u00admalarda istifad\u0259 olunan onko\u00admar\u00adkerdir. X\u00fcsusil\u0259 hepatosellular kar\u00adsinomalarda proqnozun v\u0259 m\u00fca\u00adli\u00adc\u0259nin effektivliyinin m\u00fc\u015fahid\u0259si ba\u00adx\u0131m\u0131ndan \u00e7ox faydal\u0131d\u0131r. R\u00fc\u015feym h\u00fc\u00adceyr\u0259li karsinomalar\u0131n t\u0259snifat\u0131 v\u0259 d\u0259r\u0259c\u0259l\u0259ndirilm\u0259sind\u0259 hCG il\u0259 bir\u00adlik\u00adt\u0259 istifad\u0259 olunur. Dig\u0259r b\u0259zi x\u0259r\u00ad\u00e7\u0259ngl\u0259rd\u0259 d\u0259 (m\u0259s. pankreas, m\u0259d\u0259, yo\u011fun ba\u011f\u0131rsaq, a\u011fciy\u0259r v\u0259 s.) AFP s\u0259viyy\u0259si y\u00fcks\u0259l\u0259 bil\u0259r. H\u0259m\u00e7inin sirroz, hepatit v\u0259 alkaqol il\u0259 \u0259laq\u0259li qaraciy\u0259r x\u0259st\u0259likl\u0259ri kimi b\u0259zi xo\u015f\u00adxass\u0259li prosesl\u0259rd\u0259 d\u0259 serumda AFP s\u0259viyy\u0259l\u0259rind\u0259 y\u00fcks\u0259lm\u0259 m\u00fc\u015fahid\u0259 oluna bil\u0259r (Bax C\u0259dv\u0259l-7). Ha\u00admi\u00adl\u0259lik m\u00fcdd\u0259tind\u0259 maternal AFP s\u0259\u00adviyy\u0259sinin \u00f6l\u00e7\u00fclm\u0259sid\u0259 \u0259h\u0259miyy\u0259t\u00adli\u00addir. Maternal AFP 12-ci h\u0259ft\u0259d\u0259n eti\u00adbar\u0259n artma\u011fa ba\u015flay\u0131r (hamil\u0259likd\u0259 AFP-nin istifad\u0259si \u00fc\u00e7\u00fcn\u00a0 bax: \u00dc\u00e7l\u00fc skrininq testi v\u0259 AFP \u2013 hamil\u0259lik).<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ADRENOKORT\u0130KOTROP HORMON<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ACTH; Kortikotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir. N\u00fcmun\u0259nin al\u0131nma zaman\u0131 \u0259h\u0259miyy\u0259tlidir. Plazmadak\u0131 ACTH miqdar\u0131\u00a0 saat 06.00 \u2013 08.00 aras\u0131nda maksimum, 21.00 \u2013 22.00 aras\u0131nda is\u0259 minimum s\u0259viyy\u0259d\u0259 olur. Bundan ba\u015fqa hamil\u0259lik, mens\u00adtrual sikl v\u0259 stres zaman\u0131 da plaz\u00admadak\u0131 s\u0259viyy\u0259 d\u0259yi\u015fir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00adsiz hemoliz, lipemiya, n\u00fcmun\u0259nin tam qan formas\u0131nda g\u00f6nd\u0259rilm\u0259si<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
S\u0259h\u0259r<\/td>\n<100 pg\/ml<\/td>\n<\/tr>\n
Ax\u015fam<\/td>\n<80 pg\/ml<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipofiz v\u0259zinin fun\u00adkiyas\u0131n\u0131 g\u00f6st\u0259rir. Hiperkortizolizm (Cushing sindromu, ektopik ACTH sindromu v\u0259 ektopik CRH ifraz\u0131), hipokortizolizm (Addison x\u0259st\u0259liyi, ikincili\u00a0 adrenal \u00e7at\u0131\u015fmazl\u0131q, hipota\u00adlamus hormonlar\u0131n\u0131n \u00e7at\u0131\u015fmazl\u0131\u011f\u0131), kongenital adrenal hiperplaziya v\u0259 adrenal karsinomalar\u0131n differensial diaqnostikas\u0131nda istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

COMPOUND S (11-DEOKS\u0130KORT\u0130ZOL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Compound S<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<8 ng\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>11 \u03b2-hidroksilaza \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131 il\u0259 \u0259laq\u0259dar adrenokortikal hiperplaziya, adrenal karsinomalar v\u0259 ACTH s\u0259viyy\u0259sinin artd\u0131\u011f\u0131 hal\u00adlarda serumda 11-deoksikortizolun s\u0259viyy\u0259si d\u0259 art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

DEH\u0130DROEP\u0130ANDROSTERON SULFAT<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0DHEA-S; DHEA-SO4<\/sub>; DHEA-sulfat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
1-12 ya\u015f<\/td>\n100-835 ng\/mL<\/td>\n100-995 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n700-2500 ng\/mL<\/td>\n200-2500 ng\/mL<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n700-4500 ng\/mL<\/td>\n200-3500 ng\/mL<\/td>\n<\/tr>\n
21-30 ya\u015f<\/td>\n700-4700 ng\/mL<\/td>\n480-4000 ng\/mL<\/td>\n<\/tr>\n
31-40 ya\u015f<\/td>\n540-2800 ng\/mL<\/td>\n200-3400 ng\/mL<\/td>\n<\/tr>\n
41-50 ya\u015f<\/td>\n520-2800 ng\/mL<\/td>\n100-2800 ng\/mL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n215-2000 ng\/mL<\/td>\n100-2500 ng\/mL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n100-2000 ng\/mL<\/td>\n100-1100 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Androgen azl\u0131\u011f\u0131 v\u0259 ya art\u0131ql\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0131sind\u0259 is\u00adti\u00adfad\u0259 olunur. Hir\u015futizm, amenoreya, yumurtal\u0131qlar\u0131n polikistoz sindromu, anadang\u0259lm\u0259 adrenal hiperplaziya v\u0259 adrenal karsi\u00adnomalar\u0131n qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 \u0259h\u0259miyy\u0259tlidir. Dig\u0259r androgenl\u0259rl\u0259 (testesteron v\u0259 andro\u00adstenedion) b\u0259rab\u0259r qiym\u0259tl\u0259ndiril\u00adm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

DHEA SULFAT (DEH\u0130DROEP\u0130ANDROSTERON SULFAT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0DHEA-S; DHEA-SO4<\/sub>; DHEA-sulfat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
1-12 ya\u015f<\/td>\n100-835 ng\/mL<\/td>\n100-995 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n700-2500 ng\/mL<\/td>\n200-2500 ng\/mL<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n700-4500 ng\/mL<\/td>\n200-3500 ng\/mL<\/td>\n<\/tr>\n
21-30 ya\u015f<\/td>\n700-4700 ng\/mL<\/td>\n480-4000 ng\/mL<\/td>\n<\/tr>\n
31-40 ya\u015f<\/td>\n540-2800 ng\/mL<\/td>\n200-3400 ng\/mL<\/td>\n<\/tr>\n
41-50 ya\u015f<\/td>\n520-2800 ng\/mL<\/td>\n100-2800 ng\/mL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n215-2000 ng\/mL<\/td>\n100-2500 ng\/mL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n100-2000 ng\/mL<\/td>\n100-1100 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Androgen azl\u0131\u011f\u0131 v\u0259 ya art\u0131ql\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0131sind\u0259 is\u00adti\u00adfad\u0259 olunur. Hir\u015futizm, amenoreya, yumurtal\u0131qlar\u0131n polikistoz sindromu, anadang\u0259lm\u0259 adrenal hiperplaziya v\u0259 adrenal karsi\u00adnomalar\u0131n qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 \u0259h\u0259miyy\u0259tlidir. Dig\u0259r androgenl\u0259rl\u0259 (testesteron v\u0259 andro\u00adstenedion) b\u0259rab\u0259r qiym\u0259tl\u0259ndiril\u00adm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

DHEA-SO4 (DEH\u0130DROEP\u0130ANDROSTERON SULFAT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0DHEA-S; DHEA-SO4<\/sub>; DHEA-sulfat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
1-12 ya\u015f<\/td>\n100-835 ng\/mL<\/td>\n100-995 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n700-2500 ng\/mL<\/td>\n200-2500 ng\/mL<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n700-4500 ng\/mL<\/td>\n200-3500 ng\/mL<\/td>\n<\/tr>\n
21-30 ya\u015f<\/td>\n700-4700 ng\/mL<\/td>\n480-4000 ng\/mL<\/td>\n<\/tr>\n
31-40 ya\u015f<\/td>\n540-2800 ng\/mL<\/td>\n200-3400 ng\/mL<\/td>\n<\/tr>\n
41-50 ya\u015f<\/td>\n520-2800 ng\/mL<\/td>\n100-2800 ng\/mL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n215-2000 ng\/mL<\/td>\n100-2500 ng\/mL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n100-2000 ng\/mL<\/td>\n100-1100 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Androgen azl\u0131\u011f\u0131 v\u0259 ya art\u0131ql\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0131sind\u0259 is\u00adti\u00adfad\u0259 olunur. Hir\u015futizm, amenoreya, yumurtal\u0131qlar\u0131n polikistoz sindromu, anadang\u0259lm\u0259 adrenal hiperplaziya v\u0259 adrenal karsi\u00adnomalar\u0131n qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 \u0259h\u0259miyy\u0259tlidir. Dig\u0259r androgenl\u0259rl\u0259 (testesteron v\u0259 andro\u00adstenedion) b\u0259rab\u0259r qiym\u0259tl\u0259ndiril\u00adm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

E2 (ESRTAD\u0130OL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>E2<\/sub>\u00a0; 17-\u03b2-estradiol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<12 ya\u015f<\/td>\n2-18 pg\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n11-38 pg\/mL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n30-119 pg\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n10-35 pg\/mL<\/td>\n<\/tr>\n
Menopauza<\/td>\n10-35 pg\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n30-119 pg\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n149-350 pg\/mL<\/td>\n<\/tr>\n
Luteal faza<\/td>\n97-216 pg\/mL<\/td>\n<\/tr>\n
Ovulasiya m\u00fc\u015fahid\u0259si<\/td>\n29-97 pg\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<12 ya\u015f<\/td>\n2-18 pg\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n11-38 pg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Orqanizimd\u0259ki \u0259n t\u0259sirli endogen esterogendir. Puberte pre\u00adkoks, amenoreya,\u00a0 ovulyasiya\u00a0 in\u00adduk\u00adsiyas\u0131n\u0131n m\u00fc\u015fahid\u0259si v\u0259 ki\u015fil\u0259rd\u0259 gineko\u00admastiyan\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsind\u0259 isitifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

E3 (ESTR\u0130OL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>E3<\/sub>\u00a0; Unkonjuge E3<\/sub>\u00a0; uE3<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildiril\u0259c\u0259kdir<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Fetoplasental d\u00f6vr\u00fcn qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. S\u0259rb\u0259st E3<\/sub>\u00a0miqdar\u0131 \u00fcmumi E3<\/sub>-l\u0259\u00a0 m\u00fc\u00adqa\u00adyis\u0259d\u0259 daha spesifikdir. N\u0259tic\u0259l\u0259r x\u0259st\u0259d\u0259n as\u0131l\u0131 olaraq d\u0259yi\u015f\u0259 bil\u00addi\u00adyind\u0259n bir ne\u00e7\u0259 ard\u0131c\u0131l m\u00fcayin\u0259 apa\u00adr\u0131lmal\u0131d\u0131r. Bundan ba\u015fqa, s\u0259h\u0259rl\u0259r konsentrasiyas\u0131 daha y\u00fcks\u0259k olur. Hamil\u0259lik m\u00fcdd\u0259tind\u0259 s\u0259rb\u0259st E3\u00a0<\/sub>daim y\u00fcks\u0259lir, do\u011fu\u015fun ba\u015flamas\u0131 il\u0259 birlikd\u0259 daha k\u0259skin y\u00fcks\u0259lm\u0259 ba\u015f verir. Diabetli hamil\u0259l\u0259r, post-date hestasiya v\u0259 b\u0259tndaxili inki\u015faf\u0131n ge\u00addi\u015finin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 s\u0259r\u00adb\u0259st E3\u00a0<\/sub>istifad\u0259 oluna bil\u0259r. D\u00f6ld\u0259 m\u0259rk\u0259zi sinir sisteminin malfor\u00adma\u00adsiyas\u0131, anadang\u0259lm\u0259 qapaq x\u0259st\u0259\u00adlik\u00adl\u0259ri v\u0259 ya Daun sindromunda se\u00adrum\u00adda s\u0259rb\u0259st E3\u00a0\u00a0<\/sub>s\u0259viyy\u0259sind\u0259 azal\u00adma m\u00fc\u015fahid\u0259 oluna bil\u0259r. Hami\u00adl\u0259\u00adliyin 35-36-c\u0131 h\u0259ft\u0259l\u0259rind\u0259 d\u00f6l\u00fcn ya\u015f\u0131n\u0131n hesablanmas\u0131nda da s\u0259rb\u0259st E3\u00a0<\/sub>isti\u00adfad\u0259 oluna bil\u0259r. H\u0259m\u00e7inin II tri\u00admes\u00adterd\u0259 hCG v\u0259 AFP il\u0259 birg\u0259 istifad\u0259 olunaraq risk skrininqi apar\u0131la bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ESRTAD\u0130OL<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>E2<\/sub>\u00a0; 17-\u03b2-estradiol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n

<tdrowspan=’9′>Qad\u0131n<\/tdrowspan=’9′><tdrowspan=’2′>Ki\u015fi<\/tdrowspan=’2′><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<12ya\u015f<\/td>\n2-18pg\/mL<\/td>\n<\/tr>\n
13-15ya\u015f<\/td>\n11-38pg\/mL<\/td>\n<\/tr>\n
16-50ya\u015f<\/td>\n30-119pg\/mL<\/td>\n<\/tr>\n
>50ya\u015f<\/td>\n10-35pg\/mL<\/td>\n<\/tr>\n
Menopauza<\/td>\n10-35pg\/mL<\/td>\n<\/tr>\n
Follikulyarfaza<\/td>\n30-119pg\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n149-350pg\/mL<\/td>\n<\/tr>\n
Lutealfaza<\/td>\n97-216pg\/mL<\/td>\n<\/tr>\n
Ovulasiyam\u00fc\u015fahid\u0259si<\/td>\n29-97pg\/mL<\/td>\n<\/tr>\n
<12ya\u015f<\/td>\n2-18pg\/mL<\/td>\n<\/tr>\n
>12ya\u015f<\/td>\n11-38pg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Orqanizimd\u0259ki \u0259n t\u0259sirli endogen esterogendir. Puberte pre\u00adkoks, amenoreya,\u00a0 ovulyasiya\u00a0 in\u00adduk\u00adsiyas\u0131n\u0131n m\u00fc\u015fahid\u0259si v\u0259 ki\u015fil\u0259rd\u0259 gineko\u00admastiyan\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsind\u0259 isitifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

REN\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Plazma renin aktivliyi; PRA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 al\u0131nd\u0131qdan sonra plazma hemoliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Az duzlu p\u0259hriz, ayaq \u00fcst\u0259 durmaq, diuretikl\u0259r v\u0259 hamil\u0259lik plazmada reninin s\u0259viyy\u0259sini art\u0131r\u0131r, y\u00fcks\u0259k duzlu p\u0259hriz is\u0259 renin s\u0259viyy\u0259sini azald\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n att\u0131q hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259m\u0259si<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<1 ya\u015f<\/td>\n2.4-37.0 ng\/mL\/saat<\/td>\n<\/tr>\n
2-3 ya\u015f<\/td>\n1.7-11.2 ng\/mL\/saat<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n1.0-6.5 ng\/mL\/saat<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n0.5-5.9 ng\/mL\/saat<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.5-5.0 ng\/mL\/saat<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.2-3.4 ng\/mL\/saat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hipertenziyan\u0131n qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. B\u00f6yr\u0259k parenximas\u0131n\u0131n x\u0259st\u0259likl\u0259ri, renin ifraz ed\u0259n \u015fi\u015fl\u0259r, oral kon\u00adtraseptiv m\u0259n\u015f\u0259li hipertenziya, feo\u00adxro\u00admasitoma, sirroz, hepatit, \u00fcr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131, Bartter sindromu v\u0259 elektrolit itkisi olan hallarda plaz\u00admada renin aktivliyi art\u0131r, birincili al\u00addosteronizm, psevdohipe\u00adraldos\u00adte\u00adro\u00adnizm v\u0259 hiperkalemiyada is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PTH (PARAT\u0130RO\u0130D HORMON (\u0130NTAKT))<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PTH; Parathyrin; Pa\u00adrathormon<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 plazma, serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 plazma), q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin 1 saatdan art\u0131q otaq temperaturunda saxlan\u0131lmas\u0131<\/p>\n

Referens:<\/strong>10-65 pg\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sad\u0259c\u0259 bioloji baximdan intakt olan PTH molekullar\u0131 \u00f6l\u00e7\u00fcl\u00fcr. \u0130lkin hiperparatiroidizm v\u0259 b\u0259d\u00adxas\u00ads\u0259li t\u00f6r\u0259m\u0259 m\u0259n\u015f\u0259li hiperkal\u00adse\u00admi\u00adyan\u0131n differensasiyas\u0131nda istifad\u0259 olunur. \u0130onla\u015fm\u0131\u015f kalsium t\u0259r\u0259find\u0259n t\u0259nziml\u0259nir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PSA (PROSTAT-SPES\u0130F\u0130K ANT\u0130GEN)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PSA; f\/t PSA; S\u0259r\u00adb\u0259st\/total PSA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

Test i\u00e7eri\u011fi:<\/strong>\u00a0Total v\u0259 s\u0259rb\u0259st PSA v\u0259 onlar\u0131n bir-birin\u0259 nisb\u0259ti<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Rektal m\u00fcayin\u0259 v\u0259 kateter istifad\u0259\u00adsind\u0259n sonra n\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 72 saat g\u00f6zl\u0259m\u0259k laz\u0131md\u0131r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0PSA s\u0259\u00adviyy\u0259si g\u00fcnd\u0259n-g\u00fcn\u0259 d\u0259yi\u015f\u0259 bil\u0259r v\u0259 ya\u015fla birlikd\u0259 art\u0131r. H\u0259m\u00e7inin ar\u00adxas\u0131\u00fcstd\u0259 v\u0259ziyy\u0259t PSA s\u0259viyy\u0259sini azald\u0131r, prostat manipulyasiyalar\u0131 is\u0259 PSA s\u0259viyy\u0259sind\u0259 art\u0131ma s\u0259b\u0259b olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
>20 ya\u015f Total PSA<\/td>\n<4 ng\/mL<\/td>\n<\/tr>\n
S\u0259rb\u0259st PSA<\/td>\n<1 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Prostat x\u0259st\u0259likl\u0259rinin (x\u00fcsusil\u0259 prostat karsinomalar\u0131 v\u0259 xo\u015fxass\u0259li prostat hiperplaziyas\u0131) diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROSTAT\u0130K TUR\u015e FOSFATAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PAP; Prostat spesifik tur\u015f fosfataza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Rek\u00adtal m\u00fcayin\u0259 v\u0259 kateter istifad\u0259sin\u00add\u0259n sonra n\u00fcmun\u0259 al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 72 saat g\u00f6zl\u0259m\u0259k laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 radioizotop istifad\u0259si<\/p>\n

Referens:<\/strong>\u00a0<3 ng\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Prostatdan ifraz olunan qlikoproteindir. Prostat v\u0259zinin b\u0259d\u00adxass\u0259li \u015fi\u015fl\u0259ri, biopsiya, kate\u00adteri\u00adzasiya, \u0259laq\u0259d\u0259n sonra, \u0259m\u0259liyyatdan sonrak\u0131 d\u00f6vr, xo\u015fxass\u0259li prostat hiperplaziyas\u0131, prostatit, prostat infarkt\u0131 v\u0259 s. hallarda prostatik tur\u015f fosfataza s\u0259viyy\u0259si art\u0131r. Prostat x\u0259r\u00e7\u0259ngl\u0259ri \u00fc\u00e7\u00fcn skrininq m\u0259qs\u0259dil\u0259 istifad\u0259 etm\u0259k olmaz. Klinik istifad\u0259si metastatik prostat v\u0259zi x\u0259r\u00e7\u0259ngl\u0259rinin t\u0259sdiql\u0259nm\u0259si v\u0259 d\u0259r\u0259c\u0259l\u0259nd\u0259rilm\u0259si il\u0259 m\u0259hduddur. H\u0259m\u00e7inin radikal prostatektomiyal\u0131 x\u0259st\u0259l\u0259rd\u0259 t\u0259krarlanman\u0131n (rekur\u00adrens) m\u00fc\u015fahid\u0259si v\u0259 m\u00fcalic\u0259y\u0259 cavab\u0131n m\u00fc\u015fahid\u0259sind\u0259 d\u0259 k\u00f6m\u0259k\u00e7i testdir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROSTAT-SPES\u0130F\u0130K ANT\u0130GEN<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PSA; f\/t PSA; S\u0259r\u00adb\u0259st\/total PSA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

Test i\u00e7eri\u011fi:<\/strong>\u00a0Total v\u0259 s\u0259rb\u0259st PSA v\u0259 onlar\u0131n bir-birin\u0259 nisb\u0259ti<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Rektal m\u00fcayin\u0259 v\u0259 kateter istifad\u0259\u00adsind\u0259n sonra n\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 72 saat g\u00f6zl\u0259m\u0259k laz\u0131md\u0131r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0PSA s\u0259\u00adviyy\u0259si g\u00fcnd\u0259n-g\u00fcn\u0259 d\u0259yi\u015f\u0259 bil\u0259r v\u0259 ya\u015fla birlikd\u0259 art\u0131r. H\u0259m\u00e7inin ar\u00adxas\u0131\u00fcstd\u0259 v\u0259ziyy\u0259t PSA s\u0259viyy\u0259sini azald\u0131r, prostat manipulyasiyalar\u0131 is\u0259 PSA s\u0259viyy\u0259sind\u0259 art\u0131ma s\u0259b\u0259b olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
>20 ya\u015f Total PSA<\/td>\n<4 ng\/mL<\/td>\n<\/tr>\n
S\u0259rb\u0259st PSA<\/td>\n<1 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Prostat x\u0259st\u0259likl\u0259rinin (x\u00fcsusil\u0259 prostat karsinomalar\u0131 v\u0259 xo\u015fxass\u0259li prostat hiperplaziyas\u0131) diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROQESTERON<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0C-21 steroid; P4<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<12 ya\u015f<\/td>\n0.10-0.31 ng\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n0.10-1.00 ng\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n0.10-1.10 ng\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n0.10-1.10 ng\/mL<\/td>\n<\/tr>\n
L\u00fcteal faza<\/td>\n3.00-20.00 ng\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<12 ya\u015f<\/td>\n0.10-0.31 ng\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n0.10-1.00 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0 Ovulyasiya, sar\u0131 cisimin funksiyalar\u0131 v\u0259 hamil\u0259likd\u0259 plasental funksiyalar\u0131n qiym\u0259tl\u0259ndirilm\u0259si, in\u00adduk\u00adsiyan\u0131n m\u00fc\u015fahid\u0259si, proqes\u00adteron m\u00fcalic\u0259sinin v\u0259 erk\u0259n abort riski olan x\u0259st\u0259l\u0259rin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur. Anadang\u0259lm\u0259 ad\u00adre\u00adnal hiper\u00adpla\u00adziya, lipoid yumurtal\u0131q \u015fi\u015fl\u0259ri, teka l\u00fctein kistas\u0131, molyar hamil\u0259lik v\u0259 yumurtal\u0131q xorioepi\u00adteliomalar\u0131nda pro\u00adqesteron s\u0259viyy\u0259si art\u0131r, d\u00fc\u015f\u00fck (abortus) riskind\u0259, bi\u00adrin\u00adcili v\u0259 ya ikincili hipoqonadizm v\u0259 q\u0131sa l\u00fcteal faza sindromunda is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROLAKT\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PRL<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Yuxu, stress, idman, hamil\u0259lik v\u0259 cinsi \u0259laq\u0259d\u0259n (koitus) sonra prolaktin s\u0259viyy\u0259si art\u0131r. S\u0259h\u0259rl\u0259r prolaktin s\u0259viyy\u0259si maksimum olur. Buna g\u00f6r\u0259 d\u0259 x\u0259st\u0259 oyand\u0131qdan 3-4 saat sonra n\u00fcmun\u0259 al\u0131nmal\u0131d\u0131r.\u00a0 H\u0259m\u00e7inin x\u0259s\u00adt\u0259nin acqar\u0131na\u00a0 olmas\u0131 m\u0259sl\u0259h\u0259tdir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259dd\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n<5650 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
Yenido\u011fulmu\u015f<\/td>\n<330 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n<495 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n<125 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
Ya\u015f<\/td>\nQad\u0131n<\/td>\nKi\u015fi<\/td>\n<\/tr>\n
2-12 ay<\/td>\n8.25-41.25 ng\/mL<\/td>\n8.25-24.75 ng\/mL<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n3.00-19.75 ng\/mL<\/td>\n4.60-16.50 ng\/mL<\/td>\n<\/tr>\n
4-15 ya\u015f<\/td>\n5.25-29.50 ng\/mL<\/td>\n4.60-18.00 ng\/mL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n6.50-30.00 ng\/mL<\/td>\n3.50-20.00 ng\/mL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n4.50-25.00 ng\/mL<\/td>\n3.50-20.00 ng\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n6.50-30.00 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
Pik<\/td>\n6.50-30.00 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
L\u00fcteal faza<\/td>\n6.50-33.00 ng\/mL<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Prolaktin ifraz ed\u0259n \u015fi\u015fl\u0259r, hipotalamo-hipofizar x\u0259st\u0259lik\u00adl\u0259r, birincili hipotiroidizim, ano\u00adreksiya nervosa, yumurtal\u0131qlar\u0131n po\u00adlikistoz sindromu, b\u00f6yr\u0259k \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, insulin m\u0259n\u015f\u0259li hipo\u00adqli\u00adke\u00admiya v\u0259 b\u00f6yr\u0259k\u00fcst\u00fc v\u0259zin \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131nda serumda prolaktin s\u0259viyy\u0259si art\u0131r, Sheehan sindromunda is\u0259 prolaktin s\u0259viyy\u0259si azal\u0131r. Prolaktin ifraz ed\u0259n \u015fi\u015fl\u0259rd\u0259 m\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 \u0259h\u0259miyy\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PRL (PROLAKT\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PRL<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Yuxu, stress, idman, hamil\u0259lik v\u0259 cinsi \u0259laq\u0259d\u0259n (koitus) sonra prolaktin s\u0259viyy\u0259si art\u0131r. S\u0259h\u0259rl\u0259r prolaktin s\u0259viyy\u0259si maksimum olur. Buna g\u00f6r\u0259 d\u0259 x\u0259st\u0259 oyand\u0131qdan 3-4 saat sonra n\u00fcmun\u0259 al\u0131nmal\u0131d\u0131r.\u00a0 H\u0259m\u00e7inin x\u0259s\u00adt\u0259nin acqar\u0131na\u00a0 olmas\u0131 m\u0259sl\u0259h\u0259tdir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259dd\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n<5650 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
Yenido\u011fulmu\u015f<\/td>\n<330 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n<495 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n<125 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
Ya\u015f<\/td>\nQad\u0131n<\/td>\nKi\u015fi<\/td>\n<\/tr>\n
2-12 ay<\/td>\n8.25-41.25 ng\/mL<\/td>\n8.25-24.75 ng\/mL<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n3.00-19.75 ng\/mL<\/td>\n4.60-16.50 ng\/mL<\/td>\n<\/tr>\n
4-15 ya\u015f<\/td>\n5.25-29.50 ng\/mL<\/td>\n4.60-18.00 ng\/mL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n6.50-30.00 ng\/mL<\/td>\n3.50-20.00 ng\/mL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n4.50-25.00 ng\/mL<\/td>\n3.50-20.00 ng\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n6.50-30.00 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
Pik<\/td>\n6.50-30.00 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
L\u00fcteal faza<\/td>\n6.50-33.00 ng\/mL<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Prolaktin ifraz ed\u0259n \u015fi\u015fl\u0259r, hipotalamo-hipofizar x\u0259st\u0259lik\u00adl\u0259r, birincili hipotiroidizim, ano\u00adreksiya nervosa, yumurtal\u0131qlar\u0131n po\u00adlikistoz sindromu, b\u00f6yr\u0259k \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, insulin m\u0259n\u015f\u0259li hipo\u00adqli\u00adke\u00admiya v\u0259 b\u00f6yr\u0259k\u00fcst\u00fc v\u0259zin \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131nda serumda prolaktin s\u0259viyy\u0259si art\u0131r, Sheehan sindromunda is\u0259 prolaktin s\u0259viyy\u0259si azal\u0131r. Prolaktin ifraz ed\u0259n \u015fi\u015fl\u0259rd\u0259 m\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 \u0259h\u0259miyy\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PRA (REN\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Plazma renin aktivliyi; PRA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 al\u0131nd\u0131qdan sonra plazma hemoliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Az duzlu p\u0259hriz, ayaq \u00fcst\u0259 durmaq, diuretikl\u0259r v\u0259 hamil\u0259lik plazmada reninin s\u0259viyy\u0259sini art\u0131r\u0131r, y\u00fcks\u0259k duzlu p\u0259hriz is\u0259 renin s\u0259viyy\u0259sini azald\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n att\u0131q hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259m\u0259si<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<1 ya\u015f<\/td>\n2.4-37.0 ng\/mL\/saat<\/td>\n<\/tr>\n
2-3 ya\u015f<\/td>\n1.7-11.2 ng\/mL\/saat<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n1.0-6.5 ng\/mL\/saat<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n0.5-5.9 ng\/mL\/saat<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.5-5.0 ng\/mL\/saat<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.2-3.4 ng\/mL\/saat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hipertenziyan\u0131n qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. B\u00f6yr\u0259k parenximas\u0131n\u0131n x\u0259st\u0259likl\u0259ri, renin ifraz ed\u0259n \u015fi\u015fl\u0259r, oral kon\u00adtraseptiv m\u0259n\u015f\u0259li hipertenziya, feo\u00adxro\u00admasitoma, sirroz, hepatit, \u00fcr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131, Bartter sindromu v\u0259 elektrolit itkisi olan hallarda plaz\u00admada renin aktivliyi art\u0131r, birincili al\u00addosteronizm, psevdohipe\u00adraldos\u00adte\u00adro\u00adnizm v\u0259 hiperkalemiyada is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PLAZMA REN\u0130N AKT\u0130VL\u0130Y\u0130 (REN\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Plazma renin aktivliyi; PRA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 al\u0131nd\u0131qdan sonra plazma hemoliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Az duzlu p\u0259hriz, ayaq \u00fcst\u0259 durmaq, diuretikl\u0259r v\u0259 hamil\u0259lik plazmada reninin s\u0259viyy\u0259sini art\u0131r\u0131r, y\u00fcks\u0259k duzlu p\u0259hriz is\u0259 renin s\u0259viyy\u0259sini azald\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n att\u0131q hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259m\u0259si<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<1 ya\u015f<\/td>\n2.4-37.0 ng\/mL\/saat<\/td>\n<\/tr>\n
2-3 ya\u015f<\/td>\n1.7-11.2 ng\/mL\/saat<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n1.0-6.5 ng\/mL\/saat<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n0.5-5.9 ng\/mL\/saat<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.5-5.0 ng\/mL\/saat<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.2-3.4 ng\/mL\/saat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hipertenziyan\u0131n qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. B\u00f6yr\u0259k parenximas\u0131n\u0131n x\u0259st\u0259likl\u0259ri, renin ifraz ed\u0259n \u015fi\u015fl\u0259r, oral kon\u00adtraseptiv m\u0259n\u015f\u0259li hipertenziya, feo\u00adxro\u00admasitoma, sirroz, hepatit, \u00fcr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131, Bartter sindromu v\u0259 elektrolit itkisi olan hallarda plaz\u00admada renin aktivliyi art\u0131r, birincili al\u00addosteronizm, psevdohipe\u00adraldos\u00adte\u00adro\u00adnizm v\u0259 hiperkalemiyada is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

P\u0130TU\u0130TAR GONADOTROP\u0130N (FOLL\u0130KUL ST\u0130MULLA\u015eTIRICI HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>FSH; Follitropin; Pituiter gonadotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<6 ay<\/td>\n1.0-4.0 mIU\/mL<\/td>\n<\/tr>\n
7ay-12 ya\u015f<\/td>\n0.2-3.0 mIU\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n1.0-8.0 mIU\/mL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n20.0-140.0 mIU\/mL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n30.0-118.0 mIU\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n8.5-30.0 mIU\/mL<\/td>\n<\/tr>\n
L\u00fcteal faza<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Menopauza<\/td>\n20.0-140.0 mIU\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<6 ay<\/td>\n1.0-4.0 mIU\/mL<\/td>\n<\/tr>\n
7 ay-12 ya\u015f<\/td>\n0.2-3.0 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n1.0-15.0 mIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hipofiz funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. X\u00fc\u00adsusil\u0259 ilkin v\u0259 ikincili yu\u00admurtal\u0131q \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131n\u0131n differen\u00adsiasiyas\u0131 \u00fc\u00e7\u00fcn qiy\u00adm\u0259t\u00adlidir. \u0130lkin qonadal \u00e7at\u0131\u015fmazl\u0131q, ova\u00adrial v\u0259 tes\u00adti\u00adkulyar agenez, Turner v\u0259 Kleinifelter sidnromu, kastrasiya, alko\u00adqo\u00ad\u00adlizm, me\u00adnopauza v\u0259 orxit za\u00adman\u0131 serumda FSH s\u0259viyy\u0259si y\u00fcks\u0259lir, hipo\u00adfizin \u00f6n pay\u0131n\u0131n hipofunksiyas\u0131, hipo\u00adta\u00adla\u00admu\u00adsun x\u0259st\u0259likl\u0259ri, hamil\u0259lik, ano\u00adrek\u00adsia nervosa, yumurtal\u0131qlar\u0131n polikistoz sind\u00adromu, hemaxromatoz, oraq h\u00fc\u00adcey\u00adr\u0259li anemiya, hiperprolak\u00adti\u00adne\u00admi\u00adya v\u0259 es\u00ad\u00adte\u00adrogen v\u0259 ya andro\u00adgen\u00adl\u0259rl\u0259 m\u00fcalic\u0259 edil\u0259n x\u0259st\u0259l\u0259rd\u0259 is\u0259 FSH s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PARAT\u0130RO\u0130D HORMON (\u0130NTAKT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PTH; Parathyrin; Pa\u00adrathormon<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 plazma, serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 plazma), q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin 1 saatdan art\u0131q otaq temperaturunda saxlan\u0131lmas\u0131<\/p>\n

Referens:<\/strong>10-65 pg\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sad\u0259c\u0259 bioloji baximdan intakt olan PTH molekullar\u0131 \u00f6l\u00e7\u00fcl\u00fcr. \u0130lkin hiperparatiroidizm v\u0259 b\u0259d\u00adxas\u00ads\u0259li t\u00f6r\u0259m\u0259 m\u0259n\u015f\u0259li hiperkal\u00adse\u00admi\u00adyan\u0131n differensasiyas\u0131nda istifad\u0259 olunur. \u0130onla\u015fm\u0131\u015f kalsium t\u0259r\u0259find\u0259n t\u0259nziml\u0259nir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PARATHYR\u0130N (PARAT\u0130RO\u0130D HORMON (\u0130NTAKT))<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PTH; Parathyrin; Pa\u00adrathormon<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 plazma, serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 plazma), q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin 1 saatdan art\u0131q otaq temperaturunda saxlan\u0131lmas\u0131<\/p>\n

Referens:<\/strong>10-65 pg\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sad\u0259c\u0259 bioloji baximdan intakt olan PTH molekullar\u0131 \u00f6l\u00e7\u00fcl\u00fcr. \u0130lkin hiperparatiroidizm v\u0259 b\u0259d\u00adxas\u00ads\u0259li t\u00f6r\u0259m\u0259 m\u0259n\u015f\u0259li hiperkal\u00adse\u00admi\u00adyan\u0131n differensasiyas\u0131nda istifad\u0259 olunur. \u0130onla\u015fm\u0131\u015f kalsium t\u0259r\u0259find\u0259n t\u0259nziml\u0259nir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

P4 (PROQESTERON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0C-21 steroid; P4<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<12 ya\u015f<\/td>\n0.10-0.31 ng\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n0.10-1.00 ng\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n0.10-1.10 ng\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n0.10-1.10 ng\/mL<\/td>\n<\/tr>\n
L\u00fcteal faza<\/td>\n3.00-20.00 ng\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<12 ya\u015f<\/td>\n0.10-0.31 ng\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n0.10-1.00 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0 Ovulyasiya, sar\u0131 cisimin funksiyalar\u0131 v\u0259 hamil\u0259likd\u0259 plasental funksiyalar\u0131n qiym\u0259tl\u0259ndirilm\u0259si, in\u00adduk\u00adsiyan\u0131n m\u00fc\u015fahid\u0259si, proqes\u00adteron m\u00fcalic\u0259sinin v\u0259 erk\u0259n abort riski olan x\u0259st\u0259l\u0259rin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur. Anadang\u0259lm\u0259 ad\u00adre\u00adnal hiper\u00adpla\u00adziya, lipoid yumurtal\u0131q \u015fi\u015fl\u0259ri, teka l\u00fctein kistas\u0131, molyar hamil\u0259lik v\u0259 yumurtal\u0131q xorioepi\u00adteliomalar\u0131nda pro\u00adqesteron s\u0259viyy\u0259si art\u0131r, d\u00fc\u015f\u00fck (abortus) riskind\u0259, bi\u00adrin\u00adcili v\u0259 ya ikincili hipoqonadizm v\u0259 q\u0131sa l\u00fcteal faza sindromunda is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

OSTEOKALS\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0S\u00fcm\u00fck gla proteini; BGP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0S\u0259h\u0259r acl\u0131\u011f\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n
6 ay-5 ya\u015f<\/td>\n10-40 ng\/mL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n5-60 ng\/mL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n2-15 ng\/mL<\/td>\n<\/tr>\n
<50 ya\u015f<\/td>\nKi\u015fi: 2-10 ng\/mL<\/td>\n<\/tr>\n
Qad\u0131n: 2-22 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Serumda osteokalsin s\u0259\u00adviy\u00ady\u0259si s\u00fcm\u00fck sintezi il\u0259 \u0259laq\u0259lidir. Bu bax\u0131mdan osteokalsin s\u0259viy\u00ady\u0259\u00adsinin y\u00fcks\u0259lm\u0259si osteoblastik aktiv\u00adli\u00adyin artd\u0131\u011f\u0131n\u0131 g\u00f6st\u0259rir. Serumda os\u00adteokalsin s\u0259viyy\u0259si q\u0259l\u0259vi fosfataza s\u0259viyy\u0259si il\u0259 paralel d\u0259yi\u015fir. Paget x\u0259st\u0259liyi, b\u00f6yr\u0259k m\u0259n\u015f\u0259li os\u00adteodistrofiya, birincili v\u0259 ikincili hipertiroidizim, skelet metastazlar\u0131 v\u0259 xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131nda osteokalsinin s\u0259viyy\u0259si art\u0131r, birincili biliar sirroz, hamil\u0259lik, qliko\u00adkor\u00adti\u00adkoid m\u00fcalic\u0259si v\u0259 GH \u00e7at\u0131\u015fmaz\u00adl\u0131\u00ad\u011f\u0131nda is\u0259 bu g\u00f6st\u0259rici azal\u0131r. Os\u00adteoparozda is\u0259 osteokalsin s\u0259viyy\u0259si y\u00fcks\u0259k v\u0259 ya a\u015fa\u011f\u0131 ola bil\u0259r. H\u0259m\u00e7inin kalsitriol m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 d\u0259 osteokalsin istifa\u00add\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NORMETANEFR\u0130N (METANAFER\u0130NL\u018fR)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a024 saatl\u0131q sidik, bir\u00add\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a06N HCl \u00fcz\u0259rin\u0259 top\u00adlan\u0131lmal\u0131d\u0131r. Asetat tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

Test i\u00e7eri\u011fi:<\/strong>\u00a0Metanefrin, Norme\u00adtanefrin<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nMetanefrin<\/td>\nNormetanefrin<\/td>\n<\/tr>\n
3 ay<\/td>\n5.9-37.0 \u03bcg\/g\u00fcn<\/td>\n47.0-156.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
4-6 ay<\/td>\n6.1-42.0 \u03bcg\/g\u00fcn<\/td>\n31.0-111.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
7-12 ay<\/td>\n8.5-101.0 \u03bcg\/g\u00fcn<\/td>\n23.0-103.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n6.7-52-0 \u03bcg\/g\u00fcn<\/td>\n32.0-118.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n11.0-99.0 \u03bcg\/g\u00fcn<\/td>\n50.0-111.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n54.0-198.0 \u03bcg\/g\u00fcn<\/td>\n47.0-176.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n39.0-243.0 \u03bcg\/g\u00fcn<\/td>\n53.0-290.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
15 ya\u015f<\/td>\n52.0-341.0 \u03bcg\/g\u00fcn<\/td>\n88.0-444.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Feoxromasitoma v\u0259 nev\u00adrogen \u015fi\u015fl\u0259rin diaqnoz v\u0259 m\u00fc\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. Feoxro\u00admasitoma \u00fc\u00e7\u00fcn skrininq test kimi istifad\u0259 oluna bil\u0259c\u0259k \u0259n \u0259lveri\u015fli test\u00addir. Hipertenziv \u015f\u0259xsl\u0259rd\u0259 d\u0259 si\u00addikl\u0259 ifraz olunan metanefrin s\u0259viy\u00ady\u0259si art\u0131r. Stres, buspiron, MAO inhibitorlar\u0131, amfetaminl\u0259r, kofein, klonidin, deksametazon, diure\u00adtikl\u0259r, metildopa, tsiklik antidepressantlar v\u0259 vazodilatatorlar yalan\u00e7\u0131 y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NEONATAL TSH<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>X\u00fcsusi ka\u011f\u0131za hopdurulmu\u015f qan<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin do\u011fu\u015fdan 3 g\u00fcn sonra al\u0131nmas\u0131 daha \u0259lveri\u015flidir. Yenido\u011fulanlarda do\u00ad\u011fu\u015f\u00addan sonra 15-ci g\u00fcn\u0259 q\u0259d\u0259r neotanal TSH t\u0259yin oluna bil\u0259r. Bu m\u00fcdd\u0259td\u0259n sonra TSH-\u0131n serumda t\u0259yini m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELISA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00adparinli v\u0259 ya EDTA-l\u0131 kapillyar s\u0131\u00adnaq \u015f\u00fc\u015f\u0259l\u0259rind\u0259n x\u00fcsusi ka\u011f\u0131za hopdurulmu\u015f n\u00fcmun\u0259l\u0259r, qan\u0131n m\u00fc\u00advafiq \u015f\u0259kild\u0259 ka\u011f\u0131za hopdurulmas\u0131<\/p>\n

Referens:<\/strong>\u00a0<20 mIU\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Anadan g\u0259lm\u0259 hipotiroid skrinqind\u0259 istifad\u0259 olunur. Pozitiv n\u0259tic\u0259l\u0259r, klinik \u0259lam\u0259tl\u0259r v\u0259 dig\u0259r biokimy\u0259vi testl\u0259r il\u0259 d\u0259qiql\u0259\u015f\u00addirilm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

METANAFER\u0130NL\u018fR<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a024 saatl\u0131q sidik, bir\u00add\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a06N HCl \u00fcz\u0259rin\u0259 top\u00adlan\u0131lmal\u0131d\u0131r. Asetat tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

Test i\u00e7eri\u011fi:<\/strong>\u00a0Metanefrin, Norme\u00adtanefrin<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nMetanefrin<\/td>\nNormetanefrin<\/td>\n<\/tr>\n
3 ay<\/td>\n5.9-37.0 \u03bcg\/g\u00fcn<\/td>\n47.0-156.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
4-6 ay<\/td>\n6.1-42.0 \u03bcg\/g\u00fcn<\/td>\n31.0-111.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
7-12 ay<\/td>\n8.5-101.0 \u03bcg\/g\u00fcn<\/td>\n23.0-103.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n6.7-52-0 \u03bcg\/g\u00fcn<\/td>\n32.0-118.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n11.0-99.0 \u03bcg\/g\u00fcn<\/td>\n50.0-111.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n54.0-198.0 \u03bcg\/g\u00fcn<\/td>\n47.0-176.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n39.0-243.0 \u03bcg\/g\u00fcn<\/td>\n53.0-290.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
15 ya\u015f<\/td>\n52.0-341.0 \u03bcg\/g\u00fcn<\/td>\n88.0-444.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Feoxromasitoma v\u0259 nev\u00adrogen \u015fi\u015fl\u0259rin diaqnoz v\u0259 m\u00fc\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. Feoxro\u00admasitoma \u00fc\u00e7\u00fcn skrininq test kimi istifad\u0259 oluna bil\u0259c\u0259k \u0259n \u0259lveri\u015fli test\u00addir. Hipertenziv \u015f\u0259xsl\u0259rd\u0259 d\u0259 si\u00addikl\u0259 ifraz olunan metanefrin s\u0259viy\u00ady\u0259si art\u0131r. Stres, buspiron, MAO inhibitorlar\u0131, amfetaminl\u0259r, kofein, klonidin, deksametazon, diure\u00adtikl\u0259r, metildopa, tsiklik antidepressantlar v\u0259 vazodilatatorlar yalan\u00e7\u0131 y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

METANAFER\u0130N (METANAFER\u0130NL\u018fR)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a024 saatl\u0131q sidik, bir\u00add\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a06N HCl \u00fcz\u0259rin\u0259 top\u00adlan\u0131lmal\u0131d\u0131r. Asetat tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

Test i\u00e7eri\u011fi:<\/strong>\u00a0Metanefrin, Norme\u00adtanefrin<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nMetanefrin<\/td>\nNormetanefrin<\/td>\n<\/tr>\n
3 ay<\/td>\n5.9-37.0 \u03bcg\/g\u00fcn<\/td>\n47.0-156.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
4-6 ay<\/td>\n6.1-42.0 \u03bcg\/g\u00fcn<\/td>\n31.0-111.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
7-12 ay<\/td>\n8.5-101.0 \u03bcg\/g\u00fcn<\/td>\n23.0-103.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n6.7-52-0 \u03bcg\/g\u00fcn<\/td>\n32.0-118.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n11.0-99.0 \u03bcg\/g\u00fcn<\/td>\n50.0-111.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n54.0-198.0 \u03bcg\/g\u00fcn<\/td>\n47.0-176.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n39.0-243.0 \u03bcg\/g\u00fcn<\/td>\n53.0-290.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
15 ya\u015f<\/td>\n52.0-341.0 \u03bcg\/g\u00fcn<\/td>\n88.0-444.0 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Feoxromasitoma v\u0259 nev\u00adrogen \u015fi\u015fl\u0259rin diaqnoz v\u0259 m\u00fc\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. Feoxro\u00admasitoma \u00fc\u00e7\u00fcn skrininq test kimi istifad\u0259 oluna bil\u0259c\u0259k \u0259n \u0259lveri\u015fli test\u00addir. Hipertenziv \u015f\u0259xsl\u0259rd\u0259 d\u0259 si\u00addikl\u0259 ifraz olunan metanefrin s\u0259viy\u00ady\u0259si art\u0131r. Stres, buspiron, MAO inhibitorlar\u0131, amfetaminl\u0259r, kofein, klonidin, deksametazon, diure\u00adtikl\u0259r, metildopa, tsiklik antidepressantlar v\u0259 vazodilatatorlar yalan\u00e7\u0131 y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MAKROPROLAKT\u0130N SKR\u0130N\u0130NQ\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0PEG \u00e7\u00f6kt\u00fcrm\u0259+ ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Klinik \u0259lam\u0259tl\u0259rl\u0259 uy\u011fun olmayan hiperprolaktinemiyal\u0131 x\u0259s\u00adt\u0259\u00adl\u0259rd\u0259 makroprolaktinin t\u0259yinind\u0259 istifad\u0259 olunur.\u00a0 Prolaktinin IgG il\u0259 \u0259laq\u0259li olan v\u0259 fizioloji baximdan inaktiv formas\u0131d\u0131r. \u018fhali aras\u0131nda makroprolaktin rastg\u0259lm\u0259 tezliyi 1,5% olsa da, hiperprolaktinemiyas\u0131 olan \u015f\u0259xsl\u0259rd\u0259 bu r\u0259q\u0259m daha y\u00fcks\u0259kdir. Hiperprolaktinemiyan\u0131n deferensial diaqnozunda makro\u00adprolaktin varl\u0131\u011f\u0131 inkar edilm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u00dcTE\u0130NL\u018f\u015eD\u0130R\u0130C\u0130 HORMON<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LH; Lutotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sutkal\u0131q variasiyas\u0131\u00a0 var. X\u00fcsusil\u0259 pubertat d\u00f6vr\u00fcnd\u0259 yuxuda ifraz olunan LH miqdar\u0131 y\u00fcks\u0259k olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<6ay<\/td>\n1.0-18.0 mIU\/mL<\/td>\n<\/tr>\n
7 ay-5 ya\u015f<\/td>\n0.2-5.0 mIU\/mL<\/td>\n<\/tr>\n
6-12 ya<\/td>\n0.1-5.0 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n20.0-90.0 mIU\/mL<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
Menopauza<\/td>\n10.0-90.0 mIU\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n12.0-80.0 mIU\/mL<\/td>\n<\/tr>\n
Luteal faza<\/td>\n5.0-20.0 mIU\/mL<\/td>\n<\/tr>\n
Ovulyasiyan\u0131n m\u00fc\u015fahid\u0259si<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<6 ay<\/td>\n1.0-18.0 mIU\/mL<\/td>\n<\/tr>\n
6 ay-12 ya\u015f<\/td>\n0.2-5.0 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si: Hipotalamus v\u0259 hipofizin funksiyalar\u0131n\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsin\u00add\u0259 v\u0259 birincili-ikincili cinsi \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131n differensasiyas\u0131nda istifad\u0259 olu\u00adnur. Birincili qonadal disfunksiyalar, PKOS v\u0259 postmeno\u00adpauzada LH s\u0259\u00adviyy\u0259si art\u0131r, hipofiz v\u0259 ya hipo\u00adtalamusun z\u0259d\u0259l\u0259nm\u0259si, Kallmann sindromu (izolyasiya olunmu\u015f qona\u00addotropik \u00e7at\u0131\u015fmazl\u0131q), anoreksiya ner\u00advoza, stress, malnutrisiya v\u0259 xroniki x\u0259st\u0259likl\u0259rd\u0259 LH-\u0131n s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LUTOTROP\u0130N (L\u00dcTE\u0130NL\u018f\u015eD\u0130R\u0130C\u0130 HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LH; Lutotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sutkal\u0131q variasiyas\u0131\u00a0 var. X\u00fcsusil\u0259 pubertat d\u00f6vr\u00fcnd\u0259 yuxuda ifraz olunan LH miqdar\u0131 y\u00fcks\u0259k olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<6ay<\/td>\n1.0-18.0 mIU\/mL<\/td>\n<\/tr>\n
7 ay-5 ya\u015f<\/td>\n0.2-5.0 mIU\/mL<\/td>\n<\/tr>\n
6-12 ya<\/td>\n0.1-5.0 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n20.0-90.0 mIU\/mL<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
Menopauza<\/td>\n10.0-90.0 mIU\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n12.0-80.0 mIU\/mL<\/td>\n<\/tr>\n
Luteal faza<\/td>\n5.0-20.0 mIU\/mL<\/td>\n<\/tr>\n
Ovulyasiyan\u0131n m\u00fc\u015fahid\u0259si<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<6 ay<\/td>\n1.0-18.0 mIU\/mL<\/td>\n<\/tr>\n
6 ay-12 ya\u015f<\/td>\n0.2-5.0 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si: Hipotalamus v\u0259 hipofizin funksiyalar\u0131n\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsin\u00add\u0259 v\u0259 birincili-ikincili cinsi \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131n differensasiyas\u0131nda istifad\u0259 olu\u00adnur. Birincili qonadal disfunksiyalar, PKOS v\u0259 postmeno\u00adpauzada LH s\u0259\u00adviyy\u0259si art\u0131r, hipofiz v\u0259 ya hipo\u00adtalamusun z\u0259d\u0259l\u0259nm\u0259si, Kallmann sindromu (izolyasiya olunmu\u015f qona\u00addotropik \u00e7at\u0131\u015fmazl\u0131q), anoreksiya ner\u00advoza, stress, malnutrisiya v\u0259 xroniki x\u0259st\u0259likl\u0259rd\u0259 LH-\u0131n s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LH (L\u00dcTE\u0130NL\u018f\u015eD\u0130R\u0130C\u0130 HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LH; Lutotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sutkal\u0131q variasiyas\u0131\u00a0 var. X\u00fcsusil\u0259 pubertat d\u00f6vr\u00fcnd\u0259 yuxuda ifraz olunan LH miqdar\u0131 y\u00fcks\u0259k olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<6ay<\/td>\n1.0-18.0 mIU\/mL<\/td>\n<\/tr>\n
7 ay-5 ya\u015f<\/td>\n0.2-5.0 mIU\/mL<\/td>\n<\/tr>\n
6-12 ya<\/td>\n0.1-5.0 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n20.0-90.0 mIU\/mL<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
Menopauza<\/td>\n10.0-90.0 mIU\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n12.0-80.0 mIU\/mL<\/td>\n<\/tr>\n
Luteal faza<\/td>\n5.0-20.0 mIU\/mL<\/td>\n<\/tr>\n
Ovulyasiyan\u0131n m\u00fc\u015fahid\u0259si<\/td>\n2.0-15.0 mIU\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<6 ay<\/td>\n1.0-18.0 mIU\/mL<\/td>\n<\/tr>\n
6 ay-12 ya\u015f<\/td>\n0.2-5.0 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si: Hipotalamus v\u0259 hipofizin funksiyalar\u0131n\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsin\u00add\u0259 v\u0259 birincili-ikincili cinsi \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131n differensasiyas\u0131nda istifad\u0259 olu\u00adnur. Birincili qonadal disfunksiyalar, PKOS v\u0259 postmeno\u00adpauzada LH s\u0259\u00adviyy\u0259si art\u0131r, hipofiz v\u0259 ya hipo\u00adtalamusun z\u0259d\u0259l\u0259nm\u0259si, Kallmann sindromu (izolyasiya olunmu\u015f qona\u00addotropik \u00e7at\u0131\u015fmazl\u0131q), anoreksiya ner\u00advoza, stress, malnutrisiya v\u0259 xroniki x\u0259st\u0259likl\u0259rd\u0259 LH-\u0131n s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KORT\u0130ZOL (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Sidikd\u0259 s\u0259rb\u0259st kortizol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a024 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Bor tur\u015fusu \u00fcz\u0259rin\u0259 toplan\u0131lmal\u0131d\u0131r. Asetat tur\u015fusu \u00fcz\u0259tin\u0259 y\u0131\u011f\u0131lan v\u0259 y\u0131\u011f\u0131lma \u0259r\u0259f\u0259sind\u0259 soyuq \u015f\u0259raitd\u0259 saxlan\u0131lan sidikl\u0259r d\u0259 q\u0259bul edilir. Soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
<12 ya\u015f<\/td>\n2-27 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n5-55 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
Koproporfirin III<\/td>\n75 mg\/g\u00fcn<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n10-100 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KORT\u0130ZOL<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Hidrokortizon; Compound F<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum v\u0259 ya EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), b\u0259n\u00f6v\u015f\u0259yi qa\u00adpaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 plazma)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Sut\u00adkal\u0131q variasiyas\u0131 oldu\u011fundan qan al\u00adma zaman\u0131 \u0259h\u0259miyy\u0259tlidir. S\u0259h\u0259r saat 06.00-08.00 aras\u0131nda maksi\u00admum, g\u00fcnortadan sonra saat 16.00-a is\u0259 minimum s\u0259viyy\u0259d\u0259 olur. N\u00fcmu\u00adn\u0259nin al\u0131nd\u0131\u011f\u0131 saat laboratoriyaya bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131\u00adl\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n
S\u0259h\u0259r<\/td>\n7.0-29.0 \u03bcg\/dL<\/td>\n<\/tr>\n
Ax\u015fam<\/td>\n7.0-17.5 \u03bcg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipotalamus-hipofiz-ad\u00adre\u00adnal korteks \u0259ks \u0259laq\u0259sinin qiym\u0259t\u00adl\u0259n\u00ad\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. Cushing x\u0259st\u0259liyi, b\u00f6yr\u0259k\u00fcst\u00fc v\u0259zin adenomalar\u0131 v\u0259 karsinomalar\u0131, ekto\u00adpik ACTH sindromu, hamil\u0259lik v\u0259 eksternal esterogen istifad\u0259si il\u0259 se\u00adrumda kortizolun s\u0259viyy\u0259si art\u0131r, Ad\u00addison\u00a0 x\u0259st\u0259liyi, kongenital adrenal hiperplaziya v\u0259 hipopituiterizmd\u0259 kortizolun s\u0259viyy\u0259si azal\u0131r. K\u0259skin stress, alkoqolizm, depressiya v\u0259 b\u0259zi d\u0259rmanlar normal sutkal\u0131q va\u00adriyasiyan\u0131 pozaraq bazal s\u0259viyy\u0259y\u0259 t\u0259sir edir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KORT\u0130KOTROP\u0130N (ADRENOKORT\u0130KOTROP HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ACTH; Kortikotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir. N\u00fcmun\u0259nin al\u0131nma zaman\u0131 \u0259h\u0259miyy\u0259tlidir. Plazmadak\u0131 ACTH miqdar\u0131\u00a0 saat 06.00 \u2013 08.00 aras\u0131nda maksimum, 21.00 \u2013 22.00 aras\u0131nda is\u0259 minimum s\u0259viyy\u0259d\u0259 olur. Bundan ba\u015fqa hamil\u0259lik, mens\u00adtrual sikl v\u0259 stres zaman\u0131 da plaz\u00admadak\u0131 s\u0259viyy\u0259 d\u0259yi\u015fir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
S\u0259h\u0259r<\/td>\n<100 pg\/ml<\/td>\n<\/tr>\n
Ax\u015fam<\/td>\n<80 pg\/ml<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KATEXOLAM\u0130NL\u018fR (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu \u00fcz\u0259\u00adrin\u0259 y\u0131\u011f\u0131lmal\u0131d\u0131r. 6N HCl v\u0259 bor tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidikl\u0259r d\u0259 q\u0259bul olunur<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>10 mL<\/p>\n

Testin t\u0259rkibi:<\/strong>\u00a0Epinefrin, Nore\u00adpinefrin, Dopamin<\/p>\n

undefined<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0\u018fg\u0259r m\u00fcm\u00adk\u00fcns\u0259 bir h\u0259ft\u0259 \u0259vv\u0259lc\u0259d\u0259n isifad\u0259 olunan b\u00fct\u00fcn d\u0259rmanlar k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Epinefrin<\/td>\n<1ya\u015f<\/td>\n2.5 mg\/g\u00fcn<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n3.5 mg\/g\u00fcn<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n6.0 mg\/g\u00fcn<\/td>\n<\/tr>\n
6-11 ya\u015f<\/td>\n10.0 mg\/g\u00fcn<\/td>\n<\/tr>\n
>11 ya\u015f<\/td>\n20.0 mg\/g\u00fcn<\/td>\n<\/tr>\n
Norepinefrin<\/td>\n<1 ya\u015f<\/td>\n10 mg\/g\u00fcn<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n1-17 mg\/g\u00fcn<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n4-29 mg\/g\u00fcn<\/td>\n<\/tr>\n
6-11 ya\u015f<\/td>\n13-65 mg\/g\u00fcn<\/td>\n<\/tr>\n
>11 ya\u015f<\/td>\n15-80 mg\/g\u00fcn<\/td>\n<\/tr>\n
Dopamin<\/td>\n<1 ya\u015f<\/td>\n85 mg\/g\u00fcn<\/td>\n<\/tr>\n
2-3 ya\u015f<\/td>\n10-140 mg\/g\u00fcn<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n40-260 mg\/g\u00fcn<\/td>\n<\/tr>\n
>5 ya\u015f<\/td>\n60-400 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Katexolamin sintezinin qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. \u0130dman h\u0259r\u0259k\u0259tl\u0259ri, stres, siqaret istifad\u0259si v\u0259 a\u011fr\u0131 sidikl\u0259 ifraz olunan katexolomin s\u0259viyy\u0259sini art\u0131r\u0131r. Ka\u00adtexolamin ifraz\u0131 gec\u0259l\u0259r minumum s\u0259viyy\u0259d\u0259 olur. H\u0259m\u00e7inin menstrual tsiklin luteal fazas\u0131nda epinefrin v\u0259 norepinefrin ifraz\u0131 artd\u0131\u011f\u0131 halda, ovul\u00adyasion fazada \u0259n a\u015fa\u011f\u0131 s\u0259\u00adviyy\u0259y\u0259 enir. K\u0259skin hipertonik krizin qiym\u0259tl\u0259ndirilm\u0259si \u00fc\u00e7\u00fcn kriz zaman\u0131 al\u0131nan bird\u0259f\u0259lik sidikd\u0259 m\u00fcayin\u0259 m\u0259sl\u0259h\u0259tdir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KATEXOLAM\u0130NL\u018fR<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Ya\u015f\u0131l qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>3 mL<\/p>\n

Testin t\u0259rkibi:\u00a0<\/strong>Epinefrin, Nore\u00adpinefrin, Dopamin<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00adliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn x\u0259st\u0259 acqar\u0131na ol\u00admal\u0131d\u0131r. Qan alma stresi v\u0259 ayaq\u00fcst\u0259 durma il\u0259 plazmada katexolamin s\u0259viyy\u0259si art\u0131r. Bu s\u0259b\u0259bd\u0259n venoz kateter il\u0259 s\u0259h\u0259r 30 d\u0259qiq\u0259 istirah\u0259tin ard\u0131ndan uzanm\u0131\u015f v\u0259ziyy\u0259td\u0259 qan al\u0131nmal\u0131d\u0131r. H\u0259m\u00e7inin trisiklik anti-depressantlar\u0131n iki h\u0259ft\u0259 \u0259vv\u0259lc\u0259d\u0259n, L-dopa, katexolamin t\u0259rkibli b\u0259zi d\u0259rmanlar (m\u0259s. dekongestanlar), amtefaminl\u0259r, buspion, psixoaktiv d\u0259rmanlar, metildopa, etanol v\u0259 benzodiazepinl\u0259rin q\u0259bulu is\u0259 bir h\u0259ft\u0259 \u0259vv\u0259lc\u0259d\u0259n dayand\u0131r\u0131lmal\u0131d\u0131r. Amfetaminl\u0259r v\u0259 amfetamin\u0259 b\u0259nz\u0259r birl\u0259\u015fm\u0259l\u0259r, i\u015ftah k\u0259sicil\u0259r, brom\u00adkriptin, buspiron, kafein, karbidopa-levadopa, klonidin, deksametazon, diuretikl\u0259r, etanol, izoprotenol, lebo\u00adtolol, metildopa, MAO inhibitorlar\u0131, nikotin, burun damc\u0131lar\u0131, rezerpin, pro\u00adpafenone, teofillin, trisiklik anti\u00addepressantlar v\u0259 vazodilatatorlar\u0131n ka\u00adtexolaminl\u0259rin t\u0259yinind\u0259 (\u00f6l\u00e7\u00fcl\u00adm\u0259sind\u0259) interferensiyaya s\u0259b\u0259b ola bilm\u0259 ehtimal\u0131 n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r. Bununla yana\u015f\u0131, bu d\u0259rmanlar\u0131n katexolamin s\u0259viyy\u0259sin\u0259 t\u0259siri \u00f6nc\u0259\u00add\u0259n t\u0259xmin edil\u0259 bilm\u0259z<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Epinefrin<\/td>\n<60 pg\/mL<\/td>\n<\/tr>\n
Norepinefrin<\/td>\n120-680 pg\/mL<\/td>\n<\/tr>\n
Dopamin<\/td>\n<87 pg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Referens aral\u0131\u011f\u0131 bir m\u00fcdd\u0259t oturaq v\u0259ziyy\u0259td\u0259 dinc\u0259lmi\u015f \u015f\u0259xsl\u0259r \u00fc\u00e7\u00fcn ke\u00e7\u0259rlidir. Ayaq \u00fcst\u0259 duranlarda norepinefrin s\u0259viyy\u0259sinin 700 pg\/mL, epinefrin s\u0259viyy\u0259sinin is\u0259 900 pg\/mL-\u0259 q\u0259d\u0259r y\u00fcks\u0259l\u0259 bil\u0259c\u0259yi n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r. Dopamin s\u0259viy\u00ady\u0259si is\u0259 v\u0259ziyy\u0259t\u0259 g\u00f6r\u0259 d\u0259yi\u015fmir. H\u0259m\u00ad\u00e7inin qan alma zaman\u0131 stresl\u0259 \u0259la\u00adq\u0259li olaraq katexolamin s\u0259viyy\u0259\u00adsind\u0259 art\u0131m ba\u015f ver\u0259 bil\u0259r<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hipertenziyan\u0131n qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 v\u0259 feoxroma\u00adsitoma, neyroblastoma v\u0259 qanqlioney\u00adro\u00adma\u00adlar\u0131n diaqnoz v\u0259 m\u00fcalic\u0259\u00adsinin m\u00fc\u00ad\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Selektiv venoz n\u00fcmun\u0259l\u0259m\u0259 il\u0259 \u015fi\u015fin loka\u00adli\u00adzasiyas\u0131nda da qiym\u0259tlidir. Orto\u00adstatik hipotenziyal\u0131 x\u0259st\u0259\u00adl\u0259rin diaq\u00adnozunda is\u0259 plazmadak\u0131 norepinefrin s\u0259viyy\u0259sinin \u00f6l\u00e7\u00fclm\u0259si faydal\u0131d\u0131r. Ayaq \u00fcsd\u0259 durmaqla norepinefrin s\u0259viyy\u0259sinin artmamas\u0131 simpatik si\u00adnir sistemind\u0259 poz\u011funluq oldu\u011funu g\u00f6st\u0259rir. Neyroblas\u00adtoma, qanqlioney\u00adroblastoma v\u0259 paraqanqliomalar, AMI, stres, idman h\u0259r\u0259k\u0259tl\u0259ri, ayaq \u00fcst\u0259 dayanma, hipotiroidizim v\u0259 diabetik ketoasi\u00addozda plazmada ka\u00adtexolamin s\u0259viyy\u0259si artd\u0131\u011f\u0131 halda, avtonom neyropatiyalarda plazmada katexolomin s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KARS\u0130NOEMBR\u0130ON\u0130K ANT\u0130GEN (CEA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Karsinoembirionik antigen<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<4 ng\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Yo\u011fun v\u0259 d\u00fcz ba\u011f\u0131rsaq, a\u011fciy\u0259r, s\u00fcd v\u0259zi, qaraciy\u0259r, pan\u00adkreaz, prostat, m\u0259d\u0259 v\u0259 yumurtal\u0131q x\u0259r\u00e7\u0259ngl\u0259rind\u0259 CEA s\u0259viyy\u0259si art\u0131r. \u018fsas\u0259n kolorektal x\u0259r\u00e7\u0259ngl\u0259r v\u0259 s\u00fcd v\u0259zi x\u0259r\u00e7\u0259ngl\u0259rinin gec d\u00f6vrl\u0259rinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 edilir. Xo\u015f\u00adxass\u0259li qaraciy\u0259r x\u0259st\u0259likl\u0259ri, xoral\u0131 kolit v\u0259 polipoz kimi b\u0259zi xo\u015fxass\u0259li m\u0259d\u0259-ba\u011f\u0131rsaq prosesl\u0259ri, xo\u015fxass\u0259li s\u00fcd v\u0259zi x\u0259st\u0259likl\u0259ri, a\u011fciy\u0259r in\u00adfek\u00adsiyalar\u0131, emfizema v\u0259 b\u00f6yr\u0259k \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131nda da CEA s\u0259viyy\u0259si arta bil\u0259r. H\u0259m\u00e7inin siqaret \u00e7\u0259k\u0259nl\u0259rd\u0259 d\u0259 CEA s\u0259viyy\u0259sind\u0259 m\u00fclayim y\u00fck\u00ads\u0259lm\u0259 qeyd edilir. Buna g\u00f6r\u0259 d\u0259 skrininq testi kimi istifad\u0259 olun\u00admamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KANSER ANT\u0130GEN 72-4 (CA 72-4)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>X\u0259r\u00e7\u0259ng antigeni 72-4; TAG 72; Tumor associated glico\u00adpro\u00adtein 72<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens: <<\/strong>6.9 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>Qastrointestinal sistem, yumurtal\u0131q v\u0259 s\u00fcd v\u0259zi toxumas\u0131n\u0131n ilkin adenokarsinomalar\u0131n\u0131n t\u0259krar\u00adlan\u00admas\u0131 v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. X\u00fcsusil\u0259 meta\u00adstatik m\u0259d\u0259 karsinomalar\u0131nda CA72-4 s\u0259viyy\u0259si y\u00fcks\u0259lir. H\u0259m\u00e7inin b\u0259zi xo\u015fxass\u0259li halarda da (pankreatit, qaraciy\u0259r sirrozu, a\u011fciy\u0259r x\u0259s\u00adt\u0259\u00adlik\u00adl\u0259ri, revmatoid x\u0259st\u0259\u00adlikl\u0259r, ginekoloji x\u0259st\u0259likl\u0259r, qastrointestinal sistem x\u0259st\u0259likl\u0259ri v\u0259 s.) CA72-4 s\u0259viyy\u0259si arta bil\u0259r. Skrininq test kimi istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KANSER ANT\u0130GEN 19-9 (CA 19-9)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>X\u0259r\u00e7\u0259ng antigeni 19-9; Karbohidrat antigeni 19-9<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens: <<\/strong>37 U\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>B\u00fct\u00fcn qastrointestinal sistem x\u0259r\u00e7\u0259ngl\u0259ri (m\u0259d\u0259alt\u0131 v\u0259z x\u0259r\u00e7\u0259ngl\u0259ri, xolangiokarsinomalar, yogun ba\u011f\u0131rsaq x\u0259r\u00e7\u0259ngl\u0259ri v\u0259 s.) v\u0259 dig\u0259r adenokarsinomalarda\u00a0 CA19-9-un s\u0259viyy\u0259si art\u0131r. M\u0259d\u0259alt\u0131 v\u0259z x\u0259r\u00e7\u0259ngl\u0259rind\u0259 h\u0259ssasl\u0131\u011f\u0131 70-80 %-dir. CA19-9 s\u0259viyy\u0259si il\u0259 \u015fi\u015fin k\u00fctl\u0259si aras\u0131nda \u0259laq\u0259 yoxdur. CEA il\u0259 b\u0259rab\u0259r istifad\u0259 olunduqda m\u0259d\u0259 x\u0259rc\u0259nginin t\u0259krarlanmas\u0131n\u0131n t\u0259yi\u00adnind\u0259 h\u0259sasl\u0131\u011f\u0131 94 %-\u0259 q\u0259d\u0259r y\u00fck\u00ads\u0259lir. H\u0259m\u00e7inin xroniki pankreatit, xolangit v\u0259 sirroz kimi b\u0259zi xo\u015f\u00adxa\u00ads\u0259\u00adli prosesl\u0259rd\u0259 d\u0259 CA19-9 s\u0259viy\u00ady\u0259\u00adsind\u0259 y\u00fcks\u0259lm\u0259 m\u00fc\u015fahid\u0259 oluna bi\u00adl\u0259r. Skrininq testi kimi istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KANSER ANT\u0130GEN 15-3 (CA 15-3)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Canser antigen 15-3, X\u0259r\u00e7\u0259ng antigeni 15-3<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong><<\/strong>29 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0S\u00fcd v\u0259zi x\u0259r\u00e7\u0259nginin diaq\u00adno\u00adzunda, x\u0259st\u0259liyin t\u0259krarlan\u00admas\u0131n\u0131n v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur. X\u00fcsusil\u0259 metastatik s\u00fcd v\u0259\u00adzi x\u0259r\u00e7\u0259ngl\u0259rinin 80%-d\u0259 CA 15-3 s\u0259\u00adviyy\u0259si art\u0131r. H\u0259m\u00e7inin b\u0259zi b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r (m\u0259d\u0259alt\u0131 v\u0259z, a\u011fciy\u0259r, yu\u00admur\u00adtal\u0131q, yo\u011fun ba\u011f\u0131rsaq, qaraciy\u0259r v\u0259 s.), hepatit, sirroz, sarkoidoz, v\u0259r\u0259m v\u0259 SLE-d\u0259 d\u0259 CA 15-3 s\u0259viyy\u0259si y\u00fck\u00ads\u0259lir. Skrininq testi kimi istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KANSER ANT\u0130GEN 125 (CA 125)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Canser antigen 125, X\u0259r\u00e7\u0259ng antigeni125<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Ovul\u00adyasiya v\u0259 menstruasiya m\u0259rh\u0259l\u0259l\u0259ri n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens: <<\/strong>35 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u018fsas\u0259n yumurtal\u0131q x\u0259r\u00ad\u00e7\u0259ngl\u0259rinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunan onkomarkerdir. Seroz, endo\u00admetrial, \u015f\u0259ffaf h\u00fcceyr\u0259li v\u0259 dif\u00adfe\u00adren\u00adsiasiya etm\u0259y\u0259n yumurtal\u0131q karsino\u00admalar\u0131, endometrium v\u0259 ya fallop bo\u00adru\u00adlar\u0131n\u0131n adenokarsinomalar\u0131, b\u0259zi qey\u00adri-genikoloji b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r v\u0259 b\u0259zi xo\u015f xass\u0259li hallarda (hami\u00adl\u0259\u00adlik, menstruasiya, peritoneal v\u0259 ya plev\u00adral iltihabi prosesl\u0259r, yumurtal\u0131q kistalar\u0131, endometrioz) CA 125-in s\u0259\u00adviy\u00ady\u0259si art\u0131r. H\u0259m\u00e7inin sa\u011flam insanlar\u0131n 1%-d\u0259 d\u0259 CA 125 s\u0259\u00adviyy\u0259si y\u00fcks\u0259k ola bil\u0259r. Buna g\u00f6r\u0259 d\u0259 normal hallarda skrininq m\u0259q\u00ads\u0259dil\u0259 istifad\u0259 olunma\u00admal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KALS\u0130TON\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Tirokalsitonin; hCT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Tiroid m\u00fcayin\u0259sind\u0259n sonra n\u00fcmun\u0259 al\u0131n\u00adma\u00admal\u0131d\u0131r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin bir gec\u0259lik acl\u0131qdan sonra al\u0131nmas\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q (x\u00fcsusil\u0259 hemoliz yalan\u00e7\u0131 y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b olur)<\/p>\n

Referens:<\/strong>\u00a0<30 pg\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Medullyar tiroid karsino\u00adma\u00ad\u00adlar\u0131n\u0131n diaqnoz v\u0259 kalsium me\u00adta\u00adbo\u00adlizminin qiym\u0259tl\u0259\u0131ndirilm\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur. B\u0259zi a\u011fciy\u0259r, s\u00fcd v\u0259zi v\u0259 m\u0259\u00add\u0259alt\u0131 v\u0259z x\u0259r\u00e7\u0259ngl\u0259ri, Zollinger-Elli\u00adson sindromu, per\u00adnisioz anemiya, xroniki b\u00f6yr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131, psevdo\u00adhi\u00adpopa\u00adratiroidizm, APUD h\u00fcceyr\u0259li \u015fi\u015f\u00adl\u0259r, karsinoid sindrom, alkoqol m\u0259n\u00ad\u015f\u0259li sirroz, ha\u00admil\u0259lik v\u0259 xo\u015fxass\u0259li a\u011fciy\u0259r x\u0259s\u00adt\u0259likl\u0259rind\u0259 serumda kal\u00adsitoninin s\u0259viyy\u0259si y\u00fcks\u0259lir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

\u0130NSUL\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0M\u00fcalic\u0259 h\u0259\u00ad\u00adkiminin ist\u0259yind\u0259n as\u0131l\u0131 olaraq ac v\u0259 ya toxqar\u0131na i\u015fl\u0259nil\u0259 bil\u0259r. Ac\u00adqar\u0131na insulin miqdar\u0131n\u0131n t\u0259yinind\u0259 n\u00fcmu\u00adn\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 8-12 sa\u00adat\u00adl\u0131q acl\u0131q t\u0259l\u0259b olunur. Eyni za\u00admanda x\u0259st\u0259 oral hipoqlikemik d\u0259r\u00adman v\u0259 insulin istifad\u0259 etm\u0259mi\u015f olmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
Acl\u0131q<\/td>\n<7 g\u00fcn<\/td>\n3-20 \u03bcIU\/mL<\/td>\n<\/tr>\n
>7 g\u00fcn<\/td>\n5-25 \u03bcIU\/mL<\/td>\n<\/tr>\n
Toxluq<\/td>\n<\/td>\n16-166 \u03bcIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>I v\u0259 II tip \u015f\u0259k\u0259rli diabet, hipoqlikemiya, insulinoma v\u0259 insu\u00adlin\u0259 rezistent diabetin qiym\u0259tl\u0259ndiril\u00adm\u0259sind\u0259 istifad\u0259 olunur. \u0130nsulinoma, reaktiv hipoqlikemiya, h\u0259ddind\u0259n ar\u00adt\u0131q insulin q\u0259bulu, Cushing sind\u00adromu, I tip \u015f\u0259k\u0259rli diabet, feoxro\u00admasitoma v\u0259 akromeqaliya zaman\u0131 insulin miqdar\u0131 art\u0131r, pankreas beta-h\u00fcceyr\u0259 z\u0259d\u0259l\u0259nm\u0259sind\u0259 is\u0259 insulin miqdar\u0131 azal\u0131r. Acqar\u0131na insulin testi il\u0259 yana\u015f\u0131 acqar\u0131na qanda \u015f\u0259k\u0259r testi d\u0259 ist\u0259nildikd\u0259 insulin rezistentliyi \u00fc\u00e7\u00fcn HOMA-IR d\u0259y\u0259ri hesablanaraq verilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

\u0130LSUL\u0130N-L\u0130KE GROWTH FAKTOR (SOMATOMED\u0130N C)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0IGF-14 \u0130nsulin-like gro\u00adwth faktor; Growth faktor 1; GF-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Growth hor\u00admonun \u0259ksin\u0259 g\u00fcn \u0259rzind\u0259 v\u0259 yem\u0259kl\u0259rd\u0259n sonra somatomedin C s\u0259viyy\u0259si sabit olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
<3 ya\u015f<\/td>\n50-143 ng\/mL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n51-218 ng\/mL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n106-250 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n140-496 ng\/mL<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n150-562 ng\/mL<\/td>\n<\/tr>\n
21-25 ya\u015f<\/td>\n84-376 ng\/mL<\/td>\n<\/tr>\n
26-30 ya\u015f<\/td>\n90-271 ng\/mL<\/td>\n<\/tr>\n
31-35 ya\u015f<\/td>\n90-226 ng\/mL<\/td>\n<\/tr>\n
36-50 ya\u015f<\/td>\n90-210 ng\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n70-197 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0GH sekresiyas\u0131n\u0131 v\u0259 t\u0259si\u00adrini t\u0259qib etm\u0259k \u00fc\u00e7\u00fcn istifad\u0259 olunur. IGFBP3 il\u0259 birlikd\u0259 istifad\u0259 olun\u00adduqda klinik h\u0259ssasl\u0131q v\u0259 spesifikliyi GH funksiya testl\u0259rind\u0259n daha y\u00fcks\u0259k olur. IGF-1 akromeqaliyada y\u00fcks\u0259k, GH \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, anoreksiya nervosa v\u0259 malnutrisiyas\u0131 olan \u015f\u0259xs\u00adl\u0259rd\u0259 is\u0259 a\u015fa\u011f\u0131 olur. Qidalanma v\u0259\u00adziyy\u0259tinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 prealbumin, RBP v\u0259 ya transfer\u00adrin\u00add\u0259n daha h\u0259ssas olmas\u0131 Soma\u00adto\u00admedin C-nin ba\u015fqa bir x\u00fcsusiy\u00ady\u0259tidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HUMAN CHORIONIC GONADOTROPIN (BETA-hCG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim: \u03b2<\/strong>-hCG; Human chorionic gonadotropin; Hamil\u0259lik testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA \/ MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Qad\u0131n<\/td>\n<12 ya\u015f<\/td>\n2 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n6 mIU\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<2 mIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hamil\u0259liyin t\u0259yini, ekto\u00adpik (u\u015faql\u0131qdan k\u0259nar) hamil\u0259lik s\u00fcb\u00adh\u0259sinin qiym\u0259tl\u0259ndirilm\u0259si v\u0259 in vitro fertilizasiya x\u0259st\u0259l\u0259rinin m\u00fc\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. H\u0259m\u00e7inin mol hidatiform, koryo karsinomas\u0131, xayalar\u0131n \u015fi\u015fl\u0259ri, yumurtal\u0131\u011f\u0131n r\u00fc\u00ad\u015feym h\u00fcceyr\u0259li \u015fi\u015fl\u0259rinin qiym\u0259t\u00adl\u0259ndirilm\u0259si v\u0259 m\u00fc\u015fahid\u0259sind\u0259 d\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HOMA (\u0130NSUL\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0M\u00fcalic\u0259 h\u0259\u00ad\u00adkiminin ist\u0259yind\u0259n as\u0131l\u0131 olaraq ac v\u0259 ya toxqar\u0131na i\u015fl\u0259nil\u0259 bil\u0259r. Ac\u00adqar\u0131na insulin miqdar\u0131n\u0131n t\u0259yinind\u0259 n\u00fcmu\u00adn\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 8-12 sa\u00adat\u00adl\u0131q acl\u0131q t\u0259l\u0259b olunur. Eyni za\u00admanda x\u0259st\u0259 oral hipoqlikemik d\u0259r\u00adman v\u0259 insulin istifad\u0259 etm\u0259mi\u015f olmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
Acl\u0131q<\/td>\n<7 g\u00fcn<\/td>\n3-20 \u03bcIU\/mL<\/td>\n<\/tr>\n
>7 g\u00fcn<\/td>\n5-25 \u03bcIU\/mL<\/td>\n<\/tr>\n
Toxluq<\/td>\n<\/td>\n16-166 \u03bcIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>I v\u0259 II tip \u015f\u0259k\u0259rli diabet, hipoqlikemiya, insulinoma v\u0259 insu\u00adlin\u0259 rezistent diabetin qiym\u0259tl\u0259ndiril\u00adm\u0259sind\u0259 istifad\u0259 olunur. \u0130nsulinoma, reaktiv hipoqlikemiya, h\u0259ddind\u0259n ar\u00adt\u0131q insulin q\u0259bulu, Cushing sind\u00adromu, I tip \u015f\u0259k\u0259rli diabet, feoxro\u00admasitoma v\u0259 akromeqaliya zaman\u0131 insulin miqdar\u0131 art\u0131r, pankreas beta-h\u00fcceyr\u0259 z\u0259d\u0259l\u0259nm\u0259sind\u0259 is\u0259 insulin miqdar\u0131 azal\u0131r. Acqar\u0131na insulin testi il\u0259 yana\u015f\u0131 acqar\u0131na qanda \u015f\u0259k\u0259r testi d\u0259 ist\u0259nildikd\u0259 insulin rezistentliyi \u00fc\u00e7\u00fcn HOMA-IR d\u0259y\u0259ri hesablanaraq verilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

H\u0130DROKORT\u0130ZON (KORT\u0130ZOL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Hidrokortizon; Compound F<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum v\u0259 ya EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), b\u0259n\u00f6v\u015f\u0259yi qa\u00adpaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 plazma)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Sut\u00adkal\u0131q variasiyas\u0131 oldu\u011fundan qan al\u00adma zaman\u0131 \u0259h\u0259miyy\u0259tlidir. S\u0259h\u0259r saat 06.00-08.00 aras\u0131nda maksi\u00admum, g\u00fcnortadan sonra saat 16.00-a is\u0259 minimum s\u0259viyy\u0259d\u0259 olur. N\u00fcmu\u00adn\u0259nin al\u0131nd\u0131\u011f\u0131 saat laboratoriyaya bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131\u00adl\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n
S\u0259h\u0259r<\/td>\n7.0-29.0 \u03bcg\/dL<\/td>\n<\/tr>\n
Ax\u015fam<\/td>\n7.0-17.5 \u03bcg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipotalamus-hipofiz-ad\u00adre\u00adnal korteks \u0259ks \u0259laq\u0259sinin qiym\u0259t\u00adl\u0259n\u00ad\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. Cushing x\u0259st\u0259liyi, b\u00f6yr\u0259k\u00fcst\u00fc v\u0259zin adenomalar\u0131 v\u0259 karsinomalar\u0131, ekto\u00adpik ACTH sindromu, hamil\u0259lik v\u0259 eksternal esterogen istifad\u0259si il\u0259 se\u00adrumda kortizolun s\u0259viyy\u0259si art\u0131r, Ad\u00addison\u00a0 x\u0259st\u0259liyi, kongenital adrenal hiperplaziya v\u0259 hipopituiterizmd\u0259 kortizolun s\u0259viyy\u0259si azal\u0131r. K\u0259skin stress, alkoqolizm, depressiya v\u0259 b\u0259zi d\u0259rmanlar normal sutkal\u0131q va\u00adriyasiyan\u0131 pozaraq bazal s\u0259viyy\u0259y\u0259 t\u0259sir edir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

hCG (BETA-hCG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim: \u03b2<\/strong>-hCG; Human chorionic gonadotropin; Hamil\u0259lik testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA \/ MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Qad\u0131n<\/td>\n<12 ya\u015f<\/td>\n2 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n6 mIU\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<2 mIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hamil\u0259liyin t\u0259yini, ekto\u00adpik (u\u015faql\u0131qdan k\u0259nar) hamil\u0259lik s\u00fcb\u00adh\u0259sinin qiym\u0259tl\u0259ndirilm\u0259si v\u0259 in vitro fertilizasiya x\u0259st\u0259l\u0259rinin m\u00fc\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. H\u0259m\u00e7inin mol hidatiform, koryo karsinomas\u0131, xayalar\u0131n \u015fi\u015fl\u0259ri, yumurtal\u0131\u011f\u0131n r\u00fc\u00ad\u015feym h\u00fcceyr\u0259li \u015fi\u015fl\u0259rinin qiym\u0259t\u00adl\u0259ndirilm\u0259si v\u0259 m\u00fc\u015fahid\u0259sind\u0259 d\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

GROWTH HORMON<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>GH; Somatotropin; STH<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin s\u0259h\u0259r acqar\u0131na v\u0259 30 d\u0259qiq\u0259 istira\u00adh\u0259td\u0259n sonra al\u0131nmas\u0131 m\u0259sl\u0259h\u0259tdir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259ddind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong><20 \u03bcIU\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipofizin funksiyas\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259si, u\u015faqlarda dwar\u00adfizm (nanizm) v\u0259 giqantizmin, b\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 is\u0259 akromeqaliyan\u0131n diaq\u00adno\u00adzunda v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. U\u015faqlarda GH \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259\u00adsin\u00add\u0259 bazal d\u0259y\u0259rl\u0259r yet\u0259rsiz ola bil\u0259r, ona g\u00f6r\u0259 d\u0259 b\u0259z\u0259n stimuliyasiya testl\u0259rin\u0259 ehtiyac yaran\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

GROWTH FAKTORU 1 (SOMATOMED\u0130N C)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0IGF-14 \u0130nsulin-like gro\u00adwth faktor; Growth faktor 1; GF-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Growth hor\u00admonun \u0259ksin\u0259 g\u00fcn \u0259rzind\u0259 v\u0259 yem\u0259kl\u0259rd\u0259n sonra somatomedin C s\u0259viyy\u0259si sabit olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
<3 ya\u015f<\/td>\n50-143 ng\/mL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n51-218 ng\/mL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n106-250 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n140-496 ng\/mL<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n150-562 ng\/mL<\/td>\n<\/tr>\n
21-25 ya\u015f<\/td>\n84-376 ng\/mL<\/td>\n<\/tr>\n
26-30 ya\u015f<\/td>\n90-271 ng\/mL<\/td>\n<\/tr>\n
31-35 ya\u015f<\/td>\n90-226 ng\/mL<\/td>\n<\/tr>\n
36-50 ya\u015f<\/td>\n90-210 ng\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n70-197 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0GH sekresiyas\u0131n\u0131 v\u0259 t\u0259si\u00adrini t\u0259qib etm\u0259k \u00fc\u00e7\u00fcn istifad\u0259 olunur. IGFBP3 il\u0259 birlikd\u0259 istifad\u0259 olun\u00adduqda klinik h\u0259ssasl\u0131q v\u0259 spesifikliyi GH funksiya testl\u0259rind\u0259n daha y\u00fcks\u0259k olur. IGF-1 akromeqaliyada y\u00fcks\u0259k, GH \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, anoreksiya nervosa v\u0259 malnutrisiyas\u0131 olan \u015f\u0259xs\u00adl\u0259rd\u0259 is\u0259 a\u015fa\u011f\u0131 olur. Qidalanma v\u0259\u00adziyy\u0259tinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 prealbumin, RBP v\u0259 ya transfer\u00adrin\u00add\u0259n daha h\u0259ssas olmas\u0131 Soma\u00adto\u00admedin C-nin ba\u015fqa bir x\u00fcsusiy\u00ady\u0259tidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

GH (GROWTH HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>GH; Somatotropin; STH<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin s\u0259h\u0259r acqar\u0131na v\u0259 30 d\u0259qiq\u0259 istira\u00adh\u0259td\u0259n sonra al\u0131nmas\u0131 m\u0259sl\u0259h\u0259tdir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259ddind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong><20 \u03bcIU\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipofizin funksiyas\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259si, u\u015faqlarda dwar\u00adfizm (nanizm) v\u0259 giqantizmin, b\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 is\u0259 akromeqaliyan\u0131n diaq\u00adno\u00adzunda v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. U\u015faqlarda GH \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259\u00adsin\u00add\u0259 bazal d\u0259y\u0259rl\u0259r yet\u0259rsiz ola bil\u0259r, ona g\u00f6r\u0259 d\u0259 b\u0259z\u0259n stimuliyasiya testl\u0259rin\u0259 ehtiyac yaran\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FT4(S\u018fRB\u018fST T4)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0FT4<\/sub>; S\u0259rb\u0259st tiroksin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Yeni do\u011fulmu\u015f<\/td>\n18.0-40.0 pmol\/L<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n8.5-40.5 pmol\/L<\/td>\n<\/tr>\n
>7g\u00fcn<\/td>\n9.0-25.0 pmol\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qalxanab\u0259nz\u0259r v\u0259zi funk\u00adsiyalar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 is\u00adtifad\u0259 olunur. Hipertiroidizimd\u0259 se\u00adrumda FT4\u00a0<\/sub>s\u0259viyy\u0259si y\u00fcks\u0259lir, hipo\u00adti\u00adroidizimd\u0259 azal\u0131r. Total T4<\/sub>\u00a0miqda\u00adr\u0131n\u0131n t\u0259xmin\u0259n 0.02-0.04%-i FT4<\/sub>-d\u00fcr<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FT3(S\u018fRB\u018fST T3)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0FT3<\/sub>; S\u0259rb\u0259st triyodotironin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a03-9 pmol\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qalxanab\u0259nz\u0259r v\u0259zi funk\u00adsiyalar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 is\u00adti\u00adfad\u0259 olunur. Hipertiroidizim v\u0259 T3<\/sub>\u00a0tirotoksikozunda serumda FT3\u00a0<\/sub>s\u0259\u00adviyy\u0259si y\u00fcks\u0259lir, hipotiroidizimd\u0259 is\u0259 azal\u0131r. H\u0259m\u00e7inin xroniki x\u0259st\u0259liyi olan v\u0259 ya uzun m\u00fcdd\u0259t x\u0259st\u0259xanada yatm\u0131\u015f \u015f\u0259xsl\u0259r eutiroid olsalar bel\u0259 FT3<\/sub>\u00a0s\u0259viyy\u0259si a\u015fa\u011f\u0131 ola bil\u0259r. Total T3<\/sub>\u00a0miqdar\u0131n\u0131n t\u0259xmin\u0259n 0.2-0.5 %-i FT3<\/sub>-d\u00fcr<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FSH (FOLL\u0130KUL ST\u0130MULLA\u015eTIRICI HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>FSH; Follitropin; Pituiter gonadotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<6 ay<\/td>\n1.0-4.0 mIU\/mL<\/td>\n<\/tr>\n
7ay-12 ya\u015f<\/td>\n0.2-3.0 mIU\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n1.0-8.0 mIU\/mL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n20.0-140.0 mIU\/mL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n30.0-118.0 mIU\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n8.5-30.0 mIU\/mL<\/td>\n<\/tr>\n
L\u00fcteal faza<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Menopauza<\/td>\n20.0-140.0 mIU\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<6 ay<\/td>\n1.0-4.0 mIU\/mL<\/td>\n<\/tr>\n
7 ay-12 ya\u015f<\/td>\n0.2-3.0 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n1.0-15.0 mIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hipofiz funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. X\u00fc\u00adsusil\u0259 ilkin v\u0259 ikincili yu\u00admurtal\u0131q \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131n\u0131n differen\u00adsiasiyas\u0131 \u00fc\u00e7\u00fcn qiy\u00adm\u0259t\u00adlidir. \u0130lkin qonadal \u00e7at\u0131\u015fmazl\u0131q, ova\u00adrial v\u0259 tes\u00adti\u00adkulyar agenez, Turner v\u0259 Kleinifelter sidnromu, kastrasiya, alko\u00adqo\u00ad\u00adlizm, me\u00adnopauza v\u0259 orxit za\u00adman\u0131 serumda FSH s\u0259viyy\u0259si y\u00fcks\u0259lir, hipo\u00adfizin \u00f6n pay\u0131n\u0131n hipofunksiyas\u0131, hipo\u00adta\u00adla\u00admu\u00adsun x\u0259st\u0259likl\u0259ri, hamil\u0259lik, ano\u00adrek\u00adsia nervosa, yumurtal\u0131qlar\u0131n polikistoz sind\u00adromu, hemaxromatoz, oraq h\u00fc\u00adcey\u00adr\u0259li anemiya, hiperprolak\u00adti\u00adne\u00admi\u00adya v\u0259 es\u00ad\u00adte\u00adrogen v\u0259 ya andro\u00adgen\u00adl\u0259rl\u0259 m\u00fcalic\u0259 edil\u0259n x\u0259st\u0259l\u0259rd\u0259 is\u0259 FSH s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FOLL\u0130TROP\u0130N (FOLL\u0130KUL ST\u0130MULLA\u015eTIRICI HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>FSH; Follitropin; Pituiter gonadotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<6 ay<\/td>\n1.0-4.0 mIU\/mL<\/td>\n<\/tr>\n
7ay-12 ya\u015f<\/td>\n0.2-3.0 mIU\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n1.0-8.0 mIU\/mL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n20.0-140.0 mIU\/mL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n30.0-118.0 mIU\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n8.5-30.0 mIU\/mL<\/td>\n<\/tr>\n
L\u00fcteal faza<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Menopauza<\/td>\n20.0-140.0 mIU\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<6 ay<\/td>\n1.0-4.0 mIU\/mL<\/td>\n<\/tr>\n
7 ay-12 ya\u015f<\/td>\n0.2-3.0 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n1.0-15.0 mIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hipofiz funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. X\u00fc\u00adsusil\u0259 ilkin v\u0259 ikincili yu\u00admurtal\u0131q \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131n\u0131n differen\u00adsiasiyas\u0131 \u00fc\u00e7\u00fcn qiy\u00adm\u0259t\u00adlidir. \u0130lkin qonadal \u00e7at\u0131\u015fmazl\u0131q, ova\u00adrial v\u0259 tes\u00adti\u00adkulyar agenez, Turner v\u0259 Kleinifelter sidnromu, kastrasiya, alko\u00adqo\u00ad\u00adlizm, me\u00adnopauza v\u0259 orxit za\u00adman\u0131 serumda FSH s\u0259viyy\u0259si y\u00fcks\u0259lir, hipo\u00adfizin \u00f6n pay\u0131n\u0131n hipofunksiyas\u0131, hipo\u00adta\u00adla\u00admu\u00adsun x\u0259st\u0259likl\u0259ri, hamil\u0259lik, ano\u00adrek\u00adsia nervosa, yumurtal\u0131qlar\u0131n polikistoz sind\u00adromu, hemaxromatoz, oraq h\u00fc\u00adcey\u00adr\u0259li anemiya, hiperprolak\u00adti\u00adne\u00admi\u00adya v\u0259 es\u00ad\u00adte\u00adrogen v\u0259 ya andro\u00adgen\u00adl\u0259rl\u0259 m\u00fcalic\u0259 edil\u0259n x\u0259st\u0259l\u0259rd\u0259 is\u0259 FSH s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FOLL\u0130KUL ST\u0130MULLA\u015eTIRICI HORMON<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>FSH; Follitropin; Pituiter gonadotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Qad\u0131n<\/td>\n<6 ay<\/td>\n1.0-4.0 mIU\/mL<\/td>\n<\/tr>\n
7ay-12 ya\u015f<\/td>\n0.2-3.0 mIU\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n1.0-8.0 mIU\/mL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n20.0-140.0 mIU\/mL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n30.0-118.0 mIU\/mL<\/td>\n<\/tr>\n
Follikulyar faza<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Pik<\/td>\n8.5-30.0 mIU\/mL<\/td>\n<\/tr>\n
L\u00fcteal faza<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n2.0-10.0 mIU\/mL<\/td>\n<\/tr>\n
Menopauza<\/td>\n20.0-140.0 mIU\/mL<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n<6 ay<\/td>\n1.0-4.0 mIU\/mL<\/td>\n<\/tr>\n
7 ay-12 ya\u015f<\/td>\n0.2-3.0 mIU\/mL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n1.0-15.0 mIU\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hipofiz funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. X\u00fc\u00adsusil\u0259 ilkin v\u0259 ikincili yu\u00admurtal\u0131q \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131n\u0131n differen\u00adsiasiyas\u0131 \u00fc\u00e7\u00fcn qiy\u00adm\u0259t\u00adlidir. \u0130lkin qonadal \u00e7at\u0131\u015fmazl\u0131q, ova\u00adrial v\u0259 tes\u00adti\u00adkulyar agenez, Turner v\u0259 Kleinifelter sidnromu, kastrasiya, alko\u00adqo\u00ad\u00adlizm, me\u00adnopauza v\u0259 orxit za\u00adman\u0131 serumda FSH s\u0259viyy\u0259si y\u00fcks\u0259lir, hipo\u00adfizin \u00f6n pay\u0131n\u0131n hipofunksiyas\u0131, hipo\u00adta\u00adla\u00admu\u00adsun x\u0259st\u0259likl\u0259ri, hamil\u0259lik, ano\u00adrek\u00adsia nervosa, yumurtal\u0131qlar\u0131n polikistoz sind\u00adromu, hemaxromatoz, oraq h\u00fc\u00adcey\u00adr\u0259li anemiya, hiperprolak\u00adti\u00adne\u00admi\u00adya v\u0259 es\u00ad\u00adte\u00adrogen v\u0259 ya andro\u00adgen\u00adl\u0259rl\u0259 m\u00fcalic\u0259 edil\u0259n x\u0259st\u0259l\u0259rd\u0259 is\u0259 FSH s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ESTR\u0130OL (S\u0259rb\u0259st)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>E3<\/sub>\u00a0; Unkonjuge E3<\/sub>\u00a0; uE3<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildiril\u0259c\u0259kdir<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Fetoplasental d\u00f6vr\u00fcn qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. S\u0259rb\u0259st E3<\/sub>\u00a0miqdar\u0131 \u00fcmumi E3<\/sub>-l\u0259\u00a0 m\u00fc\u00adqa\u00adyis\u0259d\u0259 daha spesifikdir. N\u0259tic\u0259l\u0259r x\u0259st\u0259d\u0259n as\u0131l\u0131 olaraq d\u0259yi\u015f\u0259 bil\u00addi\u00adyind\u0259n bir ne\u00e7\u0259 ard\u0131c\u0131l m\u00fcayin\u0259 apa\u00adr\u0131lmal\u0131d\u0131r. Bundan ba\u015fqa, s\u0259h\u0259rl\u0259r konsentrasiyas\u0131 daha y\u00fcks\u0259k olur. Hamil\u0259lik m\u00fcdd\u0259tind\u0259 s\u0259rb\u0259st E3\u00a0<\/sub>daim y\u00fcks\u0259lir, do\u011fu\u015fun ba\u015flamas\u0131 il\u0259 birlikd\u0259 daha k\u0259skin y\u00fcks\u0259lm\u0259 ba\u015f verir. Diabetli hamil\u0259l\u0259r, post-date hestasiya v\u0259 b\u0259tndaxili inki\u015faf\u0131n ge\u00addi\u015finin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 s\u0259r\u00adb\u0259st E3\u00a0<\/sub>istifad\u0259 oluna bil\u0259r. D\u00f6ld\u0259 m\u0259rk\u0259zi sinir sisteminin malfor\u00adma\u00adsiyas\u0131, anadang\u0259lm\u0259 qapaq x\u0259st\u0259\u00adlik\u00adl\u0259ri v\u0259 ya Daun sindromunda se\u00adrum\u00adda s\u0259rb\u0259st E3\u00a0\u00a0<\/sub>s\u0259viyy\u0259sind\u0259 azal\u00adma m\u00fc\u015fahid\u0259 oluna bil\u0259r. Hami\u00adl\u0259\u00adliyin 35-36-c\u0131 h\u0259ft\u0259l\u0259rind\u0259 d\u00f6l\u00fcn ya\u015f\u0131n\u0131n hesablanmas\u0131nda da s\u0259rb\u0259st E3\u00a0<\/sub>isti\u00adfad\u0259 oluna bil\u0259r. H\u0259m\u00e7inin II tri\u00admes\u00adterd\u0259 hCG v\u0259 AFP il\u0259 birg\u0259 istifad\u0259 olunaraq risk skrininqi apar\u0131la bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

s-TSH (T\u0130RO\u0130D-ST\u0130MUL\u018f ED\u0130C\u0130 HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TSh; s-TSH; Tirotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sutkal\u0131q ritmi vard\u0131r. Saat 02.00-04.00 ara\u00ads\u0131n\u00adda maksimum, 17.00-18.00 aras\u0131nda is\u0259 minimum s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n0.5-20.0 \u03bcIU-mL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ya\u015f<\/td>\n0.5-10.0 \u03bcIU-mL<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n0.5-6.5 \u03bcIU-mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.5-5.5 \u03bcIU-mL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.3-4.0 \u03bcIU-mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Tiroid funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259si v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Hipo\u00adtiroidizim, Xa\u015fimoto tiroiditi, ekto\u00adpik TSH ifraz olunan hallar, yar\u0131m\u00adk\u0259skin tiroidit v\u0259 tiroid hormon re\u00adzis\u00adtentliyind\u0259 serumda TSH s\u0259viy\u00ady\u0259\u00adsi art\u0131r, hipotalamus v\u0259 hipofiz m\u0259n\u00ad\u015f\u0259li hipotiroidizim v\u0259 hiperti\u00adro\u00adidi\u00adzimd\u0259 is\u0259 TSH s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SHBG (C\u0130NS\u0130 HORMON-B\u0130RL\u018f\u015e\u00adD\u0130R\u0130C\u0130 QLOBUL\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>SHBG; Testosteron-estra\u00addiol-binding globulin; TeBG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rz\u0131m\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>FIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
1-12 ya\u015f<\/td>\n4.9-9.0 mg\/L<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n1.8-9.0 mg\/L<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n0.9-6.3 mg\/L<\/td>\n1.8-9.0 mg\/L<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n0.6-4.7 mg\/L<\/td>\n1.2-7.7 mg\/L<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n0.6-4.5 mg\/L<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Testesteron v\u0259 estero\u00adgen\u00adl\u0259r m\u0259n\u015f\u0259li cinsi hormonlar SHBG t\u0259r\u0259find\u0259n birl\u0259\u015fdirilir\u0259k qanda da\u00ad\u015f\u0131n\u0131r. Hipertiroidizim, anoreksiya\u00a0 ner\u00advosa, hamil\u0259lik v\u0259 sirrozda SHBG s\u0259viyy\u0259si azal\u0131r, hipoti\u00adroidizim, hir\u015futizm, piyl\u0259nm\u0259 v\u0259 yu\u00admurtal\u0131qlar\u0131n polikistoz sindromunda is\u0259 bu g\u00f6st\u0259rici art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TPO ANT\u0130C\u0130S\u0130ML\u018fR\u0130 (T\u0130RO\u0130D PEROKS\u0130DAZA ANT\u0130C\u0130S\u0130ML\u018fR\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TPO anticisiml\u0259ri; Anti-Tpo<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<60 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Autoimmun tiroid x\u0259st\u0259\u00adlikl\u0259rinin (Xa\u015fimoto tiroiditi, idio\u00adpa\u00adtik miks\u00f6dem, Graves x\u0259st\u0259liyi v\u0259 s.) t\u0259yinind\u0259 istifad\u0259 olunur. Auto\u00adim\u00admun tiroid x\u0259st\u0259liyi olan \u015f\u0259xsl\u0259rd\u0259, TPO konsentrasiyas\u0131 x\u0259st\u0259liyin \u015fid\u00add\u0259ti il\u0259 d\u00fcz m\u00fct\u0259nasibdir. H\u0259m\u00e7inin dig\u0259r b\u0259zi autoimmun x\u0259st\u0259likl\u0259r za\u00adman\u0131 da (Addison x\u0259st\u0259liyi, perni\u00adsitoz\u00a0 anemiya, I tip \u015f\u0259k\u0259rli diabet v\u0259 s.) pozitiv n\u0259tic\u0259l\u0259r \u0259ld\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL TR\u0130YODOT\u0130RON\u0130N (TOTAL T3)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Total triiodothyronine; TT3<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
<1 ya\u015f<\/td>\n0.79-2.60 ng\/mL<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n0.79-2.80 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.70-2.40 ng\/mL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.60-1.95 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Tiroid funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Bel\u0259 ki, TT3<\/sub>\u00a0hipertiroidizm za\u00adman\u0131 art\u0131r, hipotiroidizmd\u0259 is\u0259 azal\u0131r. Xroniki x\u0259st\u0259liyi olan v\u0259 ya uzun m\u00fcdd\u0259t x\u0259st\u0259xanada yatm\u0131\u015f x\u0259st\u0259l\u0259r eutiroid olsalar bel\u0259 TT3<\/sub>\u00a0s\u0259viyy\u0259si a\u015fa\u011f\u0131 ola bil\u0259r. H\u0259m\u00e7inin TBG-nin atrmas\u0131na s\u0259b\u0259b olan hallarda (oral kontraseptiv istifad\u0259si, hamil\u0259lik v\u0259 s.) serum TT3<\/sub>\u00a0s\u0259viyy\u0259si y\u00fcks\u0259l\u0259 bildiyi halda, TBG-nin azald\u0131\u011f\u0131 hallarda (genetik TBG \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, nefrotik sindrom v\u0259 s.) a\u015fa\u011f\u0131 en\u0259 bil\u0259r. T3<\/sub>\u00a0autoanticisiml\u0259rinin oldu\u011fu ha\u0131llarda is\u0259 TT3<\/sub>\u00a0 y\u00fcks\u0259k, TT4<\/sub>\u00a0nor\u00admal t\u0259yin oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL TR\u0130YODOT\u0130RON\u0130N (TOTAL T3)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Total triiodothyronine; TT3<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
<1 ya\u015f<\/td>\n0.79-2.60 ng\/mL<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n0.79-2.80 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.70-2.40 ng\/mL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.60-1.95 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Tiroid funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Bel\u0259 ki, TT3<\/sub>\u00a0hipertiroidizm za\u00adman\u0131 art\u0131r, hipotiroidizmd\u0259 is\u0259 azal\u0131r. Xroniki x\u0259st\u0259liyi olan v\u0259 ya uzun m\u00fcdd\u0259t x\u0259st\u0259xanada yatm\u0131\u015f x\u0259st\u0259l\u0259r eutiroid olsalar bel\u0259 TT3<\/sub>\u00a0s\u0259viyy\u0259si a\u015fa\u011f\u0131 ola bil\u0259r. H\u0259m\u00e7inin TBG-nin atrmas\u0131na s\u0259b\u0259b olan hallarda (oral kontraseptiv istifad\u0259si, hamil\u0259lik v\u0259 s.) serum TT3<\/sub>\u00a0s\u0259viyy\u0259si y\u00fcks\u0259l\u0259 bildiyi halda, TBG-nin azald\u0131\u011f\u0131 hallarda (genetik TBG \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, nefrotik sindrom v\u0259 s.) a\u015fa\u011f\u0131 en\u0259 bil\u0259r. T3<\/sub>\u00a0autoanticisiml\u0259rinin oldu\u011fu ha\u0131llarda is\u0259 TT3<\/sub>\u00a0 y\u00fcks\u0259k, TT4<\/sub>\u00a0nor\u00admal t\u0259yin oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL T\u0130ROKS\u0130N (TOTAL T4)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Total tiroksin; TT4<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Yenido\u011fulmu\u015f<\/td>\n7.40-13.00 \u03bcg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n11.80-22.60 \u03bcg\/dL<\/td>\n<\/tr>\n
7g\u00fcn-1 ya\u015f<\/td>\n7.80-17.85 \u03bcg\/dL<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n7.00-15.50 \u03bcg\/dL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n5.85-14.00 \u03bcg\/dL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n5.00-11.50 \u03bcg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Tiroid funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Bel\u0259 ki, TT3<\/sub>\u00a0hipertiroidizm za\u00adman\u0131 art\u0131r, hipotiroidizmd\u0259 is\u0259 azal\u0131r. Tiroksin \u0259v\u0259zedici m\u00fcalic\u0259 alan \u015f\u0259xs\u00adl\u0259rd\u0259 TT4<\/sub>\u00a0y\u00fcks\u0259k ola bil\u0259r. H\u0259m\u00ad\u00e7inin TBG-nin atrmas\u0131na s\u0259b\u0259b olan hallarda (oral kontraseptiv istifad\u0259si, hamil\u0259lik v\u0259 s) serum TT4<\/sub>\u00a0s\u0259viyy\u0259si y\u00fcks\u0259l\u0259 bildiyi halda, TBG-nin azal\u00add\u0131\u011f\u0131 hallarda (genetik TBG \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, nefrotik sindrom v\u0259 s.) TT4<\/sub>\u00a0s\u0259viyy\u0259si en\u0259 bil\u0259r. T4 \u00a0<\/sub>autoan\u00adtici\u00adsiml\u0259rinin oldu\u011fu ha\u0131llarda is\u0259 TT4<\/sub>\u00a0 y\u00fcks\u0259k, TT3<\/sub>\u00a0normal t\u0259yin oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL T4<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Total tiroksin; TT4<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Yenido\u011fulmu\u015f<\/td>\n7.40-13.00 \u03bcg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n11.80-22.60 \u03bcg\/dL<\/td>\n<\/tr>\n
7g\u00fcn-1 ya\u015f<\/td>\n7.80-17.85 \u03bcg\/dL<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n7.00-15.50 \u03bcg\/dL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n5.85-14.00 \u03bcg\/dL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n5.00-11.50 \u03bcg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Tiroid funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Bel\u0259 ki, TT3<\/sub>\u00a0hipertiroidizm za\u00adman\u0131 art\u0131r, hipotiroidizmd\u0259 is\u0259 azal\u0131r. Tiroksin \u0259v\u0259zedici m\u00fcalic\u0259 alan \u015f\u0259xs\u00adl\u0259rd\u0259 TT4<\/sub>\u00a0y\u00fcks\u0259k ola bil\u0259r. H\u0259m\u00ad\u00e7inin TBG-nin atrmas\u0131na s\u0259b\u0259b olan hallarda (oral kontraseptiv istifad\u0259si, hamil\u0259lik v\u0259 s) serum TT4<\/sub>\u00a0s\u0259viyy\u0259si y\u00fcks\u0259l\u0259 bildiyi halda, TBG-nin azal\u00add\u0131\u011f\u0131 hallarda (genetik TBG \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, nefrotik sindrom v\u0259 s.) TT4<\/sub>\u00a0s\u0259viyy\u0259si en\u0259 bil\u0259r. T4 \u00a0<\/sub>autoan\u00adtici\u00adsiml\u0259rinin oldu\u011fu ha\u0131llarda is\u0259 TT4<\/sub>\u00a0 y\u00fcks\u0259k, TT3<\/sub>\u00a0normal t\u0259yin oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL T3<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Total triiodothyronine; TT3<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
<1 ya\u015f<\/td>\n0.79-2.60 ng\/mL<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n0.79-2.80 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.70-2.40 ng\/mL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.60-1.95 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Tiroid funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Bel\u0259 ki, TT3<\/sub>\u00a0hipertiroidizm za\u00adman\u0131 art\u0131r, hipotiroidizmd\u0259 is\u0259 azal\u0131r. Xroniki x\u0259st\u0259liyi olan v\u0259 ya uzun m\u00fcdd\u0259t x\u0259st\u0259xanada yatm\u0131\u015f x\u0259st\u0259l\u0259r eutiroid olsalar bel\u0259 TT3<\/sub>\u00a0s\u0259viyy\u0259si a\u015fa\u011f\u0131 ola bil\u0259r. H\u0259m\u00e7inin TBG-nin atrmas\u0131na s\u0259b\u0259b olan hallarda (oral kontraseptiv istifad\u0259si, hamil\u0259lik v\u0259 s.) serum TT3<\/sub>\u00a0s\u0259viyy\u0259si y\u00fcks\u0259l\u0259 bildiyi halda, TBG-nin azald\u0131\u011f\u0131 hallarda (genetik TBG \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, nefrotik sindrom v\u0259 s.) a\u015fa\u011f\u0131 en\u0259 bil\u0259r. T3<\/sub>\u00a0autoanticisiml\u0259rinin oldu\u011fu ha\u0131llarda is\u0259 TT3<\/sub>\u00a0 y\u00fcks\u0259k, TT4<\/sub>\u00a0nor\u00admal t\u0259yin oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

T\u0130ROTROP\u0130N (T\u0130RO\u0130D-ST\u0130MUL\u018f ED\u0130C\u0130 HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TSh; s-TSH; Tirotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sutkal\u0131q ritmi vard\u0131r. Saat 02.00-04.00 ara\u00ads\u0131n\u00adda maksimum, 17.00-18.00 aras\u0131nda is\u0259 minimum s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n0.5-20.0 \u03bcIU-mL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ya\u015f<\/td>\n0.5-10.0 \u03bcIU-mL<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n0.5-6.5 \u03bcIU-mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.5-5.5 \u03bcIU-mL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.3-4.0 \u03bcIU-mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Tiroid funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259si v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Hipo\u00adtiroidizim, Xa\u015fimoto tiroiditi, ekto\u00adpik TSH ifraz olunan hallar, yar\u0131m\u00adk\u0259skin tiroidit v\u0259 tiroid hormon re\u00adzis\u00adtentliyind\u0259 serumda TSH s\u0259viy\u00ady\u0259\u00adsi art\u0131r, hipotalamus v\u0259 hipofiz m\u0259n\u00ad\u015f\u0259li hipotiroidizim v\u0259 hiperti\u00adro\u00adidi\u00adzimd\u0259 is\u0259 TSH s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

T\u0130ROQLOBUL\u0130N ANT\u0130C\u0130S\u0130ML\u018fR\u0130 (ANT\u0130-T\u0130ROQLOBUL\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Tiroqlobulin anticisiml\u0259ri<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>\u00a0<60 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qalxanab\u0259nz\u0259r v\u0259zin au\u00adto\u00adimmun x\u0259st\u0259likl\u0259rinin qiym\u0259t\u00adl\u0259ndi\u00adrilm\u0259sind\u0259 istifad\u0259 olunur. TPO anti\u00adcisiml\u0259ri il\u0259 m\u00fcqayis\u0259d\u0259 \u0259h\u0259\u00admiyy\u0259ti azd\u0131r. Hashimito ti\u00adroiditi, Graves x\u0259s\u00adt\u0259liyi, qalxa\u00adna\u00adb\u0259nz\u0259r v\u0259z karsino\u00admalar\u0131, idiopatik miksedema, per\u00adnisioz anemiya, SLE v\u0259 de-Quervain yar\u0131mk\u0259skin ti\u00adroiditind\u0259 anti-tiro\u00adqlobulin an\u00adti\u00adcism\u00adl\u0259rinin miqdar\u0131 ar\u00adt\u0131r. Normal poulyasiyan\u0131n 10%-d\u0259 az mirdarda y\u00fcks\u0259k ola bil\u0259r. H\u0259m\u00e7inin ti\u00adro\u00adqlobulin s\u0259viyy\u0259si a\u015fa\u011f\u0131 olan x\u0259s\u00adt\u0259l\u0259rd\u0259 d\u0259 anti-tiroqlobulin s\u0259\u00adviy\u00ady\u0259\u00ad\u00adsi\u00adn\u0259 bax\u0131lmal\u0131d\u0131r. Tiro\u00adqlo\u00adbulin anti\u00adci\u00adsiml\u0259rinin olmas\u0131, ti\u00adroqlo\u00adbu\u00adlinin \u00f6l\u00e7\u00fclm\u0259sind\u0259 in\u00adter\u00adferensiyaya (d\u0259yi\u00ad\u015fikliy\u0259) s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

T\u0130ROQLOBUL\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Tg<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Qal\u00adxa\u00adnab\u0259nz\u0259r v\u0259zin m\u00fcayin\u0259sind\u0259n sonra n\u00fcmun\u0259 al\u0131nmamal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<85 ng\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qalxana b\u0259nz\u0259r v\u0259zin x\u0259r\u00ad\u00e7\u0259ngi olan x\u0259st\u0259l\u0259rin m\u00fc\u015fa\u00adhi\u00add\u0259sind\u0259 istifad\u0259 olunur. Follikulyar v\u0259 papilyar tiroid karsinomalar\u0131, hipertiroidizim v\u0259 yar\u0131mk\u0259skin tiro\u00adiditd\u0259 tiroqlobulin s\u0259viyy\u0259si art\u0131r. Bu x\u0259st\u0259l\u0259rd\u0259 m\u00fcalic\u0259 il\u0259 tiroqlobulin s\u0259viyy\u0259si azald\u0131\u011f\u0131 halda, metastaz\u0131n ba\u015f verm\u0259si il\u0259 yenid\u0259n y\u00fcks\u0259lir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

T\u0130ROKS\u0130N-B\u0130RL\u018f\u015eD\u0130R\u0130C\u0130 QLOBUL\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TBG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
Yenido\u011fulmu\u015f<\/td>\n36-96 \u03bcg\/mL<\/td>\n<\/tr>\n
<1 ay<\/td>\n36-66 \u03bcg\/mL<\/td>\n<\/tr>\n
2-12 ay<\/td>\n31-56 \u03bcg\/mL<\/td>\n<\/tr>\n
1-5 ya\u015f<\/td>\n29-54 \u03bcg\/mL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n25-50 \u03bcg\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n21-46 \u03bcg\/mL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n15-34 \u03bcg\/mL<\/td>\n<\/tr>\n
Hamil\u0259lik<\/td>\n21-70 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0T3<\/sub>\u00a0v\u0259 T4<\/sub>\u00a0hormonl\u0259r\u0131n\u0131n plazmada birl\u0259\u015fdiyi da\u015f\u0131y\u0131c\u0131 z\u00fclald\u0131r. \u018fsas\u0259n TSH s\u0259viyy\u0259si il\u0259 uy\u011fun olmayan TT3<\/sub>\u00a0v\u0259 TT4<\/sub>\u00a0s\u0259viyy\u0259l\u0259rinin, TT4<\/sub>\u00a0v\u0259 FT4<\/sub>\u00a0s\u0259viyy\u0259l\u0259ri aras\u0131ndak\u0131 uy\u011funsuzluq hallar\u0131n\u0131n, h\u0259ddind\u0259n \u00e7ox artm\u0131\u015f v\u0259 ya azalm\u0131\u015f TT4<\/sub>\u00a0s\u0259viy\u00ady\u0259l\u0259rinin v\u0259 anadang\u0259lm\u0259 TBG \u00e7a\u00adt\u0131\u015fmazl\u0131qlar\u0131n\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur. \u0130nfeksion hepa\u00adtitl\u0259r, k\u0259skin fasil\u0259li porfiriya, ha\u00admi\u0259lik v\u0259 hipotiroidizmd\u0259 TBG s\u0259\u00adviyy\u0259si art\u0131r, xroniki x\u0259st\u0259likl\u0259r, c\u0259rrahi stres v\u0259 nefrotik sindromda is\u0259 TBG s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

T\u0130ROKALS\u0130TON\u0130N (KALS\u0130TON\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Tirokalsitonin; hCT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Tiroid m\u00fcayin\u0259sind\u0259n sonra n\u00fcmun\u0259 al\u0131n\u00adma\u00admal\u0131d\u0131r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin bir gec\u0259lik acl\u0131qdan sonra al\u0131nmas\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q (x\u00fcsusil\u0259 hemoliz yalan\u00e7\u0131 y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b olur)<\/p>\n

Referens:<\/strong>\u00a0<30 pg\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Medullyar tiroid karsino\u00adma\u00ad\u00adlar\u0131n\u0131n diaqnoz v\u0259 kalsium me\u00adta\u00adbo\u00adlizminin qiym\u0259tl\u0259\u0131ndirilm\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur. B\u0259zi a\u011fciy\u0259r, s\u00fcd v\u0259zi v\u0259 m\u0259\u00add\u0259alt\u0131 v\u0259z x\u0259r\u00e7\u0259ngl\u0259ri, Zollinger-Elli\u00adson sindromu, per\u00adnisioz anemiya, xroniki b\u00f6yr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131, psevdo\u00adhi\u00adpopa\u00adratiroidizm, APUD h\u00fcceyr\u0259li \u015fi\u015f\u00adl\u0259r, karsinoid sindrom, alkoqol m\u0259n\u00ad\u015f\u0259li sirroz, ha\u00admil\u0259lik v\u0259 xo\u015fxass\u0259li a\u011fciy\u0259r x\u0259s\u00adt\u0259likl\u0259rind\u0259 serumda kal\u00adsitoninin s\u0259viyy\u0259si y\u00fcks\u0259lir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

T\u0130RO\u0130D-ST\u0130MUL\u018f ED\u0130C\u0130 HORMON<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TSh; s-TSH; Tirotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sutkal\u0131q ritmi vard\u0131r. Saat 02.00-04.00 ara\u00ads\u0131n\u00adda maksimum, 17.00-18.00 aras\u0131nda is\u0259 minimum s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n0.5-20.0 \u03bcIU-mL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ya\u015f<\/td>\n0.5-10.0 \u03bcIU-mL<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n0.5-6.5 \u03bcIU-mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.5-5.5 \u03bcIU-mL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.3-4.0 \u03bcIU-mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Tiroid funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259si v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Hipo\u00adtiroidizim, Xa\u015fimoto tiroiditi, ekto\u00adpik TSH ifraz olunan hallar, yar\u0131m\u00adk\u0259skin tiroidit v\u0259 tiroid hormon re\u00adzis\u00adtentliyind\u0259 serumda TSH s\u0259viy\u00ady\u0259\u00adsi art\u0131r, hipotalamus v\u0259 hipofiz m\u0259n\u00ad\u015f\u0259li hipotiroidizim v\u0259 hiperti\u00adro\u00adidi\u00adzimd\u0259 is\u0259 TSH s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

T\u0130RO\u0130D PEROKS\u0130DAZA ANT\u0130C\u0130S\u0130ML\u018fR\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TPO anticisiml\u0259ri; Anti-Tpo<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<60 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Autoimmun tiroid x\u0259st\u0259\u00adlikl\u0259rinin (Xa\u015fimoto tiroiditi, idio\u00adpa\u00adtik miks\u00f6dem, Graves x\u0259st\u0259liyi v\u0259 s.) t\u0259yinind\u0259 istifad\u0259 olunur. Auto\u00adim\u00admun tiroid x\u0259st\u0259liyi olan \u015f\u0259xsl\u0259rd\u0259, TPO konsentrasiyas\u0131 x\u0259st\u0259liyin \u015fid\u00add\u0259ti il\u0259 d\u00fcz m\u00fct\u0259nasibdir. H\u0259m\u00e7inin dig\u0259r b\u0259zi autoimmun x\u0259st\u0259likl\u0259r za\u00adman\u0131 da (Addison x\u0259st\u0259liyi, perni\u00adsitoz\u00a0 anemiya, I tip \u015f\u0259k\u0259rli diabet v\u0259 s.) pozitiv n\u0259tic\u0259l\u0259r \u0259ld\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TG (T\u0130ROQLOBUL\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Tg<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Qal\u00adxa\u00adnab\u0259nz\u0259r v\u0259zin m\u00fcayin\u0259sind\u0259n sonra n\u00fcmun\u0259 al\u0131nmamal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<85 ng\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qalxana b\u0259nz\u0259r v\u0259zin x\u0259r\u00ad\u00e7\u0259ngi olan x\u0259st\u0259l\u0259rin m\u00fc\u015fa\u00adhi\u00add\u0259sind\u0259 istifad\u0259 olunur. Follikulyar v\u0259 papilyar tiroid karsinomalar\u0131, hipertiroidizim v\u0259 yar\u0131mk\u0259skin tiro\u00adiditd\u0259 tiroqlobulin s\u0259viyy\u0259si art\u0131r. Bu x\u0259st\u0259l\u0259rd\u0259 m\u00fcalic\u0259 il\u0259 tiroqlobulin s\u0259viyy\u0259si azald\u0131\u011f\u0131 halda, metastaz\u0131n ba\u015f verm\u0259si il\u0259 yenid\u0259n y\u00fcks\u0259lir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TESTOSTERON-ESTRAD\u0130OL-B\u0130RL\u018f\u015eD\u0130R\u0130C\u0130 QLOBUL\u0130N (C\u0130NS\u0130 HORMON-B\u0130RL\u018f\u015e\u00adD\u0130R\u0130C\u0130 QLOBUL\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>SHBG; Testosteron-estra\u00addiol-binding globulin; TeBG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rz\u0131m\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>FIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
1-12 ya\u015f<\/td>\n4.9-9.0 mg\/L<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n1.8-9.0 mg\/L<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n0.9-6.3 mg\/L<\/td>\n1.8-9.0 mg\/L<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n0.6-4.7 mg\/L<\/td>\n1.2-7.7 mg\/L<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n0.6-4.5 mg\/L<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Testesteron v\u0259 estero\u00adgen\u00adl\u0259r m\u0259n\u015f\u0259li cinsi hormonlar SHBG t\u0259r\u0259find\u0259n birl\u0259\u015fdirilir\u0259k qanda da\u00ad\u015f\u0131n\u0131r. Hipertiroidizim, anoreksiya\u00a0 ner\u00advosa, hamil\u0259lik v\u0259 sirrozda SHBG s\u0259viyy\u0259si azal\u0131r, hipoti\u00adroidizim, hir\u015futizm, piyl\u0259nm\u0259 v\u0259 yu\u00admurtal\u0131qlar\u0131n polikistoz sindromunda is\u0259 bu g\u00f6st\u0259rici art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TESTOSTERON (Total)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Total tes\u00adtes\u00adteron s\u0259viyy\u0259si saat 07.00 da mak\u00adsimum, 20.00 da is\u0259 minimum s\u0259\u00adviyy\u0259d\u0259 olur. \u0130dmandan sonra total testesteron s\u0259viyy\u0259si art\u0131r, immo\u00adbi\u00adli\u00adzasiya v\u0259 \u015f\u0259k\u0259r y\u00fckl\u0259m\u0259sind\u0259n sonra is\u0259 azal\u0131r. 50 ya\u015f\u0131ndan yuxar\u0131 \u015f\u0259xs\u00adl\u0259rd\u0259 is\u0259 proqressiv azalma ba\u015f verir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Ki\u015fi<\/td>\n<12 ya\u015f<\/td>\n0.1-0.2 ng\/mL<\/td>\n<\/tr>\n
<\/td>\n13-15 ya\u015f<\/td>\n1.0-6.0 ng\/mL<\/td>\n<\/tr>\n
<\/td>\n16-20 ya\u015f<\/td>\n3.0-6.0 ng\/mL<\/td>\n<\/tr>\n
<\/td>\n>20 ya\u015f<\/td>\n3.0-10.0 ng\/mLL<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n<12 ya\u015f<\/td>\n0.1-0.2 ng\/mLL<\/td>\n<\/tr>\n
<\/td>\n13-15 ya\u015f<\/td>\n0.1-0.4 ng\/mL<\/td>\n<\/tr>\n
<\/td>\n>15 ya\u015f<\/td>\n0.1-0.9 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Adrenal hiperplaziya, ad\u00adre\u00adnokortikal \u015fi\u015fl\u0259r, testikulyar femi\u00adnizasiya, idiopatik hir\u015futizm v\u0259 vi\u00adrilizasiya edici yumurtal\u0131q \u015fi\u015fl\u0259rind\u0259 total testesteron s\u0259viyy\u0259si artd\u0131\u011f\u0131 halda, Down sindromu, birincili v\u0259 ikincili hipoqonadizm, uremiya, mio\u00adtonik distrofiya, qaraciy\u0259r \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, kriptorxizm v\u0259 cinsi yeti\u015f\u00adk\u0259nliyin gecikm\u0259sind\u0259 is\u0259 total testesteron s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TESTOSTERON (S\u0259rb\u0259st)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0150 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ki\u015fi<\/td>\n<5 ya\u015f<\/td>\n0.15-0.60 pg\/mL<\/td>\n<\/tr>\n
<\/td>\n6-12 ya\u015f<\/td>\n0.60-5.70 pg\/mL<\/td>\n<\/tr>\n
<\/td>\n>12 ya\u015f<\/td>\n12.00-30.00 pg\/mL<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n<3 ay<\/td>\n0.10-0.60 pg\/mL<\/td>\n<\/tr>\n
<\/td>\n4 ay-12ya\u015f<\/td>\n0.15-0.60 pg\/mL<\/td>\n<\/tr>\n
<\/td>\n>12 ya\u015f<\/td>\n1.10-3.10 pg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>S\u0259rb\u0259st testosteron s\u0259\u00adviyy\u0259si, testosteron da\u015f\u0131y\u0131c\u0131 z\u00fclal olan SHBG konsentrasiyalar\u0131ndak\u0131 d\u0259yi\u015fk\u0259nlikl\u0259rd\u0259n as\u0131l\u0131 deyil. Buna g\u00f6r\u0259 d\u0259 SHBG s\u0259viyy\u0259sinin y\u00fcks\u0259k (hipertiroidizim, hamil\u0259lik, oral kon\u00adtraseptiv istifad\u0259si v\u0259 s.) v\u0259 a\u015fa\u011f\u0131 (hipotiroidizim, androgen \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, piyl\u0259nm\u0259 v\u0259 s.) oldu\u011fu hallarda s\u0259rb\u0259st testosteronun t\u0259yini total testosterondan daha \u0259h\u0259miyy\u0259tlidir. Hir\u015futizm, b\u00f6yr\u0259k\u00fcst\u00fc v\u0259zin virili\u00adzasiya edici \u015fi\u015fl\u0259rind\u0259, yumurtaqlar\u0131n polikistozu sindromunda v\u0259 andro\u00adgen rezistentlik hallar\u0131nda s\u0259rb\u0259st testosteron s\u0259viyy\u0259si art\u0131r, hipo\u00adqo\u00adnadizm v\u0259 P-450 fermentinin \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131nda is\u0259 s\u0259rb\u0259st testosteron s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TBG (T\u0130ROKS\u0130N-B\u0130RL\u018f\u015eD\u0130R\u0130C\u0130 QLOBUL\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TBG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
Yenido\u011fulmu\u015f<\/td>\n36-96 \u03bcg\/mL<\/td>\n<\/tr>\n
<1 ay<\/td>\n36-66 \u03bcg\/mL<\/td>\n<\/tr>\n
2-12 ay<\/td>\n31-56 \u03bcg\/mL<\/td>\n<\/tr>\n
1-5 ya\u015f<\/td>\n29-54 \u03bcg\/mL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n25-50 \u03bcg\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n21-46 \u03bcg\/mL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n15-34 \u03bcg\/mL<\/td>\n<\/tr>\n
Hamil\u0259lik<\/td>\n21-70 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0T3<\/sub>\u00a0v\u0259 T4<\/sub>\u00a0hormonl\u0259r\u0131n\u0131n plazmada birl\u0259\u015fdiyi da\u015f\u0131y\u0131c\u0131 z\u00fclald\u0131r. \u018fsas\u0259n TSH s\u0259viyy\u0259si il\u0259 uy\u011fun olmayan TT3<\/sub>\u00a0v\u0259 TT4<\/sub>\u00a0s\u0259viyy\u0259l\u0259rinin, TT4<\/sub>\u00a0v\u0259 FT4<\/sub>\u00a0s\u0259viyy\u0259l\u0259ri aras\u0131ndak\u0131 uy\u011funsuzluq hallar\u0131n\u0131n, h\u0259ddind\u0259n \u00e7ox artm\u0131\u015f v\u0259 ya azalm\u0131\u015f TT4<\/sub>\u00a0s\u0259viy\u00ady\u0259l\u0259rinin v\u0259 anadang\u0259lm\u0259 TBG \u00e7a\u00adt\u0131\u015fmazl\u0131qlar\u0131n\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur. \u0130nfeksion hepa\u00adtitl\u0259r, k\u0259skin fasil\u0259li porfiriya, ha\u00admi\u0259lik v\u0259 hipotiroidizmd\u0259 TBG s\u0259\u00adviyy\u0259si art\u0131r, xroniki x\u0259st\u0259likl\u0259r, c\u0259rrahi stres v\u0259 nefrotik sindromda is\u0259 TBG s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TAG 72 (CA 72-4)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>X\u0259r\u00e7\u0259ng antigeni 72-4; TAG 72; Tumor associated glico\u00adpro\u00adtein 72<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens: <<\/strong>6.9 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>Qastrointestinal sistem, yumurtal\u0131q v\u0259 s\u00fcd v\u0259zi toxumas\u0131n\u0131n ilkin adenokarsinomalar\u0131n\u0131n t\u0259krar\u00adlan\u00admas\u0131 v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. X\u00fcsusil\u0259 meta\u00adstatik m\u0259d\u0259 karsinomalar\u0131nda CA72-4 s\u0259viyy\u0259si y\u00fcks\u0259lir. H\u0259m\u00e7inin b\u0259zi xo\u015fxass\u0259li halarda da (pankreatit, qaraciy\u0259r sirrozu, a\u011fciy\u0259r x\u0259s\u00adt\u0259\u00adlik\u00adl\u0259ri, revmatoid x\u0259st\u0259\u00adlikl\u0259r, ginekoloji x\u0259st\u0259likl\u0259r, qastrointestinal sistem x\u0259st\u0259likl\u0259ri v\u0259 s.) CA72-4 s\u0259viyy\u0259si arta bil\u0259r. Skrininq test kimi istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u018fRB\u018fST T4<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0FT4<\/sub>; S\u0259rb\u0259st tiroksin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Yeni do\u011fulmu\u015f<\/td>\n18.0-40.0 pmol\/L<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n8.5-40.5 pmol\/L<\/td>\n<\/tr>\n
>7g\u00fcn<\/td>\n9.0-25.0 pmol\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qalxanab\u0259nz\u0259r v\u0259zi funk\u00adsiyalar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 is\u00adtifad\u0259 olunur. Hipertiroidizimd\u0259 se\u00adrumda FT4\u00a0<\/sub>s\u0259viyy\u0259si y\u00fcks\u0259lir, hipo\u00adti\u00adroidizimd\u0259 azal\u0131r. Total T4<\/sub>\u00a0miqda\u00adr\u0131n\u0131n t\u0259xmin\u0259n 0.02-0.04%-i FT4<\/sub>-d\u00fcr<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u00dcMUK GLA PROTE\u0130N\u0130 (OSTEOKALS\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0S\u00fcm\u00fck gla proteini; BGP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0S\u0259h\u0259r acl\u0131\u011f\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n
6 ay-5 ya\u015f<\/td>\n10-40 ng\/mL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n5-60 ng\/mL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n2-15 ng\/mL<\/td>\n<\/tr>\n
<50 ya\u015f<\/td>\nKi\u015fi: 2-10 ng\/mL<\/td>\n<\/tr>\n
Qad\u0131n: 2-22 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Serumda osteokalsin s\u0259\u00adviy\u00ady\u0259si s\u00fcm\u00fck sintezi il\u0259 \u0259laq\u0259lidir. Bu bax\u0131mdan osteokalsin s\u0259viy\u00ady\u0259\u00adsinin y\u00fcks\u0259lm\u0259si osteoblastik aktiv\u00adli\u00adyin artd\u0131\u011f\u0131n\u0131 g\u00f6st\u0259rir. Serumda os\u00adteokalsin s\u0259viyy\u0259si q\u0259l\u0259vi fosfataza s\u0259viyy\u0259si il\u0259 paralel d\u0259yi\u015fir. Paget x\u0259st\u0259liyi, b\u00f6yr\u0259k m\u0259n\u015f\u0259li os\u00adteodistrofiya, birincili v\u0259 ikincili hipertiroidizim, skelet metastazlar\u0131 v\u0259 xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131nda osteokalsinin s\u0259viyy\u0259si art\u0131r, birincili biliar sirroz, hamil\u0259lik, qliko\u00adkor\u00adti\u00adkoid m\u00fcalic\u0259si v\u0259 GH \u00e7at\u0131\u015fmaz\u00adl\u0131\u00ad\u011f\u0131nda is\u0259 bu g\u00f6st\u0259rici azal\u0131r. Os\u00adteoparozda is\u0259 osteokalsin s\u0259viyy\u0259si y\u00fcks\u0259k v\u0259 ya a\u015fa\u011f\u0131 ola bil\u0259r. H\u0259m\u00e7inin kalsitriol m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 d\u0259 osteokalsin istifa\u00add\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

STH (GROWTH HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>GH; Somatotropin; STH<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin s\u0259h\u0259r acqar\u0131na v\u0259 30 d\u0259qiq\u0259 istira\u00adh\u0259td\u0259n sonra al\u0131nmas\u0131 m\u0259sl\u0259h\u0259tdir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259ddind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong><20 \u03bcIU\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipofizin funksiyas\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259si, u\u015faqlarda dwar\u00adfizm (nanizm) v\u0259 giqantizmin, b\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 is\u0259 akromeqaliyan\u0131n diaq\u00adno\u00adzunda v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. U\u015faqlarda GH \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259\u00adsin\u00add\u0259 bazal d\u0259y\u0259rl\u0259r yet\u0259rsiz ola bil\u0259r, ona g\u00f6r\u0259 d\u0259 b\u0259z\u0259n stimuliyasiya testl\u0259rin\u0259 ehtiyac yaran\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SOMATOTROP\u0130N (GROWTH HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>GH; Somatotropin; STH<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin s\u0259h\u0259r acqar\u0131na v\u0259 30 d\u0259qiq\u0259 istira\u00adh\u0259td\u0259n sonra al\u0131nmas\u0131 m\u0259sl\u0259h\u0259tdir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259ddind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong><20 \u03bcIU\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipofizin funksiyas\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259si, u\u015faqlarda dwar\u00adfizm (nanizm) v\u0259 giqantizmin, b\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 is\u0259 akromeqaliyan\u0131n diaq\u00adno\u00adzunda v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. U\u015faqlarda GH \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259\u00adsin\u00add\u0259 bazal d\u0259y\u0259rl\u0259r yet\u0259rsiz ola bil\u0259r, ona g\u00f6r\u0259 d\u0259 b\u0259z\u0259n stimuliyasiya testl\u0259rin\u0259 ehtiyac yaran\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TSH (T\u0130RO\u0130D-ST\u0130MUL\u018f ED\u0130C\u0130 HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TSh; s-TSH; Tirotropin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sutkal\u0131q ritmi vard\u0131r. Saat 02.00-04.00 ara\u00ads\u0131n\u00adda maksimum, 17.00-18.00 aras\u0131nda is\u0259 minimum s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n0.5-20.0 \u03bcIU-mL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ya\u015f<\/td>\n0.5-10.0 \u03bcIU-mL<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n0.5-6.5 \u03bcIU-mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.5-5.5 \u03bcIU-mL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.3-4.0 \u03bcIU-mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Tiroid funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259si v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Hipo\u00adtiroidizim, Xa\u015fimoto tiroiditi, ekto\u00adpik TSH ifraz olunan hallar, yar\u0131m\u00adk\u0259skin tiroidit v\u0259 tiroid hormon re\u00adzis\u00adtentliyind\u0259 serumda TSH s\u0259viy\u00ady\u0259\u00adsi art\u0131r, hipotalamus v\u0259 hipofiz m\u0259n\u00ad\u015f\u0259li hipotiroidizim v\u0259 hiperti\u00adro\u00adidi\u00adzimd\u0259 is\u0259 TSH s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TSH RESEPTOR ANT\u0130C\u0130S\u0130M\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015fl\u0259m\u0259 zaman\u0131:\u00a0<\/strong>\u00c7\u0259r\u015f\u0259nb\u0259 ax\u015fam\u0131, C\u00fcm\u0259<\/p>\n

N\u0259tic\u0259 verm\u0259 zaman\u0131:\u00a0<\/strong>H\u0259min g\u00fcn saat 18.00<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Radio receptor assay<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259dd\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<10 U\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hipertiroidizm s\u0259b\u0259binin ara\u015fd\u0131r\u0131lmas\u0131nda istifad\u0259 olunur. X\u00fc\u00ad\u00adsu\u00adsil\u0259 Graves x\u0259st\u0259liyi il\u0259 hiper\u00adtiroidizmin differensasiyas\u0131 v\u0259 anti-tiroid d\u0259rman m\u00fcalic\u0259sin\u0259 cavab\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TUMOR ASSOCIATED GLYCOPROTE\u0130N 72 (CA 72-4)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>X\u0259r\u00e7\u0259ng antigeni 72-4; TAG 72; Tumor associated glico\u00adpro\u00adtein 72<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens: <<\/strong>6.9 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>Qastrointestinal sistem, yumurtal\u0131q v\u0259 s\u00fcd v\u0259zi toxumas\u0131n\u0131n ilkin adenokarsinomalar\u0131n\u0131n t\u0259krar\u00adlan\u00admas\u0131 v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. X\u00fcsusil\u0259 meta\u00adstatik m\u0259d\u0259 karsinomalar\u0131nda CA72-4 s\u0259viyy\u0259si y\u00fcks\u0259lir. H\u0259m\u00e7inin b\u0259zi xo\u015fxass\u0259li halarda da (pankreatit, qaraciy\u0259r sirrozu, a\u011fciy\u0259r x\u0259s\u00adt\u0259\u00adlik\u00adl\u0259ri, revmatoid x\u0259st\u0259\u00adlikl\u0259r, ginekoloji x\u0259st\u0259likl\u0259r, qastrointestinal sistem x\u0259st\u0259likl\u0259ri v\u0259 s.) CA72-4 s\u0259viyy\u0259si arta bil\u0259r. Skrininq test kimi istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

UNKONJUGE E3 (ESTR\u0130OL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>E3<\/sub>\u00a0; Unkonjuge E3<\/sub>\u00a0; uE3<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildiril\u0259c\u0259kdir<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Fetoplasental d\u00f6vr\u00fcn qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. S\u0259rb\u0259st E3<\/sub>\u00a0miqdar\u0131 \u00fcmumi E3<\/sub>-l\u0259\u00a0 m\u00fc\u00adqa\u00adyis\u0259d\u0259 daha spesifikdir. N\u0259tic\u0259l\u0259r x\u0259st\u0259d\u0259n as\u0131l\u0131 olaraq d\u0259yi\u015f\u0259 bil\u00addi\u00adyind\u0259n bir ne\u00e7\u0259 ard\u0131c\u0131l m\u00fcayin\u0259 apa\u00adr\u0131lmal\u0131d\u0131r. Bundan ba\u015fqa, s\u0259h\u0259rl\u0259r konsentrasiyas\u0131 daha y\u00fcks\u0259k olur. Hamil\u0259lik m\u00fcdd\u0259tind\u0259 s\u0259rb\u0259st E3\u00a0<\/sub>daim y\u00fcks\u0259lir, do\u011fu\u015fun ba\u015flamas\u0131 il\u0259 birlikd\u0259 daha k\u0259skin y\u00fcks\u0259lm\u0259 ba\u015f verir. Diabetli hamil\u0259l\u0259r, post-date hestasiya v\u0259 b\u0259tndaxili inki\u015faf\u0131n ge\u00addi\u015finin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 s\u0259r\u00adb\u0259st E3\u00a0<\/sub>istifad\u0259 oluna bil\u0259r. D\u00f6ld\u0259 m\u0259rk\u0259zi sinir sisteminin malfor\u00adma\u00adsiyas\u0131, anadang\u0259lm\u0259 qapaq x\u0259st\u0259\u00adlik\u00adl\u0259ri v\u0259 ya Daun sindromunda se\u00adrum\u00adda s\u0259rb\u0259st E3\u00a0\u00a0<\/sub>s\u0259viyy\u0259sind\u0259 azal\u00adma m\u00fc\u015fahid\u0259 oluna bil\u0259r. Hami\u00adl\u0259\u00adliyin 35-36-c\u0131 h\u0259ft\u0259l\u0259rind\u0259 d\u00f6l\u00fcn ya\u015f\u0131n\u0131n hesablanmas\u0131nda da s\u0259rb\u0259st E3\u00a0<\/sub>isti\u00adfad\u0259 oluna bil\u0259r. H\u0259m\u00e7inin II tri\u00admes\u00adterd\u0259 hCG v\u0259 AFP il\u0259 birg\u0259 istifad\u0259 olunaraq risk skrininqi apar\u0131la bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

VAZOPRESS\u0130N (ANT\u0130D\u0130URET\u0130K HORMON)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ADH; Vazoperssin; Argi\u00adnin vazopressin hormon; AVP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 Plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admu\u00ad\u00adn\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admo\u00ad\u00adliz\u0259 u\u011framadan soyuq \u015f\u0259raitd\u0259 t\u0259\u00adcili ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6n\u00add\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Plazmadak\u0131 ADH s\u0259viyy\u0259sin\u0259 t\u0259sir ed\u0259n bir \u00e7ox fak\u00ad\u00adtor var. Ayaq \u00fcst\u0259 durmaq, a\u011fr\u0131, sters, gimnastika, plazma osmol\u00adyar\u00adl\u0131\u00ad\u011f\u0131n\u0131n (osmolalite) artmas\u0131 v\u0259 qan\u0131n h\u0259c\u00adminin, yaxud, arterial t\u0259zyiqin azal\u00admas\u0131 v\u0259 gec\u0259l\u0259r ADH ifraz\u0131 art\u0131r, isti\u00adra\u00adh\u0259t, hipoosmolyarl\u0131q, qan\u0131n h\u0259c\u00ad\u00adminin art\u00admas\u0131 v\u0259 hipertenziya zaman\u0131is\u0259 aza\u00adl\u0131r. H\u0259m\u00e7inin xlor\u00adpro\u00adpa\u00admid, tiazid, di\u00adu\u00adretk\u00adl\u0259r v\u0259 s. d\u0259r\u00admanlar da ADH ifraz\u0131n\u0131 art\u0131r\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q v\u0259 n\u00fcmun\u0259nin tam qan olaraq g\u00f6nd\u0259rilm\u0259si<\/p>\n

Referens:<\/strong>\u00a0<8 pg\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Ektopik ADH ifraz ed\u0259n \u015fi\u015f\u00adl\u0259r, k\u0259skin intermittant porfiriya, Gu\u00adillian-Barre sindromu, beyin \u015fi\u015f\u00adl\u0259ri, vas\u00adkulyar v\u0259 infeksion beyin x\u0259s\u00adt\u0259lik\u00adl\u0259\u00adri, pnevmoniya, a\u011fciy\u0259r v\u0259\u00adr\u0259mi, v\u0259\u00adr\u0259m meningiti v\u0259 beyin m\u0259n\u00ad\u015f\u0259li \u015f\u0259\u00adk\u0259r\u00adsiz diabet, psixogen poli\u00addipsiya v\u0259 nef\u00adrotik sindromda ADH s\u0259viyy\u0259si azal\u0131r. M\u0259rk\u0259zi v\u0259 nefro\u00adgen \u015f\u0259k\u0259rsiz diabet v\u0259 ya psixogen polidipsiyan\u0131n diffe\u00adren\u00adsial diaqnos\u00adi\u00adkas\u0131 \u00fc\u00e7\u00fcn ADH stimuli\u00adyasiya testl\u0259ri istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CONNECT\u0130NG PEPT\u0130DE (C-PEPT\u0130D)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u0130nsulin C-peptid; CPR; Birl\u0259\u015fdirici peptid; C-peptid reak\u00adtivliyi)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>0.15-1.30 pmol\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0C-peptid yaln\u0131z\u00a0 m\u0259d\u0259alt\u0131 v\u0259zin \u03b2 h\u00fcceyr\u0259l\u0259rind\u0259n ifraz olun\u00addu\u011fu \u00fc\u00e7\u00fcn, x\u00fcsusil\u0259 ekzogen insulin istifad\u0259 ed\u0259n diabet x\u0259st\u0259l\u0259rind\u0259, en\u00addogen insulin ifraz\u0131n\u0131n qiym\u0259tl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. \u0130nsu\u00adlinoma, oral hipoqlikemik d\u0259\u00adr\u00adman\u00adlar, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, II tip \u015f\u0259k\u0259rli diabet, ql\u00fckoza q\u0259bulu, azan sinirin sti\u00admuliyasiyas\u0131, tirotoksikoz, Cu\u00adshing sindromu, hipokalemiya, ha\u00admil\u0259lik v\u0259 akromeqaliya zaman\u0131 se\u00adrumda C-peptid s\u0259viyy\u0259si art\u0131r, I tip\u00a0 \u015f\u0259k\u0259rli diabet, insulin m\u00fcalic\u0259si, tiazid qrupundan olan diuretikl\u0259r, alkaqol q\u0259bulu v\u0259 pan\u00adkreatek\u00adto\u00admi\u00adyadan sonra is\u0259 C-peptid s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CPR (C-PEPTID)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u0130nsulin C-peptid; CPR; Birl\u0259\u015fdirici peptid; C-peptid reak\u00adtivliyi)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>0.15-1.30 pmol\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0C-peptid yaln\u0131z\u00a0 m\u0259d\u0259alt\u0131 v\u0259zin \u03b2 h\u00fcceyr\u0259l\u0259rind\u0259n ifraz olun\u00addu\u011fu \u00fc\u00e7\u00fcn, x\u00fcsusil\u0259 ekzogen insulin istifad\u0259 ed\u0259n diabet x\u0259st\u0259l\u0259rind\u0259, en\u00addogen insulin ifraz\u0131n\u0131n qiym\u0259tl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. \u0130nsu\u00adlinoma, oral hipoqlikemik d\u0259\u00adr\u00adman\u00adlar, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, II tip \u015f\u0259k\u0259rli diabet, ql\u00fckoza q\u0259bulu, azan sinirin sti\u00admuliyasiyas\u0131, tirotoksikoz, Cu\u00adshing sindromu, hipokalemiya, ha\u00admil\u0259lik v\u0259 akromeqaliya zaman\u0131 se\u00adrumda C-peptid s\u0259viyy\u0259si art\u0131r, I tip\u00a0 \u015f\u0259k\u0259rli diabet, insulin m\u00fcalic\u0259si, tiazid qrupundan olan diuretikl\u0259r, alkaqol q\u0259bulu v\u0259 pan\u00adkreatek\u00adto\u00admi\u00adyadan sonra is\u0259 C-peptid s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

GF-1 (SOMATOMED\u0130N C)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0IGF-14 \u0130nsulin-like gro\u00adwth faktor; Growth faktor 1; GF-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Growth hor\u00admonun \u0259ksin\u0259 g\u00fcn \u0259rzind\u0259 v\u0259 yem\u0259kl\u0259rd\u0259n sonra somatomedin C s\u0259viyy\u0259si sabit olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
<3 ya\u015f<\/td>\n50-143 ng\/mL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n51-218 ng\/mL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n106-250 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n140-496 ng\/mL<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n150-562 ng\/mL<\/td>\n<\/tr>\n
21-25 ya\u015f<\/td>\n84-376 ng\/mL<\/td>\n<\/tr>\n
26-30 ya\u015f<\/td>\n90-271 ng\/mL<\/td>\n<\/tr>\n
31-35 ya\u015f<\/td>\n90-226 ng\/mL<\/td>\n<\/tr>\n
36-50 ya\u015f<\/td>\n90-210 ng\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n70-197 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0GH sekresiyas\u0131n\u0131 v\u0259 t\u0259si\u00adrini t\u0259qib etm\u0259k \u00fc\u00e7\u00fcn istifad\u0259 olunur. IGFBP3 il\u0259 birlikd\u0259 istifad\u0259 olun\u00adduqda klinik h\u0259ssasl\u0131q v\u0259 spesifikliyi GH funksiya testl\u0259rind\u0259n daha y\u00fcks\u0259k olur. IGF-1 akromeqaliyada y\u00fcks\u0259k, GH \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, anoreksiya nervosa v\u0259 malnutrisiyas\u0131 olan \u015f\u0259xs\u00adl\u0259rd\u0259 is\u0259 a\u015fa\u011f\u0131 olur. Qidalanma v\u0259\u00adziyy\u0259tinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 prealbumin, RBP v\u0259 ya transfer\u00adrin\u00add\u0259n daha h\u0259ssas olmas\u0131 Soma\u00adto\u00admedin C-nin ba\u015fqa bir x\u00fcsusiy\u00ady\u0259tidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HAGEMAN FAKTORU (FAKTOR XII)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hageman faktoru<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sitratl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Mavi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fcmun\u0259 al\u0131nd\u0131qdan sonra plazma hemoliz\u0259 u\u011framadan tez ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Risk qiym\u0259tl\u0259ndirm\u0259 apar\u0131ld\u0131qdan sonra heparin m\u00fcalic\u0259si m\u00fcayin\u0259d\u0259n 2 g\u00fcn \u0259vv\u0259l k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Koaqulometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan qan\/antikoaqulyant nis\u00adb\u0259ti, laxtal\u0131, hemolizli, heparinli n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
Normal aktivliyin %-i<\/td>\n<7g\u00fcn<\/td>\n25-50<\/td>\n<\/tr>\n
7g\u00fcn-1ay<\/td>\n30-70<\/td>\n<\/tr>\n
2-3ay<\/td>\n40-100<\/td>\n<\/tr>\n
4-6ay<\/td>\n50-130<\/td>\n<\/tr>\n
>60ay<\/td>\n50-150<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130rsi XII faktor \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131 olan x\u0259st\u0259l\u0259rin \u0259ks\u0259riyy\u0259tind\u0259 qan\u00adaxma probleml\u0259ri olmad\u0131\u011f\u0131 hal\u00adda, trombembolik probleml\u0259r daha \u00e7ox rast g\u0259linir. Bu x\u0259st\u0259l\u0259rd\u0259 PT normal, APTT uzanm\u0131\u015f olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

\u0130NSUL\u0130N C-PEPT\u0130D (C-PEPT\u0130D)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u0130nsulin C-peptid; CPR; Birl\u0259\u015fdirici peptid; C-peptid reak\u00adtivliyi)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>0.15-1.30 pmol\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0C-peptid yaln\u0131z\u00a0 m\u0259d\u0259alt\u0131 v\u0259zin \u03b2 h\u00fcceyr\u0259l\u0259rind\u0259n ifraz olun\u00addu\u011fu \u00fc\u00e7\u00fcn, x\u00fcsusil\u0259 ekzogen insulin istifad\u0259 ed\u0259n diabet x\u0259st\u0259l\u0259rind\u0259, en\u00addogen insulin ifraz\u0131n\u0131n qiym\u0259tl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. \u0130nsu\u00adlinoma, oral hipoqlikemik d\u0259\u00adr\u00adman\u00adlar, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, II tip \u015f\u0259k\u0259rli diabet, ql\u00fckoza q\u0259bulu, azan sinirin sti\u00admuliyasiyas\u0131, tirotoksikoz, Cu\u00adshing sindromu, hipokalemiya, ha\u00admil\u0259lik v\u0259 akromeqaliya zaman\u0131 se\u00adrumda C-peptid s\u0259viyy\u0259si art\u0131r, I tip\u00a0 \u015f\u0259k\u0259rli diabet, insulin m\u00fcalic\u0259si, tiazid qrupundan olan diuretikl\u0259r, alkaqol q\u0259bulu v\u0259 pan\u00adkreatek\u00adto\u00admi\u00adyadan sonra is\u0259 C-peptid s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NEYRON SPES\u0130F\u0130K ENOLAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0NSE<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0 N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra hemoliz\u0259 u\u011framadan serum d\u0259rhal ayr\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

Referens:<\/strong>\u00a0<12.5 \u03bcg\/dL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0APUD h\u00fcceyr\u0259li neyro\u00adendokrin \u015fi\u015fl\u0259r\u0259 (m\u0259s. neyro\u00adblas\u00adtoma, retinoblastoma, tiroid medullar karsinomas\u0131, karsinoid \u015fi\u015fl\u0259r, feoxro\u00admositoma v\u0259 ki\u00e7ik h\u00fcceyr\u0259li a\u011fciy\u0259r karsinomas\u0131) spesifik markerdir. Bu \u015fi\u015fl\u0259rin diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 NSE istifad\u0259 olunur. X\u00fcsusil\u0259 neyro\u00adblastoma v\u0259 a\u011fciy\u0259r ca \u00fc\u00e7\u00fcn h\u0259s\u00adsasl\u0131\u011f\u0131 y\u00fcks\u0259kdir. H\u0259m\u00e7inin septik \u015fok, pnevmoniya v\u0259 sinir travmalar\u0131 da NSE s\u0259viyy\u0259sind\u0259 y\u00fcks\u0259lm\u0259y\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TRP (BORUCUQ FOSFAT REABSORBS\u0130YASI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Tubulyar fosfat reabsorb\u00adsiyas\u0131, TRP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0S\u0259h\u0259r 2-4 saatl\u0131q\u00a0 sidik v\u0259 eyni zamanda al\u0131nan serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum). Y\u0131\u011f\u0131lan sidik so\u00adyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6n\u00add\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL serum v\u0259 10 mL sidik<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0X\u0259st\u0259 m\u00fca\u00adyin\u0259d\u0259n\u00a0 \u0259vv\u0259lki 5 g\u00fcn \u0259rzind\u0259 nor\u00admal kalsium v\u0259 fosfor t\u0259rkibli p\u0259hriz q\u0259bul etm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a078-91 %<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Paratiroid v\u0259zi funksi\u00adya\u00adlar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur. Hipoparatiroidizm v\u0259 psev\u00addohipoparatiroidizmd\u0259 TRP ar\u00adt\u0131r, hiperparatiroidizmd\u0259 is\u0259 azal\u0131r. Hiperparatiroidizmi olan x\u0259st\u0259l\u0259rin 25 %-d\u0259 yalan\u00e7\u0131 neqativ n\u0259tic\u0259 \u0259ld\u0259 oluna bil\u0259r.
\nTRP %=100x(1<\/strong>\u2013 sidik fosforu\u00a0x<\/strong>\u00a0serum kreatinini\u00a0\/<\/strong>\u00a0sidik kreatinini\u00a0x\u00a0<\/strong>serum fosforu)<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section><\/div>[\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-15879","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/comments?post=15879"}],"version-history":[{"count":2,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15879\/revisions"}],"predecessor-version":[{"id":15918,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15879\/revisions\/15918"}],"wp:attachment":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/media?parent=15879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}